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Background The demands of type 1 diabetes (T1D) may constitute a great burden for 
people living with the disease. Diabetes distress reflects a range of emotional 
experiences, such as worry, guilt, and fear, potentially impairing self-management 
and glycaemic control. Serious diabetes distress is reported by 20-40% of adults with 
T1D. Consequently, regular assessment in clinical care is recommended. Using 
Patient-Reported Outcome Measures (PROMs) to assess diabetes distress is 
considered useful as tools to improve screening and communication between 
clinicians and people with T1D. Therefore, we developed the Diabetes Patient-
Reported Outcome Measure (DiaPROM) trial, an empowerment-based intervention 
using the Problem Areas in Diabetes (PAID) scale to assess diabetes distress and as a 
dialogue tool in adult T1D consultations. 
Aims The overall aim of the studies conducted as part of this thesis was to feasibility 
and pilot test the DiaPROM trial, thereby investigate uncertainties associated with 
running a full-scale randomised controlled trial (RCT). The specific aims were as 
follows: 
1. To examine the feasibility and acceptability of capturing PROMs electronically on 
a touchscreen computer in clinical diabetes practice (Paper I).  
2. To develop a study protocol for the DiaPROM pilot trial (Paper II).  
3. To pilot test the proposed DiaPROM trial components and address uncertainties 
associated with conducting a full-scale RCT in order to evaluate whether the trial 
methods and the intervention are feasible (Paper III).  
4. To explore young adults’ experiences with outpatient follow-up appointments, 
completing electronic PROMs and using the PAID scale during the DiaPROM 
pilot trial (Paper IV). 
Materials and methods Three studies designed to complement each other: a 
feasibility study, a pilot trial and a qualitative study, were conducted at the 
endocrinology outpatient clinic at Haukeland University Hospital, Bergen. Eligible 
participants were adults with T1D and a minimum of one year diabetes duration. In 
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the feasibility study, we invited adults ≥ 40 years to avoid including potential 
candidates for the upcoming pilot trial, in which we recruited younger adults aged 18-
39 years. In the qualitative study, we invited pilot trial participants after they had 
attended the 12-month follow-up visit. 
The feasibility study had a cross-sectional design (Paper I). The participants 
completed a set of electronic PROMs on a touchscreen computer at the outpatient 
clinic. The set contained five validated PROMs (42 items; covering diabetes distress, 
emotional wellbeing, perceived diabetes competence, hypoglycaemia awareness and 
health-related quality of life), three glucose variability items and two items 
concerning current glucose monitoring. Participants also completed a paper 
questionnaire regarding their perceptions about the PROMs. In addition, we 
monitored the touchscreen computer’s technical performance, observed the 
participants’ actions and collected data on the time needed to complete the PROMs, 
and we also recorded any missing items.  
The pilot trial was a two-arm RCT with baseline and 12-month data collection points 
(Papers II & III). All participant completed electronic PROMs before two annual 
check-ups. We used computer-generated block-randomisation without blinding to 
assign participants in a 1:1 ratio, stratified by sex, to receive the intervention or 
standard care. All intervention arm participants’ PAID scores were reviewed by and 
discussed with a physician, and participants with PAID scores ≥30 or items scored ≥3 
were offered additional follow-up. During a minimum of two diabetes specialist nurse 
consultations guided by an empowerment-based communication manual, reported 
problem areas were further discussed. Our primary outcome measure was the 
Diabetes Distress Scale (DDS), secondary outcome measures were the WHO 5-Well-
being Index, the Perceived Competence for Diabetes Scale and glycaemic control 
measured by HbA1c. The pilot trial outcomes were recruitment and retention rates, 
estimation of variance, between-group differences of follow-up scores and 
correlations of DDS scores to assist sample size calculations and, finally, 
participants’ perceptions about the intervention components.  
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In the qualitative study, we performed semi-structured individual telephone 
interviews of pilot trial participants, asking about their experiences with diabetes 
follow-up and participation in the pilot trial (Paper IV). We analysed the data using 
Braun & Clarke’s thematic analysis. 
Results In the feasibility study, we recruited 69 participants (50.7% men; median age 
51.0 years; median diabetes duration 26.0 years). The median time for completing the 
electronic PROMs was 8 minutes and 19 seconds, and the average completion rate 
was 81.4%. Overall, the touchscreen computer functioned well, and the participants 
found the PROMs understandable and relevant and acceptable for annual completion.  
In the pilot trial, we randomised 80 participants (mean age 27.2 years; mean diabetes 
duration 13.7 years) to the control or intervention arm (one participant was later 
excluded); 23 of 39 intervention arm participants qualified for additional 
consultations and 17 of these were referred. At 12 months, 67 participants attended 
the follow-up (15.2% attrition); thereof, 5 (29.4%) of the 17 referred to additional 
nurse consultations were lost to follow-up. Participants found the PROMs relevant 
and acceptable but rated the additional nurse consultations’ usefulness as moderate. 
Furthermore, using results from the primary outcome measure, the DDS, we 
estimated that at least 107 participants would be required per arm in a fully powered, 
single-site RCT. 
In the qualitative study, we interviewed 19 participants (age 22-39 years; diabetes 
duration 5-32 years): 8 from the control arm and 11 from the intervention arm. The 
analyses generated three themes, each with two subthemes: (1) Follow-up with 
limitations; Marginal dialogue about everyday challenges and Value of supportive 
relationships and continuity indicated that the participants experienced the previous 
follow-up as challenging and insufficient. (2) New insights and raised awareness; 
More life-oriented insights and Moving out of the comfort zone suggested mostly 
positive experiences with completing the PAID and using the scores in the dialogue. 
(3) Addressing problem areas with an open mind; Need for elaboration and 
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Preparedness for dialogue indicated that further exploration of the PAID scores and 
openness were essential. 
Conclusions The studies’ findings highlight the value of combining quantitative and 
qualitative methods in feasibility and pilot testing to uncover factors that may impede 
effective interventions in clinical practice. Capturing electronic PROMs was 
technically feasible and accepted by the participants. Although they found it 
somewhat uncomfortable and challenging to disclose their diabetes-related problem 
areas, addressing diabetes distress as part of the consultations was considered highly 
relevant and important for future diabetes follow-up. Using the PAID helped the 
healthcare providers see beyond biomedical outcomes, which promoted patient 
empowerment and person-centred care and facilitated improved patient-provider 
relationships.  
However, we decided not to proceed directly to a full-scale evaluation trial. This 
decision was based on findings indicating attrition, fidelity issues related to 
implementation and low acceptance or over-inclusion of cases, suggesting that the 
intervention requires additional development. Consequently, before commencing a 
full-scale RCT, the intervention requires modifications and additional development 
and possibly further feasibility and acceptability testing, focusing on inclusion 
criteria, intervention flexibility and healthcare provider training, specifically using the 
PAID in the patient-provider interaction. 
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1. Introduction 
Diabetes mellitus is a cluster of chronic endocrine diseases characterised by 
persistently elevated blood glucose (1). Diabetes is typically classified into broad 
etiologic groups to reflect the clinical heterogeneity: type 1 diabetes (T1D), latent 
autoimmune diabetes in adults, type 2 diabetes (T2D), gestational diabetes, specific 
types of diabetes due to genetic defects or diseases of the exocrine pancreas and 
medically or chemically induced diabetes (2). The International Diabetes Federation 
estimates that 463 million adults (20-79 years) presently live with diabetes and that 
1.1 million children and adolescents (0-19 years) have T1D, with an estimated 
128,900 new cases per year (3). Diabetes thus poses a significant public health 
challenge. Because the focus of this thesis is on adults with T1D, the review of the 
literature is restricted to this group. 
1.1 Type 1 diabetes 
T1D is caused by destruction of the insulin-producing β-cells in the Langerhans islets 
in the pancreas, and people with T1D, therefore, require lifelong exogenous insulin 
therapy (4). The pathogenesis of T1D is not fully understood. An estimated 70-90% 
of cases are presumably caused by an autoimmune response, whilst the remaining 
cases are considered idiopathic. Environmental agents most likely trigger the β-cell 
destruction in genetically predisposed people, typically developing over months or 
years without the individual noticing any symptoms (4, 5). T1D may be diagnosed at 
any age but most commonly during childhood and adolescence (4, 6). Boys and men 
are slightly more affected compared to girls and women (1.5:1 ratio). Studies also 
suggest seasonal variation with more cases diagnosed in colder months (4, 7). At T1D 
onset, classic symptoms are polyuria, polydipsia and weight loss due to 
hyperglycaemia effects and, in some cases, ketoacidosis (7). Standardised laboratory 
methods for measuring glycaemia levels through plasma glucose or Haemoglobin A1c 
(HbA1c) are used as diagnostic tools (8, 9). Current diagnostic criteria are either 
fasting plasma glucose levels ≥7.0 mmol/L, non-fasting plasma glucose levels ≥11.1 
mmol/L or HbA1c ≥48 mmol/mol (6.5%). Two abnormal tests are required for 
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diagnosis unless the patient has random plasma glucose levels ≥11.1 mmol/L and 
hyperglycaemia symptoms.  
Internationally, T1D incidence and prevalence vary considerably between countries 
and underlying mechanisms for this variation is unknown (4, 10). Over decades, an 
increased incidence was observed (11), which later seemed to level off in some 
countries (4). To date, the exact diabetes prevalence and incidence in Norway is 
unclear, apart from T1D in children and adolescents. The Norwegian Childhood 
Diabetes Registry’s annual report for 2019 reports an incidence of 37.7 per 100,000 
person-years for the age group 0-14 years (12). The Norwegian Diabetes Register for 
Adults’ (NDR-A, 76.1% coverage for hospital outpatient clinics) 2019 estimate was 
9.2 new cases of T1D per 100,000 person-years in adults >18 years (61% aged 18-39 
years) (13). Data from the national prescription database and regional population-
based health studies combined with diagnosis codes from primary and specialist care 
suggests that approximately 23,000 Norwegians have T1D (14).  
When Banting & Best introduced insulin replacement therapy in 1922, the lives of 
people with T1D changed dramatically as the disease was transformed from fatal to 
chronic (15). Later, long-term survival resulted in the discovery of microvascular and 
macrovascular diabetes complications (16). The specific complications were 
retinopathy, nephropathy and neuropathy, causing blindness, kidney failure and 
amputations, and cardiovascular diseases, causing myocardial infarctions, angina and 
strokes. However, the aetiology of diabetes complications and whether they were 
glucose-dependent or not was debated for years. In 1986, the Oslo study reported 
preventive effects of long term (2 years) near normoglycaemia on the progression of 
microvascular complications in a sample of 45 people with T1D (17). In 1993, this 
finding was corroborated by the Diabetes Control and Complications Trial (DCCT), 
which had followed 1441 people with T1D over 6.5 years (18). The DCCT 
demonstrated that intensive insulin therapy (at least three insulin injections per day) 
compared to conventional therapy of the time (one or two daily insulin injections) led 
to improved glycaemic control; however, with a 3-fold increased risk of 
hypoglycaemia. Twenty years later, the combined results from the DCCT with its 
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longitudinal Epidemiology of Diabetes Interventions and Complications (EDIC) 
follow-up study demonstrated that achieving near-to-normal glycaemia as safely as 
possible reduced microvascular and macrovascular diabetes complications (19). 
These results have played an important role in T1D treatment as the insulin 
replacement therapy evolved from taking fixed doses to a more complex regimen 
with dose adjustments. Together with other treatment innovations, this has led to 
markedly improved long-term health for people with T1D. 
1.1.1 Treatment of type 1 diabetes 
The overarching goal for all treatment is for people with diabetes to live their lives in 
full, in principal unrestricted lives, and prevent acute and long-term complications of 
the disease and its treatment (9). Worldwide, the most commonly recommended 
glycaemic target for non-pregnant adults with T1D is currently HbA1c of 53 
mmol/mol (7%) (3). Other important measures to maintain adequate treatment in 
everyday life are blood or interstitial glucose levels. In adults without long-term 
complications or additional health challenges, the glucose target range is specified as 
3.9-10.0 mmol/L while minimising time in hypoglycaemia (<3.9 mmol/L) and 
hyperglycaemia (>10.0 mmol/L) and trying to completely avoid glucose <3.0 mmol/L 
and >13.9 mmol/L (20). In addition, blood pressure, weight/BMI, lipids and 
albuminuria are important markers and measures targeted in treatment and follow-up 
as these are involved with the development of complications (9). However, treatment 
targets should always be individualised, weighing the benefits of intensified treatment 
against the risk of frequent or severe hypoglycaemia episodes, which can seriously 
impact the quality of life (9). 
International and national publications suggest that only 20-30% of adults with T1D 
reach the recommended HbA1c targets (<53 mmol/mol or <7.0%) (13, 21-23). 
Furthermore, higher HbA1c levels are associated with younger age among adults (22-
25). In a Norwegian study of adolescents and young adults with T1D, approximately 
10% of those aged 14-24 achieved target HbA1c (25). In the age group 25-30 years, 
this varied between 13% and 22%. According to the NDR’s 2019 annual report, 14% 
of adults (≥ 18 years) with T1D had HbA1c >75 mmol/mol (9.0%) (13). Another 
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study using NDR-A data found that high educational levels, not living alone, and 
higher frequencies of glucose monitoring and symptomatic hypoglycaemia were 
associated with lower HbA1c levels (23).  
Glucose monitoring 
HbA1c alone is insufficient to direct T1D therapy, which also involves frequent 
glucose level monitoring to inform and direct insulin dosage (26). The options are 
Self-Monitoring Blood Glucose (SMBG), Continuous Glucose Monitoring (CGM) 
and Flash Glucose Monitoring (FGM). SMBG measures capillary blood using 
fingerpricks and glucose meters (26). CGM systems measure interstitial glucose 
levels using a subcutaneously injected sensor connected to a transmitter which 
communicates glucose values to a receiver (20, 27, 28). Therefore, CGMs allows for 
direct observation of glycaemic excursions and daily glucose profiles that provide an 
overview of glucose variability over time, especially beneficial for people who 
experience frequent or severe hypoglycaemic episodes and/or have developed 
hypoglycaemia unawareness. FGM functions as a hybrid between SMBG and CGM 
and is the latest developed method for measuring interstitial glucose levels (29). 
Users scan a subcutaneously injected sensor by passing a reader over it to get glucose 
readings.  
Insulin replacement therapy 
Today’s insulin therapy recommendations for people with T1D are largely based on 
the DCCT and EDIC studies (18, 19). The goal is to resemble the physiological 
insulin profile of a non-diabetic pancreas through administering insulin by Multiple 
Daily Injections (MDI) using insulin pens or Continuous Subcutaneous Insulin 
Infusion (CSII) via an insulin pump (26, 30). Basal insulin is administered to 
maintain a near fasting normoglycaemic state by suppressing hepatic glucose 
production and delivered by injecting long-acting insulin once or twice daily by pen 
or continuous infusion of rapid-acting insulin via a pump. In comparison, bolus 
insulin refers to rapid-acting insulin administered via pen or pump to decrease 
postprandial glucose excursions by covering the extra need for insulin after meals are 
absorbed (26). Boluses are ideally not fixed doses but adjusted to match the 
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physiologic insulin requirement, which depends on carbohydrate intake, current and 
previous glucose levels, taken and/or planned physical activity and the individual’s 
general state (27).  
Pens are used by approximately 60% of insulin users worldwide, although variations 
exist between countries and age groups (31). Reusable or prefilled insulin pens are 
usually offered to adults with T1D at diagnosis. While in paediatric clinics, CSII is 
more often the first choice (27). Several pumps can receive CGM data. Some also 
allow the CGM data to address hypo- and hyperglycaemia by automatically adjusting 
basal insulin delivery (sensor-augmented pumps). In 2019, 79% of Norwegian 
children and adolescents with T1D used CSII, while 74% used CGMs (12). 
Corresponding figures for adults were 34% and 46%, respectively (13).  
Technological breakthroughs frequently occur; for example, hybrid artificial 
pancreases (closed-loop systems), ‘Do-it-yourself’ artificial pancreas systems and 
implantable insulin pumps are being developed and tested, although not yet 
commonly used (32). In addition, new insulin formulas are also under development. 
Nevertheless, people with T1D still carry an increased risk of developing 
complications. Achieving and maintaining glucose levels necessary to prevent 
complications requires that people with T1D acquire, implement and maintain 
complex self-management skills (33). In the care for people with chronic diseases, it 
is important to recognise that their everyday lives are lived despite illness, symptoms 
or disabilities (34).  
1.2 Self-management 
Being diagnosed with a chronic disease usually means that the individual has to attain 
considerable knowledge about the disease and its treatment, integrate new routines, 
lifestyles or behaviours and learn how to cope with major changes in everyday life 
(35). Further, people are expected to maintain these often complex and demanding 
behavioural and practical everyday efforts and make decisions that affect diseases 
management without advice from healthcare providers (34). Knowledge is an 
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essential element of disease management; however, increased knowledge alone is not 
enough. The concept self-management refers to “the individual's ability to manage 
the symptoms, treatment, physical and psychosocial consequences and lifestyle 
changes inherent in living with a chronic condition. Efficacious self-management 
encompasses ability to monitor one's condition and to affect the cognitive, 
behavioural and emotional responses necessary to maintain a satisfactory quality of 
life. Thus, a dynamic and continuous process of self-regulation is established” (35, p. 
178). However, acquiring and sustaining self-management is challenging and 
dependent on self-efficacy and resilience and acquiring the needed knowledge (34).  
1.2.1 Diabetes self-management 
Diabetes self-management can be described as the continuous efforts to lead a 
‘normal’ life by balancing physical and psychosocial well-being with the treatment 
regimen (36). Active and sustained self-management is a prerequisite for optimal 
treatment and a key determinant of treatment outcomes. In addition to practical skills 
such as insulin delivery and glucose monitoring, as mentioned earlier, self-
management also involves a comprehensive understanding of nutritional, hormonal, 
physical and emotional impacts on glycaemia to match the individual need for insulin 
(26, 37). Core self-management behaviours critical to T1D treatment, therefore, 
include glucose monitoring, carbohydrate awareness and/or counting, managing 
equipment and injection sites, insulin dose adjustments, managing hypo- and 
hyperglycaemia, handling physical activity and accessing healthcare (37). The 
complexity of T1D self-management has recently been highlighted in a study that 
identified 150 self-regulatory behaviours needed for optimal and sustained self-
management and 39 barriers and enablers to these behaviours (38). 
Diabetes treatment requires the use of technology. Choice of insulin delivery method 
and glucose monitoring device should ideally be based on individual preference and 
willingness and ability to take on technical tasks. Irrespective of the insulin delivery 
method, there are several factors related to injection technique that can affect insulin 
absorption and thereby the effect, such as needle length, rotation of injection sites and 
lipodystrophy (31, 39). Nevertheless, the MDI and CSII regimens support a flexible 
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lifestyle with fewer restrictions than simpler insulin regimes with fewer injections 
(40). Achieving near-normoglycaemia without increasing hypoglycaemic events is 
possible using MDI and CSII (41). However, potential CSII advantages include more 
precise insulin delivery and the possibility to adjust basal insulin levels, which can be 
particularly effective if target HbA1c is not achieved, for example, due to escalations 
of hypoglycaemia or hypoglycaemia unawareness (41, 42). Improved blood glucose 
variability also contributes to greater lifestyle flexibility and higher treatment 
satisfaction (41, 43). However, in cases of technical malfunction or user errors, the 
lack of circulating long-acting insulin means that hypoinsulinaemia is imminent. In 
addition, CGM can contribute to reduced HbA1c and hypoglycaemia, increased time 
in range and improved treatment satisfaction in people with T1D (44). However, CSII 
and CGM equipment is typically worn on the body, which can serve as a constant 
reminder and make the disease visible. Further, all devices used to optimise clinical 
outcomes require active, knowledgeable users who interpret the data and act 
appropriately (26).  
Despite technological innovations, many people with T1D struggle to achieve 
optimal glycaemic control, especially young adults (21-23, 25). The young adult 
phase ranges from about 19 to 40 years of age (45). The transition from adolescence 
to adulthood can be challenging in its own right, and adding T1D brings a unique set 
of challenges (46). As young people with T1D adapt to new adult roles and seek 
normalcy, they are also assuming responsibility and taking charge over their diabetes 
management (47) or being diagnosed and starting their life with diabetes. 
Paradoxically, reaching recommended glucose targets increases the risk of 
hypoglycaemic events (18), partly due to insulin delivery limitations. Not 
surprisingly, poor glycaemic control is linked to suboptimal self-management 
behaviours (23, 48). Studies also report less self-management engagement in 
emerging and younger adults (23, 24, 49). However, self-management inattentiveness 
is not necessarily a product of negligence but may be a consequence of competing 
priorities momentarily transcending the individual’s perceived importance of diabetes 
management (50). Poor glycaemic control and self-management are complex 
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phenomena that appear to be affected by biomedical and psychosocial factors, 
separately and in interaction (51). 
Self-management is ultimately the person’s responsibility, maybe supported by a 
partner, family or friends. Diabetes self-management is particularly challenging 
because individual efforts to achieve beneficial outcomes may not necessarily 
produce positive results (52). In everyday life, acute diabetes complications such as 
severe hypoglycaemia and hyperglycaemia, or ketoacidosis, are possibly the most 
immediate threats because these complications can lead to permanent illness or even 
death. The dilemma of striving for glycaemic control without hypoglycaemic events 
disrupting daily routines can potentially affect emotional well-being and diabetes-
related psychosocial aspects and lead to some deliberately raising their glucose levels 
(51). Overall, technological innovations have improved and will continue to 
contribute to diabetes care quality improvements; however, we have yet to alleviate 
the daily burden for those living with T1D (53). Emotional influences are potential 
drivers for sustained self-management, highlighting the importance of clinicians 
being attentive to and addressing the emotional aspects of living with T1D (38). 
1.3 Emotional burden of diabetes 
Due to the nature of the disease, people with T1D never get ‘time off’, which 
constitutes a great burden for the individual. Although far from everyone develops 
long-term complications, fear of vision loss, kidney failure and nerve damage can 
cause concern and negatively impact the person's perceived quality of life. 
Population-based studies and reviews have demonstrated that the well-being of many 
people with T1D is impaired through reduced health-related quality of life (54), 
experiencing anxiety or depression symptoms (55, 56), eating disorders and insulin 
restriction (55, 57), fear of hypoglycaemia (58) and diabetes distress (59). 
1.3.1 Diabetes distress 
Introduced in the mid-1990s, the construct diabetes distress (also known as diabetes-
specific distress or diabetes-related distress) reflects the emotional impact of living 
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with and self-managing diabetes (60-63). The construct is operationalised to include a 
range of emotional experiences such as feeling overwhelmed or frustrated by self-
management demands and diabetes-related stressors, as well as feelings of guilt, 
burden, worry, sadness and fear, and dissatisfaction with interpersonal relations and 
support from significant others and/or healthcare providers (64, 65).  
Diabetes distress is content-related and an expected response to the demands of 
diabetes that impact on well-being (61). Furthermore, diabetes distress is an affective 
state, not a trait, which may vary significantly by distress source and over time (66). 
In addition, mild distress cases may develop into severe, chronic distress if left 
untreated (67). Diabetes distress is not considered psychopathology and is distinct 
from depression (61); however, a risk factor for the incidence and persistence of 
depression (68). Furthermore, diabetes distress and depression can exist separately or 
co-occur, suggesting a bidirectional relationship (69). 
About 20-40% of people with T1D experience elevated or severe diabetes distress 
(59, 70). Regimen distress, fear of hypoglycaemia and complications, feeling 
overwhelmed and burned out and worrying about the future is most commonly 
reported (59, 71). One in four people with diabetes reports elevated levels of diabetes 
distress likely to impact clinical outcomes (72). Cross-sectional and longitudinal 
studies have investigated associations between diabetes distress and various 
demographic, clinical and social aspects. Diabetes distress is reported to be more 
prevalent among younger than older adults (73), which is possibly linked with shorter 
diabetes duration (70) and specific age-related challenges (73). Furthermore, women 
typically report higher distress levels than men (72, 74-76). There are also reports of 
associations between diabetes distress and problematic self-management behaviours 
related to insulin treatment and glucose monitoring (73, 77, 78) and between diabetes 
distress and unsatisfactory glycaemic control (73-81). These associations appear to be 
driven by regimen distress (75, 79, 81, 82). Moreover, lack of social network or low 
social support is associated with higher distress levels (70, 74). 
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The causal impact of diabetes distress on self-management behaviour and glycaemic 
control is not properly understood (62). Bidirectional relationships are likely since 
distress may influence glycaemic control indirectly via its impact on self-
management or vice versa. Diabetes distress related to self-management problems 
and/or poor glycaemic control may lead to feelings of guilt, worries and fears (62, 
71). Further, diabetes non-acceptance and fear of hypoglycaemia can cause less 
optimal treatment behaviour and poor glycaemic control. However, individuals that 
reach recommended treatment goals for glycaemic control are not exempt from 
experiencing diabetes distress (71). 
1.3.2 Monitoring diabetes distress 
Since diabetes distress is content-related, different interventions are required for 
different distress sources (e.g. worry about the future, concern about not performing 
enough glucose tests and fear of hypoglycaemia) (61). The “Monitoring of Individual 
Needs in Diabetes” study suggested that intervening on diabetes distress could be as 
straightforward as screening and discussing scores and outcomes in routine clinical 
appointments (83, 84). The authors claim that clinicians may be able to distinguish 
whether an individual is likely experiencing diabetes distress or symptoms of 
depression by addressing content and severity and thereby taking the appropriate 
actions according to their findings. A systematic review of intervention studies 
assessing diabetes distress in T1D found that numerous studies have measured 
diabetes distress but that few interventions have specifically targeted it (59). Further, 
the review identified a lack of interventions targeting elevated diabetes distress in 
younger adults. The authors listed goal-setting, problem-solving, reflection, 
supportive listening and addressing emotional challenges as aspects that seemingly 
offered greater reductions in diabetes distress but also in HbA1c (59).  
Routine monitoring of emotional well-being among people with diabetes was first 
recommended in 1994 (85). Since then, several diabetes guidelines and position 
statements have done the same (3, 86-89); however, regular assessment is still not the 
rule (90). In addition, renowned researchers in the field suggest that all people with 
diabetes may benefit from a routine follow-up where diabetes distress is 
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acknowledged as an expected part of diabetes (60, 61). Especially young adults who 
are undergoing a particularly vulnerable phase, which warrants further focus on 
diabetes distress and self-management issues (73). Others have suggested that 
addressing diabetes distress alongside biomedical measures may improve patient-
provider collaboration (91). 
1.4 Diabetes follow-up in the healthcare services 
People with T1D need skills and confidence to manage their treatment regimen in 
daily life. Also, they need lifelong healthcare services, but their follow-up 
requirements vary according to life events and transitional phases (92-94). According 
to US estimates, people with diabetes spend less than 1% of their lifetime with 
healthcare providers (or 1.5 twenty-minute consultations per year) (95). Besides 
providing a range of biomedical services and interventions, healthcare providers have 
a crucial role in care delivery and providing informed expert support and structured 
self-management training (40). Furthermore, patient-provider relationships influence 
psychological and somatic treatment outcomes and are therefore of utmost 
importance (96, 97). Long-term support by competent healthcare providers 
responsive to individuals’ needs is recommended since self-management training 
does not necessarily result in immediate adoption and maintenance of skills or 
behaviour changes (98), which poses challenges for the services and makes testing 
new intervention initiatives more challenging for researchers.  
1.4.1 Routine follow-up 
The Norwegian diabetes guideline recommends that people with T1D are offered 
interdisciplinary follow-up by specialist healthcare services (hospital outpatient 
clinics or private specialist care) (9). This follow-up should be tailored to the 
individual's needs, with at least one consultation per year. The hospitals’ diabetes 
teams involved in outpatient care typically consist of physicians (with or without 
specialisation in endocrinology or internal medicine), nurses and diabetes specialist 
nurses. Several clinics also receive support from clinical nutritionists, podiatrists, 
social workers, and other physician specialities such as ophthalmologists, 
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nephrologists, cardiologists and neurologists. To date, most Norwegian diabetes 
outpatient clinics do not employ psychologists or psychiatrists.  
Clinic non-attendance is a significant worldwide problem associated with younger 
age and subsequent suboptimal outcomes (99). Reasons for non-attendance are 
diverse, but lack of patient-provider relationships and perceived follow-up benefits 
have been identified as important barriers for regular attendance (100). 
1.4.2 Empowerment-based follow-up 
Most adults with T1D wish to engage with healthcare providers and discuss their self-
management and emotional challenges during follow-up (50, 93, 101-103). However, 
studies report that adult healthcare services focus more on glucose levels and other 
biomedical measures than the adults’ total life situation (47, 101, 104, 105). In a 
Norwegian study about the transition from paediatric to adult T1D care, young adults 
reported being less satisfied with adult care (105). The participants described a 
follow-up characterised by routine and biomedical checklists that were less personal 
with less focus on the psychosocial aspects than they had been accustomed to in 
paediatric care. Hence, holistic, person-centred approaches adapted to individual 
needs for follow-up are called for, in addition to more time and more frequent visits. 
Especially among young adults, individual life priorities may lead to diabetes 
management and follow-up not being a top priority (46, 50).  
Patient empowerment is acknowledged as a core value in achieving high-quality, 
person-centred healthcare (106). Empowerment is multidimensional and distinct 
interpretations of the concept have resulted in different definitions (107). Overall, 
empowerment-based approaches seek to strengthen peoples’ general abilities and is, 
therefore, considered health-enhancing. Also, empowerment involves shifting the 
patient-provider relationship’s power dynamics away from paternalism and towards 
collaboration (108). Since diabetes affects all aspects of a person’s life, self-
managing the disease requires the ability to make informed choices and decisions 
about treatment and self-care actions. Consequently, the philosophy of empowerment 
was proposed as relevant for diabetes care around thirty years ago (108, 109). This 
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thesis is based on a definition of the empowerment process as “the discovery and 
development of one’s inherent capacity to be responsible for one’s own life […] 
people are empowered when they have sufficient knowledge to make rational 
decisions, sufficient control and resources to implement their decisions and sufficient 
experience to evaluate the effectiveness of their decisions” (109, p. 38). 
The empowerment approach is described as collaborative, motivational and tailored 
to support patients in developing goals for managing their disease and making 
appropriate self-management decisions affecting their everyday lives (110, 111). 
Patient empowerment is seen as a process to achieve (or regain) control where the 
healthcare providers facilitate and offer information and knowledge to assist the 
patients in making informed decisions. For guiding patient-provider relationships, 
empowerment is acknowledged as an alternative to the paternalistic compliance-
oriented approach (107). However, the success of empowerment seems contingent on 
person-centredness and patient-provider communication quality (112). 
According to systematic reviews, empowerment-based interventions for people with 
diabetes can improve health status, including biomedical, psychosocial and self-
management outcomes (113, 114). Hence, empowering people with T1D is valuable; 
nevertheless, it depends on providers implementing a person-centred approach, 
acknowledging the patients’ main concern and experiences (107). Core elements and 
outcomes of empowerment-based interventions include identifying problems or 
concerns, goal setting and action planning, self-management, communication, 
problem-solving and reflection on changes (107, 115).  
1.4.3 Patient-Reported Outcome Measures 
A Patient-Reported Outcome (PRO) is defined as “a measurement of any aspect of a 
patient’s health that comes directly from the patient without interpretation of the 
patient’s response” (116, p. 101). Currently, PROs are considered essential in the 
movement towards empowerment-based and person-centred systems for structuring, 
monitoring and delivering healthcare (117, 118). PROs can be captured by Patient-
Reported Outcome Measures (PROMs), typically self-report questionnaires, that 
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assess various health-related constructs (119). PROMs were originally developed for 
research purposes and to obtain self-reports regarding issues and information that 
could not be assessed objectively by an observer or researcher (120). Integrating 
PROMs in clinical practice has the potential to improve care for people with diabetes 
by identifying patients’ problems and preferences through systematic screening, 
improving patient-provider communication, promoting self-management, facilitating 
shared decision making, monitoring progress over time and tailoring follow-up (117, 
119, 121, 122). In an overview of systematic reviews reporting on PROM use in 
routine cancer care, PROMs were found to improve pain management, symptom 
detection and patient-provider communication, in addition to increasing patient 
involvement and the use of supportive care (123). However, the authors highlight that 
healthcare services must be adequately resourced to respond to the patients’ needs. 
Capturing PROMs electronically 
PROMs can be administered on paper, web-based systems or electronic devices. 
Systematic reviews and meta-analyses report that administrating PROMs on paper or 
electronic interfaces produce equivalent data (124-127). Electronic capturing also has 
clear benefits that can produce higher quality data by reducing missing and unusable 
data, such as only allowing one response option per item and not permitting 
continuation before all items are completed (128-130). Electronically captured 
PROMs can be transferred to or integrated into the electronic patient records (EPR), 
which involves less administrative burden and responsibility and reduces potential 
errors in secondary data entry (128, 129). Electronic completion is typically preferred 
by patients and researchers over paper-based methods and might also be less time 
consuming or faster (127, 130, 131). 
1.4.4 Patient-provider communication 
Although essential in recognising individual needs, the psychological and emotional 
impact of living with diabetes has been largely unrecognised and greatly 
underreported by clinicians (132, 133). For healthcare providers to engage the patient 
as an active partner in the clinical setting, they must know the person behind the 
patient and establish a partnership (134). The first step is listening to the person’s 
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narrative. Using PROMs for screening purposes and as dialogue tools can enhance 
patient-provider communication and support patients to disclose or express their 
symptoms, worries or challenges (135, 136).  
When collected for use in clinical care, PROMs should be accompanied by a review 
and discussion of scores to elaborate on identified issues (121, 136, 137). Providers 
can use communication techniques to assist and support patients in the empowerment 
process (138, 139). Based on a positive atmosphere where providers demonstrate an 
interest in the patient, communication techniques entails asking attentive questions 
and using active listening, allowing patients to express emotions and take the 
necessary time, offering emotional and autonomy support and individualised 
information and advice, encouraging the patients to set goals and participate in 
decision-making and finally asking them to evaluate their efforts (107, 139). 
Empathy-based communication seems likely to catalyst improved self-management, 
further facilitating changes that lead to increased well-being (97). 
1.5 Rationale for the thesis 
Integrating assessment of diabetes distress using PROMs and empowerment-based 
communication techniques as dialogue tools can improve care for people with 
diabetes and enable them to become more involved in self-management. Hence, there 
is a rationale for collecting and using PROMs in clinical diabetes practice to support 
individual patients’ care (119, 140). Regular assessment of diabetes distress is 
recommended to promote the recognition of psychological and emotional challenges 
that affect diabetes self-management (60, 61). Previous studies have shown that using 
PROMs to monitor diabetes distress followed by a discussion of outcomes is feasible 
and beneficial in terms of improving well-being in adults with diabetes (83, 84, 141). 
To our knowledge, there has not been a systematic evaluation in Norwegian diabetes 
care services. Thus, before implementing PROMs and empowerment-based 
communication techniques as dialogue tools in clinical consultations, research is 
needed to evaluate their feasibility, acceptability and effect. 
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2. Aims 
The overarching aim of the Diabetes Patient-Reported Outcome Measures 
(DiaPROM) trial is to develop, test and evaluate an empowerment-based intervention 
using the patient-reported Problem Areas in Diabetes (PAID) scale as a dialogue tool 
in outpatient consultations among young adults with T1D. We propose that the 
intervention will reduce diabetes distress and improve overall emotional well-being, 
perceived competence in diabetes management and glycaemic control. 
The overall aim of the studies conducted as part of this thesis was to feasibility and 
pilot test the DiaPROM trial, thereby investigate uncertainties associated with 
running a full-scale randomised controlled trial (RCT). The specific aims were as 
follows: 
1. To examine the feasibility and acceptability of capturing PROMs electronically on 
a touchscreen computer in clinical diabetes practice (Paper I).  
2. To develop a study protocol for the DiaPROM pilot trial (Paper II).  
3. To pilot test the proposed DiaPROM trial components and address uncertainties 
associated with conducting a full-scale RCT in order to evaluate whether the trial 
methods and the intervention are feasible (Paper III).  
4. To explore young adults’ experiences with outpatient follow-up appointments, 
completing electronic PROMs and using the PAID scale during the DiaPROM 
pilot trial (Paper IV). 
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3. Materials and methods 
3.1 Study designs 
The DiaPROM trial’s overarching design is a complex intervention that consists of 
several interacting components and a number of behaviours required by those 
receiving and delivering it (142). Our work was guided by the Medical Research 
Council’s (MRC) framework for developing and evaluating complex interventions in 
health (142, 143), which describes a stepwise approach for developing, feasibility and 
pilot testing, evaluating and implementing an intervention (Figure 1).  
 
Figure 1. Phases and key components of developing, testing, evaluating, 
and implementing a complex intervention (based on a figure in Craig (142)). 
This thesis consists of studies from the feasibility and pilot phase of a complex 
intervention. While the terms feasibility and piloting have previously been used 
interchangeably, we have applied Eldridge et al.’s framework for defining such 
studies (144). Here, feasibility is considered an overarching concept involving all 
studies in preparation for the main evaluation trial. Thus, all pilot studies are 
feasibility studies, but not all feasibility studies are pilot studies. Specifically, 
feasibility studies address and test specific intervention components, procedures or 
  18
parameters important for conducting a full-scale trial (144). In comparison, pilot trials 
assess the feasibility of an entire set of procedures for a full-scale evaluation trial but 
on a smaller scale (and without testing hypotheses about the intervention’s efficacy) 
(144).  
Using different methodological approaches is considered appropriate in the feasibility 
and piloting phase of an intervention initiative (145, 146). Addressing uncertainties 
about an intervention by collecting quantitative and qualitative data may provide a 
more comprehensive assessment of feasibility and acceptability than applying solely 
quantitative measures (145, 146). Therefore, we designed quantitative and qualitative 
studies intended to complement each other (Table 1). First, we conducted a feasibility 
study with cross-sectional data (paper I). The subsequent pilot trial was designed as a 
two-arm RCT with baseline and 12-month data collection points (papers II & III). 
Finally, we undertook a qualitative study where a sample of the pilot trial participants 
was interviewed (paper IV).  





Pilot trial Qualitative study 
Paper I II III IV 
Design Cross-sectional 
study 
 Two-arm RCT Qualitative interview 
study 
Sample N=69 adults with 
type 1 diabetes  
aged ≥40 
 N=79 adults with type 1 
diabetes aged ≥18-<40 
- Intervention arm n=39 
- Control arm n=40 
N=19 recruited from the 
pilot RCT  
- Intervention arm n=11 
- Control arm n=8 
Moreover, in paper II, we outlined interviewing the healthcare providers engaged in 
the pilot trial. The study has been conducted (147), and although it is not part of the 
thesis, the results are considered in the general discussion. 
3.2 Study setting and recruitment 
The DiaPROM feasibility study and the pilot trial took place at the endocrinology 
outpatient clinic at Haukeland University Hospital, Bergen, where about 1500 adults 
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with T1D received follow-up during 2017-2019 (13, 148, 149). According to the 
NDR-A, 39% of the clinic’s T1D population used insulin pump therapy, and 43% had 
a continuous glucose monitoring device in 2019 (13). These numbers are, 
respectively, 5% above and 3% below the national average. The clinic employs 
endocrinologists, physicians specialising in endocrinology (or other internal medicine 
specialities), diabetes nurse specialists and health service secretaries.  
Recruitment for both the feasibility study and the pilot trial was performed by 
identifying eligible participants from the endocrinology outpatient clinic’s planned 
consultations. One to two weeks prior to the consultations, invitation letters with 
consent forms were sent by postal mail to eligible participants. A project group 
member was present in the clinic to assist participants and clinicians. In the 
qualitative study, we recruited pilot trial participants who had attended their 12-
month follow-up visit by contacting them by mail 3-7 days after this visit. 
3.3 Study participants 
In all three studies, eligible participants were adults with T1D and a minimum one-
year diabetes duration. We applied the following exclusion criteria obtained from the 
EPR: pregnancy, cognitive deficiency (e.g., Down’s syndrome, Alzheimer), severe 
medical comorbidity (e.g., end-stage renal disease, severe heart failure, severe 
cancer) and/or a major psychiatric diagnosis (e.g., severe depression or bipolar 
disorder, schizophrenia) as the burden of completing PROMs and addressing the 
responses might be too challenging for these groups of patients. Also, information 
about language or vision indicating that the person could not complete the electronic 
PROMs was applied as exclusion criteria. 
The sampling for the feasibility study and the pilot trial was consecutive. In the 
feasibility study, we invited adults ≥40 years to avoid including potential participants 
for the upcoming pilot trial, where we invited younger adults aged 18-39 years. In the 
pilot trial, we used computerised concealed allocation to randomise the participants in 
a 1:1 ratio to the intervention or control arm; 40 (50%) in each. Further, we stratified 
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by sex and used blocking to ensure equal numbers (20) of men and women in each 
arm. While in the qualitative study, we purposefully invited pilot trial participants 
who had attended and completed the 12-month follow-up. 
3.4 User involvement 
In health service research, the term user involvement refers to including and engaging 
service users as collaborators in the research process, for example, patients, informal 
carers, the public, healthcare providers and policymakers (150). The users’ unique 
perspective adds complementary insights to those of the researchers. Therefore, 
involving service users is found to improve research relevance, appropriateness and 
quality (151). In the DiaPROM project’s development phase, we invited a group of 
service users to collaborate in developing the intervention. The group was recruited 
from the Diabetes Association and consisted of people with lived experience of T1D 
and parents to people with T1D. Two of the service users were included in the 
DiaPROM project group, both previously experienced with user involvement in 
research. Overall, the users contributed to the research agenda and design, the 
intervention’s content, data analyses and dissemination (152, 153). Specifically, we 
consulted the group before choosing diabetes distress as the intervention’s focus. 
Further, the users provided input and opinions on the PROMs, the electronic 
collection of PROMs and the intervention’s communication techniques. Moreover, in 
the qualitative studies, one user was included as a co-researcher contributing to study 
designs, preparing the interview guides, data analyses and writing the papers. 
3.5 Data collection 
3.5.1 Sociodemographic and clinical diabetes-related data 
The following sociodemographic and clinical diabetes-related data were collected 
from the participants’ electronic patient records (EPR); age, sex, ethnic origin, 
diabetes duration, diabetes long-term complications, comorbidities, body mass index, 
HbA1c level, symptomatic hypoglycaemic events the previous month, history of 
hypoglycaemic events requiring assistance, history of hospitalisation due to 
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ketoacidosis and insulin injection device. In addition, we collected self-reported 
electronic data from the touchscreen computer on the use of glucose monitoring 
device and glucose measurement frequencies. Finally, we obtained information 
concerning first language, educational level, cohabitation status and work affiliation, 
in addition to the acceptability of completing PROMs electronically on a touchscreen 
computer from a paper-based questionnaire. 
3.5.2 Self-report questionnaires 
The electronic self-report questionnaire completed by participants in both the 
feasibility study and the pilot trial contained 47 items in total (Appendix 1); five 
validated PROMs (42 items), three glucose variability items developed for the studies 
and two items concerning current glucose monitoring device and glucose 
measurement count (daily/weekly), as these variables were not available in the EPR 
at the time. 
In Table 2, details about the validated PROMs and the glucose variability items are 
provided. Briefly, we used the Problem Areas in Diabetes (PAID) scale to identify 
and assess diabetes distress (64, 154, 155). The World Health Organisation 5-item 
Well-being Index (WHO-5) was included as a measure of overall emotional well-
being (156, 157). We used the Perceived Competence for Diabetes Scale (PCDS) to 
map self-perceived ability for diabetes self-management (158, 159). Further, we 
included the ‘Gold scale’ to assess hypoglycaemia awareness (160) and the RAND-
12 Health Status Inventory (RAND-12) to map health-related quality of life (161, 
162). In addition, we developed three items asking the participants to assess their 
self-perceived occurrence of hyperglycaemia, hypoglycaemia and fluctuating glucose 
levels over the latest couple of weeks.  
Pilot trial participants also completed the Diabetes Distress Scale (DDS) on paper at 
baseline and 12-month (Appendices 3 & 4). The DDS yields an overall diabetes 
distress score and four subscales (Table 2): emotional burden (5 items), physician-
related distress (4 items), regimen-related distress (5 items) and diabetes-related 
interpersonal distress (3 items) (163, 164).  
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We asked all feasibility study and pilot trial participants (baseline and 12 months) to 
complete a paper-based questionnaire after completing the electronic PROM and the 
consultations (Appendices 2, 3 & 4). The item wording and response alternatives 
were based on the Norwegian Institute of Public Health’s user experience 
questionnaires (165). Specifically, we asked about first language, educational level, 
marital/cohabitation status and work affiliation. In addition, we asked them about the 
relevance of the PROMs, acceptance of the number of items, the preferred method for 
completing PROMs and willingness for annual completion. Pilot trial participants 
were also asked about the consultations with physicians and nurses, specifically if 
and how the PAID was used during the consultations, and if they found the 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.5.3 Collecting electronic PROMs 
We used a stationary 17ʺ touchscreen computer for the technical and practical 
procedures for collecting PROMs. DIPS AS, the leading supplier of eHealth systems 
to Norwegian hospitals, developed the software application for completing the 
PROMs, a secure data repository for temporary PROMs data storage and the method 
for transferring these data to the participants’ diabetes-specific hospital records (166). 
The diabetes-specific record is also the Norwegian Diabetes Register for Adults’ 
electronic tool for collecting register data from outpatient clinics (167). Project funds 
paid for the computer and the software application. 
The computer was located next to the outpatient clinic’s waiting area to ensure 
visibility. The participants were not required to log in. By tapping the screen, they 
found information concerning the data collection procedure and the measured 
constructs. Next, the PROM items appeared one at a time (Figure 2). Further details 
about how the participants completed the PROMs are provided in paper I. In addition 
to PROM scores, the software registered the minutes and seconds used to complete 
the PROMs and also the number of completed and missing items.  
 
Figure 2. Example of a PROM item presented on the computer screen. 
3.5.4 Individual interviews 
In the qualitative study (paper IV), we used individual interviews. The pilot trial 
participants were offered either a face-to-face or a telephone interview, and we asked 
them to suggest the time and place. The semi-structured interview guide was 
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developed jointly in the author group, which included a service user. We used open-
ended questions pertinent to the study’s aim (Appendix 5). The guide was piloted in 
the first two interviews to assess its relevance and usefulness, which led to minor 
adjustments.  
The PhD candidate conducted the interviews, which were audio-recorded. The 
overall intention was for all participants to openly communicate their views and 
experiences and the meanings they assigned to them. This was emphasized by 
conveying that no right or wrong answers existed and striving to conduct the 
interviews in a non-judgemental manner. First, we invited all participants to share 
their experiences with previous diabetes outpatient follow-up visits. Next, they were 
asked about specific pilot trial experiences, i.e., the electronic completion and 
relevance of the PROMs. The intervention arm participants were also encouraged 
to share experiences with the physicians’ review of the PAID scores and, where 
relevant, with attending additional diabetes specialist nurse consultations. After the 
interviews, the interviewer wrote reflection notes. The data were transcribed 
verbatim within a maximum of three days, also marking pauses and sound utterances. 
Later, all transcripts were checked against the recordings for accuracy.  
3.6 The DiaPROM intervention 
The DiaPROM intervention consisted of interacting components, which required 
several behaviours from its participants and the physicians and diabetes specialist 
nurses delivering it (Figure 3). At baseline, each participant completed the electronic 
PROMs (Table 2) on the touchscreen computer prior to his or her annual diabetes 
consultation. The physician then downloaded the PROMs to the participant’s EPR 
guided by a study manual (Appendix 6), which also described the computerised and 
random allocation of participants to either an intervention or a control arm. The 
physician informed the participant about the allocation directly after the PROMs had 
been downloaded. Then the participant received follow-up according to trial arm 




Figure 3. The intervention flow chart (reprinted from paper II). 
3.6.1 Intervention arm procedures 
After the intervention arm participants’ PROMs had been downloaded, the physicians 
proceeded with reviewing the PAID, developed to identify and measure diabetes 
distress and standardised primarily for adults with T1D (64, 154, 155). The PAID is 
widely used and translated into multiple languages, including Norwegian (75). The 
twenty problem areas are rated on a 5-point Likert scale as 0 ‘not a problem’, 1 
‘minor problem’, 2 ‘moderate problem’, 3 ‘somewhat serious problem’ and 4 ‘serious 
problem’ (Appendix 1). The scale yields an overall diabetes distress score of 0-100 
(Table 2), indicating diabetes distress severity (155, 168). A total score ≥40 has been 
defined as serious diabetes distress (60, 155). Identifying specific sources of distress 
(e.g., items scored ≥3), also referred to as the ‘red flag’ approach, can serve as targets 
for intervention and conversation starters (155, 168). 
In the intervention consultations, the PAID served as a tool to identify diabetes 
distress and a dialogue tool, or starting point, for conversations about diabetes distress 
(Figure 4). The physicians were instructed to identify total scores ≥30 and items 
scored ≥3 (marked with red bars in the EPR), which qualified for additional diabetes 
specialist nurse consultations (Appendix 6). Participants with scores <30 and items 
<3 were to receive no specific follow-up of their scores but rather usual follow-up. 
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We also asked the physicians to be attentive to the WHO-5 in case of scores 
suggesting depression and thus need for specialist follow-up. 
 
Figure 4. The PAID scale as presented in the EPR. 
The additional nurse follow-up consisted of a minimum of two consultations (Figure 
3). The first consultations were planned to take place within four weeks and the 
second within another three months. We developed a manual to guide and support the 
nurses through the consultations (Appendix 7). Step-by-step, the guide described how 
to use the PAID and the empowerment-based communication principles and 
techniques as dialogue tools in the consultations. On the manual’s backside, we 
further elucidated the background for the communication principles. The specific 
techniques were asking questions, listening, responding and summing up. We also 
asked the nurse and participant to formulate and write down goals and actions and 
plan further follow-up based on the young adult’s wishes and needs. At 12 months, 
we provided the physicians with an adapted manual with information about the 
PROM downloading procedure and the PAID (and WHO-5) review among 
intervention arm participants (Appendix 8). 
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3.6.2 Control arm procedures 
For participants allocated to the control arm, the downloaded PROMs and their 
responses were not visible in the EPR neither at baseline nor at the 12-month visit. 
Hence, the controls did not receive a review of their scores. Instead, they were 
offered ‘standard outpatient care’, typically consisting of individual consultations at 
the outpatient clinic adapted to their needs (9). However, all people with T1D are 
supposed to receive at least one consultation per year with a physician (9). This 
annual consultation is characterised as a structured follow-up of glycaemic control 
and insulin dosage, assessment of symptoms and risks of microvascular and 
macrovascular complications and appraisal of treatment targets in cooperation with 
the patient; in addition, referral to other healthcare specialists if needed. Some also 
receive diabetes specialist nurse follow-up, typically regarding specific challenges 
with glycaemic control or self-management issues, or for educational purposes and 
extra support. 
3.6.3 Training the healthcare providers 
Before the pilot trial commenced, we arranged two 1-hour meetings with the 
outpatient clinic’s physicians in order to reach all of them. The participating 
physicians were trained in downloading the PROMs to the EPR (Appendices 6 & 8). 
They received oral information and written instructions on interpreting the PAID 
scores and were trained to briefly discuss the PAID scores in the annual 
consultations. In addition, instructions on the criteria for participants’ referral to 
additional follow-up by the diabetes specialist nurses were provided in the manual 
(Appendix 6). Before the 12-month follow-up, we repeated the physicians’ training. 
The diabetes specialist nurses participated in the meetings with the physicians before 
baseline. Further, they received written information prior to the 2×1 hours of specific 
training, which entailed interpretation of the PAID scores, discussion of the reported 
problem areas with the participants, in addition to how to follow the communication 
manual and agree on goals and actions to take with the participants (Appendix 7). All 
of the nurses had previously taken part in a group-based guided self-determination 
RCT (169), where they had completed a competence programme consisting of 
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multiple training sessions and workshops (170). The guided self-determination trial 
and the present pilot trial’s communication principles, presented in the training and 
the manual, were based on key empowerment-based elements, such as empathetic 
communication and autonomy support. 
3.6.4 Primary and secondary outcome measures 
In the pilot trial, primary and secondary outcomes were measured at baseline and 12 
months. The choice of outcome measures to assess the intervention’s effect in a full-
scale evaluation trial was based on a literature review and consultation with the user 
group, in addition to considerations within the project group. We decided on diabetes 
distress measured by the DDS as the primary outcome. Compared to the PAID, we 
found that the DDS appeared advantageous as an outcome measure due to its distress 
subscales (75, 171). Further, the scale has been shown to have satisfactory internal 
reliability and validity (163). The Norwegian version has also demonstrated high 
internal consistency and test-retest reliability (75).  
Further, we decided on overall emotional well-being, perceived diabetes competence 
and glycaemic control measured by the WHO-5, the PCDS and HbA1c (mmol/mol) as 
the secondary outcomes. The WHO-5 has been shown to have psychometrically 
sound properties as an outcome measure and for clinical use among people with 
diabetes (156, 157). Also, the PCDS has demonstrated good internal reliability and 
validity and high internal consistency (158, 159, 172).  
3.7 Data analyses 
3.7.1 Statistical analyses 
Statistical analyses were carried out using Stata SE for Windows, versions 15 and 16 
(173). For each study, we registered the number of invited participants. In both the 
feasibility study and the pilot trial, we registered how many attended their 
appointments, how many were excluded and how many declined to participate. 
Finally, we calculated the proportion of people who consented. All three study 
samples’ demographic and clinical characteristics were presented using descriptive 
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statistics. We used frequencies and percentages to describe categorical variables and 
either medians and minimum-maximum or means and standard deviations (SD) to 
describe continuous variables.  
Before analysing the validated PROMs, we quantified the proportion of missing items 
and subsequently handled these using person-mean substitution if at least 50 % of the 
items per scale were completed (174, 175). In both the feasibility study and the pilot 
trial, we calculated frequencies, percentages and proportions of participants with 
diabetes distress scores qualifying for additional follow-up. We quantified the self-
report variables concerning experience with participation and opinion about the 
various intervention components using frequencies, percentages and proportions. In 
the feasibility study, we also examined differences in the diabetes distress scores 
reported by male and female participants using t-tests and chi-square tests, and 
Cronbach’s alphas were calculated to estimate the internal consistency of the 
PROMs.  
In the pilot trial analyses, we used t-tests to estimate means, SD and 95% confidence 
intervals (CI) of SDs of outcome measures for each trial arm at baseline and 12 
months. For each of the time points, we used paired t-tests to calculate the within-
group variation of paired differences in the outcome measures’ means and SDs. To 
estimate means and 95% CIs of between-group differences, we used a mean-
comparison test calculator. We also compared the non-responders with the study 
population regarding sex, age, diabetes duration and HbA1c. Using Spearman’s rho, 
we estimated correlation with 95% CI between participants’ primary outcome 
measure (DDS) scores at baseline and 12 months. The primary outcome measure’s 
SD, 95% CI of SD and correlation coefficient was used to assist in the sample size 
calculations for an evaluation trial. In the pilot trial, we did not test the intervention 
with the intent of inferring or reporting effects; thus, the results are reported without 
p-values. 
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3.7.2 Qualitative analyses 
We analysed the interview data using Braun & Clarke’s thematic analysis (176). The 
analysis method is theoretically flexible and can be approached inductively or 
deductively. Thematic analysis focuses on identifying, analysing, and reporting 
themes (patterned meaning) across a dataset (176, 177). It is characterised as an 
iterative, thorough six-phase process of data familiarisation, coding, development of 
themes and revision (Table 3). Further, code development can be semantic and 
explicit or on a latent level that involves progression from description to 
interpretation (177). We applied an inductive, data-driven approach for generating 
codes and themes. Our coding was primarily semantic, focusing on the participants’ 
explicit experiences. However, as the analysis progressed, the code and theme 
development became more oriented towards the latent level and implicit meaning. 
The analysis team consisted of seven researchers, all experienced in the field of 
diabetes. We followed the six phases of analysis described in Table 3.  
Table 3. Phases of thematic analysis according to Braun & Clarke.  
Phases Description of the process 
1. Familiarising yourself  
with your data 
Transcribing data (if necessary), reading and re-reading the 
data, noting down initial ideas. 
2. Generating initial codes Coding interesting features of the data in a systematic 
fashion across the entire data set, collating data relevant to 
each code. 
3. Searching for themes Collating codes into potential themes, gathering all data 
relevant to each potential theme. 
4. Reviewing themes Checking if the themes work in relation to the coded extracts 
(Level 1) and the entire data set (Level 2), generating a 
thematic ‘map’ of the analysis.  
5. Defining and naming themes Ongoing analysis to refine the specifics of each theme and 
the overall story the analysis tells, generating clear 
definitions and names for each theme.  
6. Producing the report The final opportunity for analysis. Selection of vivid, 
compelling extracts, final analysis of selected extracts, 
relating the analysis back to the research question and the 
literature, producing a scholarly report of the analysis. 
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First, we worked individually to familiarise ourselves with the transcribed interview 
data and to prepare initial ideas of codes (phase 1). Then we met remotely on a video-
conference platform for a two-day workshop in May 2020. Each team member first 
shared their initial ideas about the data. We continued discussing interesting features 
of the data that were relevant to the aim, which led to us generating initial codes 
(phase 2). Later we collated the codes by patterns in a schematic overview before 
searching for potential candidate themes by identifying similarity and clustering 
(phase 3). After the workshop, the PhD candidate continued reviewing and naming 
the potential themes and subthemes (phase 3 & 4). When the team met for a second 
remote workshop in June 2020, we jointly reviewed and refined the themes and 
subthemes (phase 4 & 5). Defining and naming the themes (phase 5) continued while 
the written report of the findings was prepared (phase 6). As the manuscript 
developed, the team members agreed on the themes and subthemes’ wording and the 
selection of quotes. 
3.8 Ethics 
The studies in this thesis were conducted according to the Declaration of Helsinki: 
Ethical Principles for Medical Research Involving Human Subjects (178). The 
Western Norway Regional Committee for Medical and Health Research Ethics 
approved the studies. The reference numbers are 2016/2200/REK vest (Appendix 9) 
and 2017/1506/REK vest (Appendix 10). Haukeland University Hospital is the 
responsible research organisation. All participants received written study information 
and provided written consent (Appendices 11 & 12). Digital quantitative datasets and 
qualitative data (audio recordings and transcripts) are stored on the hospital’s secure 
research server in an encrypted repository only accessible for the PhD candidate and 
DiaPROM project leader.  
In the qualitative study, the pilot trial participants were asked to choose between a 
face-to-face or telephone interview and to suggest a time and place. Before the 
interviews started, the interviewer asked for permission to use an audio recorder and 
emphasised the importance of, e.g., asking her to rephrase questions if they did not 
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hear or understand. The interviewer started the recordings after the participants had 
consented, and pauses were provided if needed. Afterwards, the participants were 
allowed time to debrief. Due to the interviewer’s experience as a diabetes nurse 
specialist, she also provided information about how to get in touch with the outpatient 
clinic for guidance and support when this seemed necessary. 
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4. Summary of results 
The four papers included in this thesis have different aims and methods. Nonetheless, 
the papers are interconnected and constitute a project that increases our understanding 
of the piloted intervention’s feasibility and participant acceptability. In the feasibility 
study (paper I), we gained experience about the acceptability and technical feasibility 
of completing electronic PROMs on a touchscreen computer. Using electronic 
PROMs, we identified that about half of the participants reported clinically 
significant diabetes distress levels (papers I and III). Overall, the studies uncovered 
uncertainties with intervention feasibility and acceptability, thereby suggesting that 
we need to undertake modifications and additional development before commencing 
a full-scale RCT. We also gained insights into how the participants experienced and 
were affected by completing the PAID and using it in the consultations (paper IV). 
Table 4 provides an overview of the characteristics of the study participants. A 
summary of results from each study will be presented in the following chapters. 
Table 4. Characteristics of the study participants. 
 Feasibility study Pilot trial Qualitative study 
Participants (n) 69 79 19 
Men/Women  35/34 39/40 8/11 
Age (years)  51.0 (40-74) 27.2 ±5.0 29.8 ±5.2 
Diabetes duration (years) 26.0 (1-67) 13.7 ±7.0 16.4 ±7.4 
Late complications  35 (50.7) 16 (20.3) 4 (21.1) 
Retinopathy  28 (40.6) 15 (19.0) 4 (21.1) 
Nephropathy  7 (10.1) 1 (1.3) 0 (0.0) 
HbA1c (mmol/mol) 60.7 (41.0-107.7) 65.4 ±14.5 59.0 ±11.7 
HbA1c (%) 7.7 (5.9-12.0) 8.1 ±1.3 7.5 ±1.1 
CSII  26 (37.7) 38 (48.1) 12 (63.2) 
CGM 16 (24.2) 22 (27.9) 10 (52.6) 
Feasibility study: Data are n/n, n (%) or median (range). Pilot trial & Qualitative study: Data are n/n, n (%) or mean ± SD. 
HbA1c; Haemoglobin A1c. CSII; Continuous Subcutaneous Insulin Infusion. CGM; Continuous Glucose Monitoring. 
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4.1 Paper I  
In this feasibility study, we experienced that the computer software largely performed 
as expected, but some minor alterations were performed. Most participants had to be 
shown the location of the computer. Completing the PROMs took a median time of 8 
min 19 sec, and 29 of 69 participants (42.0%) completed the questionnaire without 
missing items, with an average measure completion rate of 81.4%. Furthermore, the 
majority of participants reported that the PROMs were understandable and relevant to 
a large or very large degree, with an acceptable number of items. The participants 
also reported that they valued that the PROMs covered psychosocial aspects of living 
with diabetes. 
4.2 Paper II 
The protocol paper describes the DiaPROM trial design, including a detailed 
description of its different components and our plans for conducting the pilot trial and 
qualitative studies. Further, we describe using the MRC framework in the 
development phase and planning the feasibility and piloting phase before potentially 
evaluating and implementing this new intervention initiative. The included PROMs 
with the process leading up to how we chose the specific instruments are also 
presented. Furthermore, we describe the technical and practical aspects for collecting 
the PROMs electronically, the intervention using the PAID scale in the diabetes 
consultations and the additional nurse follow-up of elevated scores, the control 
procedure and the clinicians’ training. We present the outcome measures and data 
analyses and, finally, discuss key strengths and limitations. 
4.3 Paper III 
In the pilot trial, we found that it was feasible to recruit and randomise 79 young 
adults with T1D attending routine diabetes consultations to a trial using the 
electronically captured PAID to assess diabetes distress and communication 
techniques as dialogue support tools. Overall, the participants found the PROMs 
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relevant and were positive towards electronic completion. Twenty-three of the 39 
(59%) intervention arm participants reported PAID scores that qualified for additional 
follow-up; 17 of these were referred, while five did not want a referral and one was 
not referred by the physician. At 12 months, we were able to retain 67 of the 79 
(84.8%) participants. Further, we performed sample size calculations for a full-scale, 
single-site RCT. However, we identified implementation challenges related to the 
consultations. In addition, 5 of the 17 (29.4%) participants referred to additional 
consultations were lost to follow-up at 12 months. The high attrition rate suggests low 
acceptability or possibly over-inclusion of cases due to our choice of intervention 
criteria. We concluded that the pilot trial revealed design and deliverability problems, 
underlining the need to modify the intervention and perform additional testing before 
initiating a full-scale trial. 
4.4 Paper IV 
We recruited eight young adults from the control arm and 11 from the intervention 
arm, of whom six had attended additional diabetes nurse consultations. All 19 
participants chose telephone interviews (average duration 39 minutes [range 26-75 
minutes]). The thematic analysis of the data generated three themes, each with two 
subthemes. In the theme Follow-up with limitations, the participants shared their 
experiences with diabetes consultations at the outpatient clinic prior to the pilot 
trial (Table 5). In the subtheme Marginal dialogue about everyday challenges, they 
conveyed their perceptions about consultations, especially annual check-ups, that 
predominantly focused on biomedical outcomes without incorporating everyday 
self-management challenges and distress, which was considered negative. While in 
the subtheme Value of supportive relationships and continuity, they described a 
lack of continuity in care that hindered the development of trust-based, supportive 
patient-provider relationships, an important factor regarding their willingness to 
open up to clinicians and engage in conversations about their diabetes challenges. 
The young adults’ experiences with completing PROMs were described in the theme 
New insights and raised awareness. The subtheme More life-oriented insights 
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conveyed that the PAID contributed positively by creating an opportunity for 
reflective thinking about life with diabetes. While in the subtheme Moving out of the 
comfort zone, they shared challenges with completing PROMs and their thoughts 
about disclosing PAID responses in the follow-up. However, they also expressed 
appreciation for how the pilot trial addressed diabetes distress. Finally, in the theme 
Addressing problem areas with an open mind, the interviewees shared experiences 
using the PAID in consultations. The subtheme Need for elaboration depicted how 
completing the questionnaire made them want to disclose reasons for their choice of 
response options to nuance and explain. Further, in the subtheme Preparedness for 
dialogue, they described using the PAID to facilitate dialogue about diabetes-related 
challenges. Intervention arm participants also conveyed experiences with the 
additional follow-up, which suggested that neither they nor the nurses fully engaged 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The overall aim of this thesis was to feasibility and pilot test the DiaPROM trial, 
thereby investigating uncertainties associated with running a full-scale RCT. In this 
section, methodological considerations, strengths and limitations will be discussed 
first, and then the main empirical findings. 
5.1 Methodological considerations 
In this thesis, different study designs tailored to our objectives were applied (179). 
The complexity of conducting the feasibility and pilot testing called for quantitative 
and qualitative methods, thereby increasing the possibility of achieving a broader 
understanding of the intervention initiative (180). While investigating the feasibility 
and acceptability of complex interventions in clinical realities, using both methods 
pragmatically by collecting multiple data types on objective and subjective aspects 
from multiple sources is considered advantageous and necessary (142, 143, 145, 
181). We approached the investigation by first conducting a feasibility study and then 
a pilot trial, evaluating the intervention using quantitative methods. However, since 
humans are inherently complex and diverse, we would probably fail to capture the 
breadth of the feasibility and acceptability issues by using only quantitative methods. 
Consequently, we explored the participants’ experiences and perceptions about the 
intervention’s components using a qualitative approach. Combining deductive and 
inductive modes of reasoning provided empirical findings that complemented each 
other, improving our understanding of pilot trial successes and failures (182). In the 
pilot trial, we discovered that the intervention required modifications and additional 
testing. The specific weaknesses will mainly be discussed in the general discussion. 
5.1.1 Developing a complex intervention 
Developing, testing, evaluating and implementing complex interventions is a lengthy, 
resource-intensive process (142, 181). The updated MRC guidance highlights that 
inadequate development, feasibility testing and piloting will most likely result in 
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poorly designed and delivered interventions, more difficult to evaluate and, therefore, 
less likely implemented (181). 
Intervention development  
To address the knowledge gap regarding PROMs in clinical diabetes practice, we 
initiated the DiaPROM pilot trial development in 2016-2017. During the 
development phase, the project group decided on an intervention focusing on diabetes 
distress and consequently, its aim and the primary outcome was to reduce diabetes 
distress. In this process, user involvement helped us gain insight into patients’ 
perspectives about the follow-up of diabetes-related challenges in general and 
diabetes distress in particular. The users’ contribution in choosing diabetes distress as 
the intervention’s focus and the PROMs to be used aided the development of a 
relevant and appropriate intervention (152). 
Overall, we used validated PROMs found reliable for use among adults with T1D, 
which is important for a future evaluation trial’s internal validity (183). At the time of 
the intervention development and presently (2021), the PAID and DDS were the 
standard self-report instruments for assessing and measuring diabetes distress among 
adults with diabetes (71). Both measures follow the International Society for Quality 
of Life Research’s (ISOQOL) minimum standards for PROMs used in research (184) 
and are free of charge for clinical practice use. A paper comparing the measures 
suggested that the PAID covers a greater variety of emotional concerns than the DDS 
(171). Further, the authors stated that the PAID seemed better suited in the dialogue 
and for achieving targeted, goal-oriented clinical consultations. Hence, we decided on 
using the PAID as a tool to identify distress and as a dialogue tool in the follow-up, 
concentrating on the higher scored items (problem areas). In addition, core aspects of 
patient empowerment were followed, namely, seeking active participation by the 
adults with T1D and a person-centred patient-provider dialogue (185). 
Another challenge was deciding which diabetes distress measure to use as the 
primary outcome measure. We sought guidance in the literature and also consulted 
the health service users. The DDS has demonstrated satisfactory psychometric 
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properties (64, 75, 155, 163), and in addition, it is recommended for research 
purposes as it identifies distress subdomains (171). Thus, we chose the DDS scale as 
the pilot trial’s primary outcome measure. However, the DDS was completed on 
paper as this decision came after the other self-report instruments had been entered 
into the electronic questionnaire. The administration mode may have increased 
missingness since paper-based PROMs are more prone to missing than electronic 
(128-130). Also, most participants completed the DDS after the consultations, which 
may have affected their responses compared to how they replied on the PAID before 
the consultations. Furthermore, numerous distress aspects unique to T1D have been 
identified (70, 93), forming the basis for the development of the T1-DDS (66, 70). 
However, this instrument has yet to be translated to Norwegian. 
In the pilot trial, we decided only to offer face-to-face follow-up. Recently, video 
consultations have become more relevant in healthcare services; however, there was 
no infrastructure for this technology at the hospital at the time of the piloting. 
Nevertheless, providing follow-up by telephone might have improved retention and 
facilitated more intervention consultations (186). Although telephone and video 
consulting are generally considered suitable, studies comparing such consultations 
modes to face-to-face consultations suggest lower quality follow-up as patients 
present fewer problems and clinicians gather less data and perform less counselling 
than in face-to-face consultations (187-189). These findings support the continued 
use of face-to-face follow-up.  
Electronic PROMs 
The high cost of software and hardware is one of the disadvantages of electronic 
PROMs, potentially limiting their use (130). On the other hand, a major benefit is that 
electronic PROMs may be transferred directly to the EPR and health registers. We 
transformed the original paper-based questionnaires into an electronic format. 
According to systematic reviews, electronic PROM scores do not diverge from scores 
obtained from the original paper-based versions (124-127). Nevertheless, certain 
populations may be excluded from responding. In our studies, we might lack 
potentially valuable insight regarding the impact of diabetes on the lives of people 
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who, for various reasons, were unable to complete electronic PROMs. Capturing 
PROMs with assistance could be an option in routine care, but this administration 
mode has been found to produce biased scores towards false positive outcomes 
compared to self-administered PROMs (190). Therefore, paper-based PROMs may 
be a better option unless eyesight is seriously impaired. However, in research, 
striving to use the same data collection method for all respondents would be ideal to 
avoid potential confounding (190).  
In the studies, we have focused on collecting PROMs electronically; therefore, 
limiting our results to people able and familiar with using IT devices. 
Notwithstanding that, digitisation has come a long way in Norway. According to the 
European Commission’s Digital Economy and Society Index for 2018-2020, ~80% of 
Norwegians had at least basic digital skills (51% above basic skills); in addition, 97% 
were internet users, and 90% had submitted electronic government forms (191). This 
indicates that most Norwegians with T1D should be able to complete PROMs 
electronically. In parallel with the DiaPROM pilot trial, a web-based interface has 
also been tested for obtaining PROMs and Patient-Reported Experience Measures 
(PREMs) for the NDR-A (192). Adding a web-based method to in-clinic electronic 
PROM collection appears promising for reaching and accommodating more people 
with diabetes in future research initiatives. 
Biases related to self-report 
In studies relying on self-reported data, there are potential biases or mechanisms 
related to the data collection process and/or the data’s nature, requiring consideration. 
Regarding PROMs, measurement biases that may affect the interpretation of results 
include selective reporting bias, recall bias, social desirability bias and response shift 
(193, 194). Selective reporting bias is linked to patients consciously or unconsciously 
ignoring to report problems they consider unrelated to their illness (193). Biased self-
report might also include positive or negative responses influenced by current mood 
and the tendency to avoid the response scale’s extremes (central tendency bias). 
Whereas recall bias typically depends on the time period the questionnaire asks 
patients to recall. Here, the response is likely to be influenced by the person’s current 
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state of mind. Social desirability bias occurs if the person responds whatever he/she 
considers the most socially appropriate answer (193). Whether deliberate or not, it 
may compromise measurement objectivity. Therefore, in trials, measurement bias 
may increase variability and thereby distort treatment effect estimates and reduce 
statistical power (193, 195). 
Response shift is considered a bias caused by subjective changes in patients’ 
perceptions of a construct over time (194). Not uncommon among patients with 
chronic diseases, the subjective changes can be a consequence of coping or adapting 
to one’s illness and includes changed expectations and new priorities, which may be 
affected by changes in person-specific characteristics. However, in clinical practice, 
one could argue that the patients’ current perception is what matters and encourage 
positive response shifts, although it can obscure assessment of intervention efficacy 
in full-scale trials (193). A related concept, measurement reactivity (or the question-
behaviour effect), occurs when questions answered for research and clinical 
assessment stimulate new thinking about specific behaviours or activities and 
introduce action-taking, resulting in changed behaviour or activity (196). However, 
the overall effects of asking questions on objective and subjective measures of 
behaviour are typically small, with considerable heterogeneity in effects across 
studies (196-198). 
5.1.2 Feasibility and pilot testing a complex intervention 
The feasibility and piloting phase is characterised by small studies that do not test 
hypotheses about intervention efficacy and are not designed with the generalisation of 
findings in mind (142, 143, 181). Thus, the key research questions in the studies 
relate to whether the intervention could be provided as planned and if it was 
acceptable to the target population, i.e. testing individual components (feasibility 
testing) and the entire RCT design with all its components (pilot testing) (199). 
Compared to laboratory experiments, feasibility and pilot work is especially 
important in healthcare research where the complexity present special challenges 
related to, e.g., standardising the design, delivering the intervention, context-specific 
features and potentially organisational difficulties (181). By addressing uncertainties 
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and establishing feasibility, the internal validity of a future full-scale RCT is 
strengthened (145, 146). However, pilot studies often uncover intervention 
weaknesses, revealing the necessity for further feasibility and pilot work. Currently, 
there are no guidelines to help determine how much an intervention can be modified 
before another pilot trial is indicated to establish feasibility and acceptability (145).  
Using quantitative and qualitative methods to investigate feasibility and acceptability 
issues in preparation for a full-scale RCT was a major strength (146, 200). Generating 
rich accounts of the participants’ experiences through interviews alongside the 
quantitative data provided important supplementing information and increased our 
understanding of how the intervention had played out in the context where it had been 
delivered (201). However, in such pilot trials, the experiences and opinions from the 
contributing clinicians’ perspective are also essential (145, 202). Therefore, it can be 
seen as a weakness that only the patients' perspective is included among the studies 
that make up this thesis. The healthcare providers engaged in the pilot trial have been 
interviewed (147), and their experiences have provided important knowledge for the 
implementation of a future full-scale RCT.  
Addressing feasibility using quantitative methods 
We started the DiaPROM feasibility studies by addressing practical and technical 
uncertainties in addition to the patients’ acceptability of the PROMs and the newly 
developed electronic procedure for collecting them. An evaluation of these 
components was necessary to inform the planned pilot trial’s further development and 
execution (199). Therefore, we first performed the feasibility study, a cross-sectional 
study with field observations (203). This work strengthened the proposed evaluation 
trial’s internal validity. The feasibility study was conducted with participants from an 
older age group (≥40 years) than the planned pilot trial intervention to avoid 
depleting the group of eligible pilot trial participants (18-39 years) in this limited 
outpatient clinic population. The pilot trial and the qualitative study’s findings 
suggest that the younger participants corroborated the older participants’ views on 
acceptability and feasibility of completing PROMs, as found in the feasibility study. 
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Also, similar proportions of moderate to high diabetes distress were reported by the 
two study populations. 
Publishing a protocol paper allowed for providing more information and details about 
the pilot trial’s development and the intervention itself than would have been 
permitted in the papers presenting the results. However, one limitation was the lack 
of explicit criteria for progression from the pilot to a full-scale trial, i.e., listing 
specific feasibility criteria, planned interpretation of the criteria and how this analysis 
would inform progression (204). A recent methodological review of pilot RCT 
protocols published in the period 2013-2017 found that insufficient reporting of 
progression criteria was common and only reported by 45/227 protocols (19.8%, 95% 
CI 14.8-25.6) (205). The consequence is that findings may receive a varied 
interpretation. Therefore, the authors called for the development of formal criteria 
guidance (205). Nevertheless, protocol papers can function as control measures 
enabling readers of the final RCT report to evaluate whether the study was carried out 
according to the original plan.  
Although an ideal step to avoid bias, blinding was not an option in the pilot trial since 
the participants and clinicians had to be involved with the intervention (206). 
However, we could have piloted the trial without randomisation (199). Advantages of 
single-arm non-RCT designs are that they are easier to conduct and that larger 
participants numbers are available for intervention as there are no controls (146, 200). 
Further, it is possible to undertake more qualitative explorations if all participants 
have received the intervention. Still, conducting a small-scale version of a full-scale 
trial is recommended when the research objectives are concerned with study 
processes and methodologies such as the randomisation procedure, attrition between 
intervention and control arms, sample size calculations and whether all components 
work collectively (204). However, there is an ethical dilemma within RCTs where 
controls are asked to complete questionnaires and then not offered support and further 
dialogue about their responses (207). Although we could not resolve this dilemma 
within the design, we applied a measure required by the ethics committee; to check 
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their WHO-5 and identify scores suggesting depression (≤28) and report this back to 
the clinicians for further assessment.  
The pilot trial was designed as a single-site trial with patient randomisation where 
participants from both trial arms met the same clinicians. Since we did not monitor 
the consultations’ content, control arm participants may have initiated conversations 
similar to the intervention arm follow-up after being activated by completing 
PROMs. Furthermore, by seeing participants from both trial arms, the clinicians’ 
consulting styles may also inadvertently have affected the control arm consultations. 
Another issue worth considering is how standard ‘standard outpatient care’ is, as the 
conditions are often less defined and monitored than an intervention (208). However, 
patient care within a study is probably often enhanced standard care, dependent on 
the clinics, the clinicians and their relationship with the patients (208). Achieving 
strict standard care without any changed behaviour within the control arm is claimed 
to be virtually unattainable (209). In diabetes care, this is possibly also unethical 
because treatment and care have to be individually adapted. Moreover, patient 
randomised evaluation trials are vulnerable to contamination of the control arm 
through possible intervention ‘leakage’ and thereby open to type II error, 
underestimating the intervention’s true effect size (206). Cluster-level randomisation 
is one alternative for reducing contamination bias (204). However, cluster trials are 
more complicated and resource-intensive and vulnerable to selection bias through 
potential systematic differences between experimental and control clinics, e.g., 
regarding standard care implementation. Nevertheless, in the pilot trial, we 
considered there to be a low risk of contamination since the availability of the PAID 
data drove the intervention consultations, and it was not accessible in the control arm. 
During the pilot trial, we monitored recruitment and retention, checked the 
randomisation procedure’s accuracy and practicality, assessed the feasibility and 
acceptability of the data collection methods, outcomes and the intervention (204). 
However, in order to perform a more comprehensive evaluation and gain more 
understanding about intervention feasibility and acceptability (210), we should have 
investigated fidelity more thoroughly. Fidelity is defined as “the degree to which an 
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intervention was implemented as was intended” (211, p. 233). Keywords for gaining 
a broad picture of fidelity are content, frequency, duration, coverage and timeliness. 
All aspects are important for understanding the specific reason(s) for intervention 
success or failure. In our data collection, we kept logs and quantified consultations, 
thereby covering frequency and timeliness. We planned to record consultations to get 
an overview of exact duration, actual content and coverage, but this was not possible 
to implement at the time. Observations and registration of what goes on in 
consultations can be considered invasive, but maybe also to an extent necessary for 
monitoring whether the intervention is being implemented as planned, thereby 
ensuring protocol fidelity. However, some argue that strict fidelity may be 
inappropriate and that allowing local adjustments may lead to better working 
interventions (181).  
Addressing feasibility using qualitative methods 
Exploring pilot trial participants’ perceptions and experiences with the intervention 
have been valuable. However, the qualitative methods require further exploration. A 
continued, complex discussion of different validation standards in qualitative research 
has resulted in several perspectives with different definitions, descriptions and 
strategies for enhancement and establishment (212, 213). Creswell & Poth describe 
validation as a process rather than a verification of trustworthiness and summarise 
frequently used validation strategies, and offer advice about applying them in studies 
(212), which align with the quality-enhancement strategies outlined by Polit & Beck 
(213). The qualitative data collection, researcher conduct, and analysis methods are 
discussed based on these strategies. 
Data collection 
We chose to perform individual interviews with participants from each trial arm 
because they had somewhat different experiences (control arm, intervention arm with 
or without additional follow-up). Alternatively, we could have organised focus 
groups (214). The group format’s key advantage is that members can react to and 
stimulate each other. However, we aimed for the individual experiences and 
perceptions of the pilot trial intervention; therefore, we chose individual interviews. 
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Overall, telephone interviews are considered valuable for collecting data (215-217). 
Compared to face-to-face interviews, they are less costly and time-efficient, which 
can yield better response rates. Another benefit includes potentially more informal 
interviews that offer privacy and limited distress about talking openly and honestly 
(217). In terms of power dynamics, not seeing the interviewer may have benefitted 
the participants (215). Since nonverbal communication was lost, rapport building was 
challenging (215-217). However, the tone of voice, volume, speed, silence or speech 
pacing, accentuating both the interviewer and participants’ message, was not lost 
(217). Nevertheless, without visual cues, the interviewer experienced being 
challenged in communicating active listening, appreciation and acknowledgement of 
the participants’ experiences (215). At present, the telephone’s limitations may be 
more easily addressed using video conferencing and remote interviewing with visual 
and auditory data. 
In qualitative data collection, the researcher is a key instrument (212). Therefore, it 
could be considered a limitation that the PhD candidate, still a novice with limited 
experience of qualitative methods, conducted the interviews. Conversely, the inside 
knowledge of the intervention may have improved the data collection. The PhD 
candidate had previous experience from the setting but did not know the participants. 
She was conscious about her background and preunderstanding, the part she played in 
the study and how her experience could affect the data collection (214). During the 
piloting phase, she also spent much time in the clinic observing, keeping field notes 
and later reflective notes about the interviews (212, 213). Despite these efforts, her 
background likely shaped her approach to the study and interpretation of the data 
(212). However, clinical experience and knowledge of the context and culture may 
also have aided rapport building, contributing positively to the participants opening 
up about their experiences (212). 
Analysis 
One of the strengths of Braun & Clarke’s thematic analysis is its theoretical 
flexibility (218). We chose to use the analysis method due to its accessibility and 
flexibility regarding research questions, sample sizes and compositions and data 
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collection methods (219). However, thematic analysis has been criticised for its lack 
of a theoretical framework and that it ‘simply’ refers to a process for identifying 
patterns. According to the developers, the critique “relies on the conflation of method 
and methodology, where the former refers to tools for data analysis (as is the case for 
thematic analysis), and the latter refers to broader frameworks for research, which 
more or less predetermine factors like theoretical frameworks, orientation to data, 
modes of data collection” (177, p. 24). Also, the focus on patterns may hinder that 
contradictory accounts among participants are conveyed (218). Nevertheless, 
thematic analysis offers researchers a systematic method for engaging with 
qualitative data and developing a robust analysis without predetermined design 
considerations (177). Our approach for identifying themes or patterns within the 
dataset was data-driven, which is considered useful when exploring new interventions 
or areas. 
Braun & Clarke are known for stating that themes do not emerge from the data; 
themes are derived from an interpretation of a dataset (176). In the qualitative study, 
the analysis collaboration benefitted from the members’ complementary backgrounds 
and experiences, facilitating investigator triangulation (212, 213). Furthermore, three 
of the seven analysis team members were independent of the quantitative studies, 
potentially strengthening the combined researcher credibility by adding an external 
view on the data (213). Transferability was informed through generating thick 
descriptions or detailed information about the data when reporting themes and 
subthemes (212, 213). The illustrative, verbatim quotes also contributed to 
authenticity. In addition, the credibility of our findings was further enhanced by 
relating the themes and subthemes to the existing literature, thereby seeking 
confirming evidence (213). 
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5.2 General discussion 
5.2.1 Assessing and addressing diabetes distress 
Identifying diabetes distress 
The studies that make up this thesis addresses the healthcare service’s outpatient 
follow-up of diabetes distress. In this endeavour, we sought to develop and pilot test 
an intervention to identify and improve diabetes distress among adults with T1D. 
Half of the study participants reported clinically significant diabetes distress levels, 
which is in line with previous research and further suggesting that people with T1D 
still have unmet needs (66, 72, 101, 105, 169, 220). The qualitative findings 
corroborate with results from studies conducted in the Netherlands, which indicated 
that simply monitoring diabetes distress and initiating conversations, where the 
clinician listens to and shows awareness and understanding of diabetes-related 
challenges, can have a beneficial impact on the individual (83, 84). 
The rationale to deviate from the commonly adopted classification of significant 
diabetes distress at PAID scores >40 was based on the literature suggesting that 
milder cases of diabetes distress left unaddressed or untreated may develop into 
severe and even chronic distress and that, therefore, even moderate distress warrants 
exploration and intervention (66, 67). Also, all people with diabetes can profit from 
follow-up where diabetes distress is acknowledged and ‘normalised’ (61). 
Furthermore, identifying a specific distress source or sources by targeting items with 
higher scores is considered beneficial as the focus for intervention, while overall 
distress level is an important generic indicator of distress (66, 71). This line of 
reasoning led us to choose the criteria PAID total score ≥30 or items scored ≥3 for 
referral to the additional follow-up and intervention. Here the ‘red flag’ approach 
(155), the initial identification of problem area(s), was aided by colouring the PAID 
item responses according to the severity. Thereby, the clinicians could more easily 
spot these items in the EPR. 
Living with T1D means being continually warned by one’s vulnerability (62). Having 
to integrate and deal with the intricate diabetes self-management tasks and behaviours 
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in everyday life can be overwhelming (38, 50, 62). Present study findings and 
previous publications highlight the importance of addressing diabetes distress in 
clinical care (61, 62, 70, 71, 84, 93, 102). However, the Norwegian diabetes guideline 
does not cover diabetes distress as a construct (9). In addition to communication, 
coping, and motivation, the guideline focuses on psychological disorders, such as 
depression and anxiety in relation to diabetes, and recommend using a generic PROM 
and diagnostic interviews. Due to the conceptual overlap, stressful experiences of 
living with diabetes may be captured by PROMs meant for detecting symptoms of 
depression (60, 61). However, clinicians and researchers that follow the Norwegian 
guideline (9) may miss out on capturing diabetes distress (49, 61). 
There is no disputing that depression is important for diabetes outcomes due to the 
increased risk for developing complications and higher mortality rates (221, 222). 
Untangling diabetes distress from depression is important to avoid false positives 
pathologising what is considered an expected part of living with diabetes (61, 223). 
Among adults with T1D, depression prevalence varies between 4-12% depending on 
publication and screening method (223, 224). In comparison, seriously elevated 
diabetes distress is found in 20-40% (59, 70). Consequently, to provide proper care 
and follow-up, it is important to distinguish symptoms of depression from diabetes 
distress and identify cases where both are present (62, 81). This can be achieved by 
asking for both constructs, for example, using the PAID and the WHO-5. 
Nevertheless, the personal and societal costs of reducing diabetes-related emotional 
challenges through interventions argue for specifically assessing and addressing 
diabetes distress in routine clinical care (61, 62, 71). 
Diabetes distress interventions 
There have been relatively few trials of interventions aiming to improve emotional or 
psychosocial outcomes in young adults with T1D (225). Additionally, those that have 
been performed are typically found to be of low quality. However, Schmidt and 
colleagues found that diabetes-tailored interventions were effective in improving 
diabetes distress in addition to HbA1c (226). Also, a recent trial reported that affective 
and educational interventions were equally effective in reducing diabetes distress 
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among adults with T1D (227). Specifically, the affective approach was efficient when 
emotion regulation was poor and diabetes knowledge adequate, whereas adequate 
emotion regulation and poor diabetes knowledge favoured the educational approach. 
These findings underline how multifaceted diabetes distress can be and that distress is 
amendable and susceptive to intervention (227). 
In order to compare the effects of different interventions, the selection of trial 
outcomes or core outcome sets is central (228). One of the issues with many trials and 
efforts to collate, synthesise and analyse the findings in systematic reviews and meta-
analyses is the wide range of outcome measures used, except glycaemic control 
measured by HbA1c (207, 228). A core outcome set for studies targeting young adults 
with T1D has now been proposed (229). The set includes measures of diabetes 
distress, diabetes-related quality of life, number of severe hypoglycaemic events and 
instances of ketoacidosis, self-management behaviour, HbA1c, level of clinic 
engagement and perceived level of diabetes control, which are supported by the 
DiaPROM studies’ findings. In addition, the recently proposed standard set of 
PROMs in clinical care may also be valuable for research (87).  
5.2.2 Using PROMs in the consultations 
Our findings suggest that the practical part of capturing the electronic PROMs was 
appropriate and relatively easy to implement once the participants had found the 
touchscreen computer. This is essential since straightforward data collection 
procedures are considered an important reason for study participation (230). Overall, 
the participants found the questionnaires highly relevant and acceptable. The 
qualitative data provided awareness of the participants’ incentives for completing 
PROMs and how the measures prompted them to reflect on their diabetes and 
diabetes-related challenges ahead of the consultations. This finding is supported by a 
realist review indicating that PROMs may help patients identify and focus on issues 
that are important to them (136). Some participants also described acquiring a deeper 
understanding of how T1D affected them, which was mainly appreciated. 
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Although the pilot trial uncovered uncertainty about the planned intervention’s 
deliverability, the initiative was not futile. Both study participants (paper IV) and 
healthcare providers were largely positive about the structured focus on diabetes 
distress (147). Thus, the PAID was deemed purposeful and appropriate for the 
context (231). The young adults generally described that using the PAID was 
valuable because it directed the dialogue towards exploring and discussing diabetes-
related problem areas, thereby targeting and structuring the consultations. Also 
resonating with the findings of a recent systematic review (232), the participants 
reported that the clinicians’ understanding of their diabetes-related concerns and 
needs was improved. Importantly, the PAID ‘permitted’ and enabled them to raise 
diabetes-related problems with the clinicians, signalling that diabetes distress was 
appropriate to address during the consultations. 
The participants conveyed that completing the PROMs could be emotionally difficult. 
Therefore, it is important to keep in mind that completing questionnaires is more than 
information retrieval (136). The interview data provided insights into how the 
participants were affected by completing the PAID and how they experienced a need 
to elaborate on their responses. With this in mind, using the ‘red flag’ approach to 
specifically focus on the problematic PAID items (155) was supported. By using 
solely total scores as criteria for intervention and dialogue, we would have risked 
losing the various problem areas’ descriptive richness, in themselves worthy of 
exploration (118). A single item response can reveal important issues about the 
respondent’s experience of diabetes-related problems that can be missed by focusing 
on the total score (118). Further, the participants’ reports of moving out of the 
comfort zone yet benefitting with new insights reinforce the previously identified 
importance of progressing beyond biomedical outcomes in consultations involving 
people with T1D (47, 93, 101, 105). 
According to the qualitative findings, PROM responses, or at least how specific items 
were answered, may have been affected by various circumstances, thereby resulting 
in somewhat biased self-reports (193). Hence, scores should be interpreted 
cautiously. As previously suggested, the electronic administration mode did not seem 
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to play a part in this (124-127). Rather, the participants’ motives for selective 
reporting appeared related to previous experiences with the follow-up, which many 
found unsatisfactory in terms of continuity and patient-provider relationships, and 
intrinsic factors such as not being completely honest with oneself. However, 
numerous forms of bias can influence questionnaires, such as the patient’s current 
mood, personal impression of health, inclinations to provide either positive or 
negative responses, understating or overstating severity, social desirability issues and 
the tendency to avoid the extremes of the response scale (193). Whether using a 
PROM or engaging in an ordinary, clinical conversation, clinicians must respect that 
patients may choose not to be completely honest about how they are doing. They 
must work towards earning the patients’ confidence (103, 105). In the pilot trial 
setting, the healthcare providers shared experiences of conflicting demands and 
priorities in their daily work, particularly related to balancing both biomedical 
assessments recommended by the diabetes guideline and the individual patient’s 
specific challenges and concerns (147). This challenge may have contributed to what 
the young adults perceived as insufficient follow-up with an excessive focus on 
biomedical measures. Regardless, our study findings suggest that it is important not 
to view the PAID responses as ‘final truths’ about how the patients feel, but rather as 
starting points for dialogue and relationship building, further supporting the 
empowerment process. 
Empowerment and person-centred communication 
In current and previous studies, we have found that one of the healthcare services’ 
main challenges is to organise adult T1D follow-up in a manner that ensures adequate 
person-centred support with continuity of care and allows patient-provider 
relationship building (105, 147). Although people with diabetes are expected to 
actively interact with the healthcare services, lack of individualised care can hinder 
young adults with diabetes in bringing up problems areas in clinical encounters (93). 
For healthcare providers, person-centredness is required for understanding the 
individual patient’s rationale for maintaining or improving self-management 
behaviours. Working towards treating the patient as a unique person with biological, 
psychological and social dimensions, demonstrating empathy, compassion, dignity 
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and respect are critical communication strategies (185). As part of individualised 
diabetes follow-up, routinely screening for diabetes distress and addressing the 
identified problem areas are clearly indicated and called for (89). Here, 
empowerment, advocating clarification of what the individual finds important to 
address, can guide person-centred and collaborative clinical encounters towards 
optimising people with diabetes’ self-management, health outcomes and quality of 
life (89, 185).  
Combined evidence supports using PROMs to enhance person-centred and 
collaborative communication in clinical settings (122, 233, 234). Also, our study 
findings were in part confirmatory of previous research papers reporting T1D adults’ 
wishes for continuity of care to build therapeutic relationships with healthcare 
providers (47, 50, 101, 102, 105). The combination of perception of low follow-up 
value, lack of relevance and patient-provider relationships has previously been 
highlighted as key reasons for dissatisfaction and clinic non-attendance among 
younger adults with T1D (99, 100) and should therefore be taken seriously. However, 
via a systematic collection of information and communication about everyday life 
impact and emotional burden of T1D, the DiaPROM intervention aided the clinicians 
to offer attentive, personalised support to the pilot trial participants, which is in line 
with patient empowerment and person-centredness (115, 134, 185). Further, by 
allowing the participants’ concerns a voice, the intervention possibly influenced the 
power balance in the patient-provider relationship and made the consultations more 
personal and relevant for the participants, which also resonates with previous research 
(136, 233).  
5.2.3 Challenges related to implementing the intervention 
Participant-related challenges 
Performing an intervention study in clinical practice is challenging. In the recruitment 
for the feasibility study and the pilot trial, 18% of the eligible participants did not 
attend their appointments and were consequently not recruited; further, 15% of those 
attending declined participation. Due to the complex intervention’s nature, recruiting 
and retaining participants is especially demanding (235). Potential consequences of 
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suboptimal trial recruitment and retention are unrepresentative sampling, 
underpowered and inconclusive studies, delays and higher expenses. Enrolling and 
retaining participants is inevitably more challenging if the intervention requires a lot 
from them compared to a ‘simpler’ intervention. Therefore, trials should ideally be 
designed as simple as possible (235). Since we do not know whether the pilot trial 
participants were representative of the outpatient clinic population, this could have 
led to selection bias and a threat to internal validity (183). However, in the pilot trial, 
we were only allowed by the ethics committee to analyse differences in sex, age, 
diabetes duration and HbA1c between participants and those who declined. The only 
difference found was that the latter group had a longer diabetes duration.  
Regarding other recruitment procedures, relying on posted letters to contact eligible 
participants and informing them about the studies was not particularly successful. 
Efficient recruitment and PROM collection were more or less contingent on the 
presence of a person at the outpatient clinic who could provide information and 
support. However, the recruitment issues did not appear related to a lack of perceived 
relevance of the project, a common reason for non-participation (230); rather, the 
participants had not read the information or forgot about it. In retrospect, one option 
could have been to send reminders by SMS to the feasibility study and pilot trial 
participants (235) like we did while recruiting participants for the interviews. 
However, that would have required additional resources. The recruitment rates may 
also have been improved if the user group had been involved in developing the 
written information and consulting on the recruitment procedures (151). Although 
user involvement cannot solve all recruitment problems, it is important to extend its 
application to increase implementation chances, reduce costs and enhance study 
validity (236). 
In the pilot trial, 67 of the 79 participants were retained at 12 months, which meant an 
attrition rate of 15.2%. Attrition or loss to follow-up rates of 20% are commonly 
expected in trials (235). However, the rates also differed between the trial arms and 
within the intervention arm, suggesting attrition bias (237). The 29.4% attrition 
among those referred to additional follow-up was a major concern. Compared to the 
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control arm’s attrition (10.0%) and among the intervention arm participants with 
lower PAID scores (20.5%), this suggested that participants with higher distress 
scores were more likely lost to follow-up. In general, it is challenging to reach the 
patients with what appears to be the greatest need for follow-up to attend 
consultations and participate in studies. Either they can refrain from participating in 
the first place (155), or, when recruited, those reporting problems suggesting the most 
need for support seem more likely to drop out (169). If a full-scale trial failed to 
achieve sufficient retention, the study would be inconclusive since it would be too 
small to detect effect sizes. A differential loss to follow-up between trial arms would 
be considered a potential confounder and a threat to internal validity (235). Attrition 
also has a cost since trials consistently compensate for participant dropping out by 
increasing the number of invited participants. 
We do not know why the participants lost to follow-up dropped out during the pilot 
trial. Investigating reasons for non-attendance and loss to follow-up usually provide 
important insights (209). A recent meta-ethnographic synthesis of studies reporting 
reasons for trial dropout highlighted the significance of participants’ opinions of 
whether the intervention was sufficiently tailored and helpful (186). Although the 
pilot trial participants lost to follow-up did not share their opinions or reasons, the 
general feedback was that the additional nurse consultations’ usefulness was 
moderate. Furthermore, participation may have been too burdensome for some, as it 
involved attending additional outpatient clinic visits. Participant burden is a common 
problem for complex interventions (145). Specifically, the participants were asked to 
come to the clinic 15 minutes before their scheduled appointment at two annual 
check-ups to complete PROMs and potentially see a diabetes specialist nurse at least 
twice over three months. Completing PROMs and being asked to talk about one’s 
challenges diverged from the follow-up many were accustomed to; however, among 
those receiving the physicians’ PAID review and discussion, this seemed sufficient 
on many occasions. Thus, they did not require additional follow-up, which may 
partially explain non-attendance or postponing appointments. There is also the 
possibility of over-inclusion of cases due to the choice of PAID scores for referral. 
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Hence, the intervention’s follow-up eligibility criteria are one of the measures that 
require more consideration before a full-scale evaluation trial (146). 
The interviewed participants described not preparing for the nurse follow-up 
consultations. Engaging trial participants is a known challenge (209). Since full 
fidelity examination was not performed, e.g., recording consultations, we cannot say 
whether the young adults or the nurses led the dialogue into other areas. We can only 
rely on the interviews and the EPR notes. However, if the consultations had been 
recorded, the nurses and participants could have felt compelled to follow the protocol, 
potentially contributing to an unnatural atmosphere and time and resource misuse. 
Some claim that seeing familiar healthcare providers improve protocol fidelity and 
attrition (209). Present and previous findings suggest that familiarity is not sufficient 
and that it depends on the relationship’s quality (99, 105). When developing and 
performing intervention studies in a clinical setting, known barriers to clinic 
attendance must be acknowledged, such as logistical issues and the perceived value 
of attending (99, 100). In the pilot trial, the additional follow-up could perhaps have 
been more flexible by allowing the individual more involvement in deciding what 
follow-up (s)he needed. This was partially fulfilled by facilitating an individualised 
number of nurse consultations. Nevertheless, the participants’ experiences culminated 
in them not finding the intervention sufficiently useful. Whether this was related to 
their engagement with the intervention, excessive burden or lack of flexibility, or a 
combination of these, is still uncertain. 
Communication-related challenges 
In the interviews, the young adults characterised previous annual check-ups as ‘sitting 
for an exam’ where clinicians ‘wagged a finger’ to signal that their diabetes outcomes 
were poor. Although this kind of provider interaction may have been unintentional, 
patient-provider communication is considered the most important factor affecting 
diabetes self-management (238). The language used by diabetes healthcare providers 
is increasingly recognised as not always helping people with diabetes (238-240). The 
pilot trial participants also conveyed that the focus on poor or suboptimal glycaemic 
control (HbA1c) elicited feelings of failure. Adding unfortunate language in such 
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situations can trigger reduced self-management commitment and satisfaction with 
care, adverse clinical outcomes and stigma (239, 240). Therefore, striving to 
understand the patients’ life circumstances and perspectives that affect self-
management and health outcomes through respectful, strengths-based and inclusive 
language is essential for promoting collaboration and person-centredness (240).  
The healthcare providers engaged in the pilot trial reported concern with identifying 
problems that they could not deal with themselves as a barrier to implementing 
routine diabetes distress assessment (147). In patient care, asking, listening and 
acknowledging is an essential intervention in itself. The first steps towards 
understanding what we do not know start with the healthcare providers showing an 
interest in the persons with T1D, inviting them to talk about diabetes-related 
problems, listening intently to their experiences (‘with the ears turned on’) and 
supporting them (47). Although this may sound straightforward, previous research 
indicates that it is somewhat more difficult in real-life clinical settings (101, 105). 
Diabetes treatment and follow-up present unique challenges for healthcare providers. 
Therefore, it is important to acknowledge that it can be stressful to work with people 
with a chronic disease where so much of the treatment depends on self-management 
(241). Providers worry about patient outcomes, limitations of time or resources to 
provide care and feel responsible for health outcomes (242). They are challenged to 
deliver person-centred care and recommended medical treatment, balance personal 
closeness and professional distance, and concurrently develop and strengthen their 
professional expertise (241).  
Clinic-related challenges 
The DiaPROM intervention was designed for implementation in a clinical setting 
without requiring extensive logistical changes. The touchscreen computer and the 
software were made available to the clinic without costs, but we relied on the clinic to 
provide clinicians for the consultations. A minimum of three consultations was 
planned in the protocol: the initial review and discussion of scores with the physician 
at baseline and two sessions with a diabetes nurse specialist. After the piloting, it 
became clear that the intervention was not carried out per protocol. The clinic mostly 
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offered the first nurse consultations in time (within 19-35 days), but many were 
rescheduled either by the clinic or by the participants and therefore performed within 
22-123 days. For some, this meant that the waiting time from PROM completion to 
the additional consultation was much longer than recommended (71, 168). Similar 
cancelling or rescheduling tendencies were observed for the second nurse 
consultations and the 12-month follow-up.  
Although much effort was put into intervention development, the pilot trial 
implementation strategy appeared insufficient. The project was initiated outside the 
clinic but with its leaders’ support and cooperation. Nevertheless, the project lacked 
local ownership, potentially contributing to the fidelity issues (211). Furthermore, the 
clinicians described challenges with the interdisciplinary teamwork, and that work-
related resource challenges hindered them in facilitating new interventions to enhance 
care quality (147). Though there was enthusiasm about the project, it seemed 
challenging for the leaders to set aside sufficient resources. Therefore, more time 
regarding organisational barriers, ambivalence towards using PROMs and preparing 
the clinic to take ownership of the project should probably have been invested to 
facilitate intervention implementation and fidelity (202, 211, 243).  
One in 5 intervention arm participants reported that the physicians did not discuss 
their PAID scores at baseline. Also, one in 4 nurse consultations was not performed 
per protocol, according to the EPR notes. In clinical practice, ensuring optimal 
engagement from those providing the intervention is challenging (209). Variation in 
how and if the clinicians applied the PAID as instructed possibly depended on their 
engagement and attitudes towards the questionnaire (123, 202). Also, since some did 
not go into the problems identified, the participants’ expectations may have been 
unmet (233). However, we did not observe these consultations; therefore, not 
following the protocol may have been justified, although there was no documentation 
of reasons for straying from the instructions.  
According to the interviewed participants, the nurses did not seem sufficiently 
prepared for the dialogue about diabetes distress. The five nurses had diabetes 
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specialist education and 15-33 years of work experience in the diabetes field (147). 
All had previously undertaken extensive training in person-centred communication as 
part of a guided self-determination trial performed at the clinic (169, 244). Before the 
piloting commenced, the nurses were provided specific training and written study 
material (Appendix 7), which we made sure was available to them at the clinic. The 
practical framework conditions for providing the intervention was in place, and later, 
the nurses have described being positive about the dialogue tools (147). Regardless, 
we may have relied too much on their previous experiences and not provided enough 
support and motivation throughout the piloting.  
In retrospect, we may have failed to sufficiently engage the clinicians in the 
intervention’s development phase. Appropriate and sufficient training of the 
intervention providers is a common problem in complex interventions (145, 245). 
Perhaps too many providers were involved in the piloting. First, it was challenging to 
gather and follow the 16 physicians and five nurses (147). Fewer physicians and 
nurses would have been easier to follow and support. However, reducing the number 
of providers by solely inviting people with T1D to attend follow-up with a limited 
group of physicians would entail practical, organisational, ethical and methodological 
issues. Secondly, many providers carried out few consultations and therefore attained 
limited experience, which may have increased heterogeneity in the intervention 
delivery (246). Nevertheless, their training should probably have been more 
comprehensive as implementing PROMs in consultations is challenging (245). In 
future work, we must consider flexible training options that support knowledge and 
experience exchange (245). Facilitation and adaption of the clinicians’ training and 
guidance and support during the trial are essential for successfully engaging them in 
using the PROMs in consultations and, consequently, implementing and evaluating a 
full-scale RCT (119, 202, 233). 
Healthcare providers in diabetes care are, to an extent, governed by guidelines and 
performance measures (9, 147). Hence, it may be difficult for them to prioritise care 
aspects not explicitly covered by the governing documents and measures while 
balancing the patients’ and healthcare service’s expectations. Perhaps we need to 
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define specific emotional and psychosocial support measures in the EPRs, 
performance measures and health registries to ensure increased attention and follow-
up in clinical practice (247). Nevertheless, our combined study findings suggest that 
the intervention helped healthcare providers gather information about diabetes 
distress that they otherwise would have had to acquire verbally, thereby saving time 
and possibly facilitating conversations that might not otherwise have occurred. Also, 
our experiences have informed a modified intervention study currently being 
undertaken at Haraldsplass Deaconess Hospital, which uses the PAID as one of its 
intervention components (Cristin-project ID: 2077355). The results from this study 






The combined findings of the studies constituting this thesis highlight the value of 
combining quantitative and qualitative methods in feasibility and pilot testing to 
uncover factors that may impede effective interventions in clinical practice. 
Capturing electronic PROMs was technically feasible and generally well accepted by 
the participants. Although they found it somewhat uncomfortable and challenging to 
disclose their diabetes-related problem areas, addressing diabetes distress as part of 
the consultations was considered highly relevant and important for future diabetes 
follow-up. Using the PAID helped the healthcare providers see beyond biomedical 
outcomes, which promoted patient empowerment and person-centred care and 
facilitated improved patient-provider relationships.  
However, we decided not to proceed directly to a full-scale evaluation trial. This 
decision was based on findings indicating attrition, fidelity issues related to 
implementation and low acceptance or over-inclusion of cases, suggesting that the 
intervention requires additional development. Consequently, before commencing a 
full-scale RCT, the intervention requires modifications and additional development 
and possibly further feasibility and acceptability testing, focusing on inclusion 
criteria, intervention flexibility and healthcare provider training, specifically using the 
PAID in the patient-provider interaction. 
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7. Implications and future perspectives 
7.1 Clinical practice 
The studies that make up this thesis were not designed to evaluate the effect of the 
DiaPROM’s intervention. Potential clinical implications are therefore not clear. 
Nevertheless, as half of the study participants reported clinically significant diabetes 
distress levels, the healthcare services should aim to reduce diabetes distress 
negatively affecting the everyday lives of adults with T1D. However, the current 
Norwegian diabetes guideline does not specifically cover diabetes distress as a 
construct (9). The main argument for addressing diabetes distress routinely as an 
integral part of diabetes care by diabetes healthcare providers is that diabetes distress 
is intertwined with diabetes self-management and, as a result, a prerequisite for 
optimal diabetes treatment and health outcomes (71, 90, 168). Therefore, assessment 
of diabetes distress should be integrated into new guideline updates.  
In diabetes care, clinicians must remember the dynamics of diabetes; the constant 
challenge to make healthy choices that have short-term and long-term consequences 
while at the same time achieving satisfactory quality of life here and now (248). 
Although biomedical measures, such as HbA1c, BMI, blood pressure and urine 
albumin levels, are undeniably vital for the health of people with diabetes, the 
measures do not necessarily reflect aspects considered most important in everyday 
life (53, 101). Our study findings suggest that by systematically targeting diabetes-
related problem areas, clinicians’ attentiveness to the personal experience of living 
with diabetes may increase and facilitate more discussion of diabetes-related issues 
not directly linked to biomedicine; however, possibly affecting biomedical and other 
health outcomes. 
People with diabetes receive healthcare services from different clinicians often 
organised in multidisciplinary teams. Discussions about diabetes distress may require 
a shift in clinicians’ perceptions of what lies within their responsibility to address 
during consultations (119). Nevertheless, clinicians need to work out what people 
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with diabetes that attend outpatient clinics find important to facilitate health outcome 
improvements (249). In addition to gathering biomedical measures, clinicians should 
elicit people with diabetes’ agendas, needs and wishes for the follow-up and ask them 
about everyday life and self-management struggles; here, PROMs can be particularly 
helpful. 
Capturing PROMs electronically and feeding the data into the EPR relieved much of 
the workload and logistics compared to using paper-based questionnaires. Also, 
adding web-based methods to in-clinic electronic collection appears promising for 
reaching and accommodating more people with diabetes in the future. When 
successfully implemented, PROMs may have the potential to improve the quality of 
diabetes care by increasing the focus on challenges that people with diabetes find 
important. It has been proclaimed that “what gets measured, gets done”, consequently 
suggesting that what is not measured is not done (247). This may also apply to using 
PROMs in clinical practice; care may be improved by identifying more of those who 
otherwise go under the clinicians’ radar. PROMs also may facilitate understanding 
and better communication. Electronic systems for self-report of other health 
outcomes ahead of consultations, e.g., smoking habits, physical activity, glucose 
readings, medication and insulin dosage, may reduce time spent on biomedical 
checklists and, thereby, free time so that the patients can address issues that are 
important to them. 
7.2 Further research 
Based on the studies that constitute this thesis, new questions have emerged that call 
for further research. Intervention studies using PROMs to assess, address and 
improve diabetes distress are still needed. In a full-scale DiaPROM RCT, we should 
consider conducting it as a multicentre trial to compensate for small sample sizes and 
allow for comparing the use of PROMs in different outpatient clinics with contextual 
factors potentially influencing follow-up. Furthermore, feasibility and pilot testing of 
the use of PROMs in clinical consultations among people with T1D of non-
Norwegian origin and people with T2D is also warranted.  
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In the feasibility study and the pilot trial, participant engagement appeared low at 
recruitment. Therefore, qualitative studies to further explore attrition rates are 
warranted. Furthermore, half of the study participants reported clinically significant 
diabetes distress levels. Hence, using PROM data from the NDR-A, prospective 
studies should be conducted to extend the knowledge on national diabetes distress 
prevalence. Such population-based studies also allow for examining diabetes distress 
and its association with other health-related outcomes and may increase our 
understanding of disease burden. 
In the qualitative study, some participants conveyed dissatisfaction with regular 
outpatient consultations, especially the focus on biomedical outcome measures. This 
finding should be further investigated in cross-sectional studies across the total 
population of outpatient clinics. In addition, using focus groups to explore and 
understand this matter further can be useful to gain more insight into patient-provider 
communication and outpatient follow-up. Following this line of inquiry, research on 
training diabetes clinicians in addressing diabetes distress and using dialogue tools at 
a competent level is needed, e.g., studies regarding effective modes for training, be it 
web-based programs or peer-support groups. Through interviews and/or surveys, we 
can investigate what clinicians need to assist them in using dialogue tools. Involving 
people with diabetes and healthcare providers in observational studies and qualitative 
studies could further investigate how dialogue tools can support patient-provider 
communication, patient empowerment and person-centred care.  
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Abstract
Background: Living with type 1 diabetes (T1D) is demanding, and emotional problems may impair ability for
diabetes self-management. Thus, diabetes guidelines recommend regular assessment of such problems. Using
patient-reported outcome measures (PROMs) to assess diabetes-related distress and psychological well-being is
considered useful. It has been proposed that future work should examine the use of PROMs to support the care of
individual patients and improve the quality of health services. To our knowledge, the use of PROMs has not been
systematically evaluated in diabetes care services in Norway. Electronically captured PROMs can be directly
incorporated into electronic patient records. Thus, the study’s overall aim was to examine the feasibility and
acceptability of capturing PROMs electronically on a touchscreen computer in clinical diabetes practice.
Methods: Adults with T1D age ≥ 40 years completed PROMs on a touchscreen computer at Haukeland University
Hospital’s diabetes outpatient clinic. We included 46 items related to diabetes-related distress, self-perceived
diabetes competence, awareness of hypoglycaemia, occurrence of hyperglycaemia, hypoglycaemia and fluctuating
glucose levels, routines for glucose monitoring, general well-being and health-related quality of life. Participants
subsequently completed a paper-based questionnaire regarding comprehension and relevance of the PROMs,
acceptance of the number of items and willingness to complete electronic PROMs annually. We wrote field notes
in the outpatient clinic based on observations and comments from the invited participants.
Results: During spring 2017, 69 participants (50.7% men), age 40 to 74 years, were recruited. Generally, the touchscreen
computer functioned well technically. Median time spent completing the PROMs was 8min 19 s. Twenty-nine (42.0%)
participants completed the PROMs without missing items, with an 81.4% average instrument completion rate. Participants
reported that the PROMs were comprehensible (n= 62) and relevant (n= 46) to a large or very large degree, with an
acceptable number of items (n = 51). Moreover, 54 were willing to complete PROMs annually. Participants commented
that the focus on living with diabetes was valued.
Conclusions: Capturing PROMs on a touchscreen computer in an outpatient clinic was technically and practically
feasible. The participants found the PROMs to be relevant and acceptable with a manageable number of items, and
reported willingness to complete PROMs annually.
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Routine assessment, Diabetes-related distress, Psychological well-being
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Background
Living with type 1 diabetes (T1D) is demanding. The
condition requires lifelong insulin therapy and constant
attention to complex self-management tasks. Among
adults with T1D, more than half do not reach recom-
mended treatment goals for glycaemic control [1–3].
Although this could be explained by improper treat-
ment regimen, psychological and psychosocial aspects
may be significant barriers for diabetes self-management
and glycaemic control [4–6]. Consequently, several dia-
betes guidelines recommend regular assessment of
psychological well-being and diabetes-related distress in
people with diabetes [7–9]. Although essential in recogni-
tion of individual needs [10, 11], psychological and psy-
chosocial aspects are greatly underreported in clinical care
[6, 12, 13].
Patient-reported outcome measures (PROMs) have
been developed to assess patients’ perceptions of living
with a condition and its impact on health status,
health-related quality of life and/or other health-related
constructs [14, 15]. PROMs are used in clinical trials to
assess the effect of interventions on health-related
outcomes, but are also useful in enabling patients with
chronic conditions to raise or share concerns with
healthcare providers in clinical consultations [16].
PROMs are typically self-administered and can be ad-
ministered on paper or by electronic devices, either in
the patient’s home or at the clinic [17–19]. Transferring
paper-based instruments to electronic interfaces may
produce data with psychometric equivalence as long as
substantive content alterations are not made [18, 20, 21].
Compared to paper-based PROMs, electronic systems
have potential benefits such as reducing missing and un-
usable data by not allowing people to continue registra-
tion without completing all items, and only allowing one
response option per item [19, 22]. Some claim scoring
on paper is more time consuming compared to elec-
tronic scoring [23]. While the logistics of entering paper
data into the electronic patient records (EPR) raise
questions regarding responsibility for the data entry,
electronically captured PROMs can be directly incorpo-
rated into the EPR resulting in less administrative bur-
den [16, 19, 22]. In recent years, the use of self-report
instruments to monitor quality of care has increased,
with data also being fed into medical quality registers
[16]. It has been proposed that future work should
examine the use of PROMs to support the care of indi-
vidual patients and at the same time improve the qual-
ity of health services [14, 24].
To our knowledge, the use of PROMs has not been
systematically evaluated in diabetes care services in
Norway. In accordance with the UK Medical Research
Council’s framework for researching complex interven-
tions [25, 26], we have therefore designed the DiaPROM
trial (ClinicalTrials.gov ID: NCT03471104) for people
with type 1 diabetes, where electronically captured
PROMs will be used to identify individual needs and
promote goal-oriented clinical diabetes consultations.
The findings of the present feasibility study will inform a
pilot randomised controlled trial (RCT).
Methods
Aim
The overall aim of the present study was to examine the
feasibility and acceptability of capturing PROMs elec-
tronically on a touchscreen computer in clinical diabetes
practice.
Our specific objectives were:
1. To evaluate our proposed recruitment strategy by
estimating the proportion of eligible participants
who consent to participate.
2. To examine the feasibility of the technical and
practical procedures for collecting PROMs on a
touchscreen computer in the outpatient clinic.
3. To assess the participants’ perceptions about the
PROMs used, including their comprehension of
items, acceptability of number of items, relevance of
items and willingness to complete electronic
PROMs at their future annual clinical consultations.
Design
We undertook an uncontrolled feasibility study using
cross-sectional data and field observations to examine
crucial elements of a subsequent pilot RCT.
Setting and participants
The study was conducted at Haukeland University Hos-
pital in Western Norway covering about one million in-
habitants including both rural and urban areas. We
recruited participants with T1D aged ≥ 40 years during
6 weeks from April to June 2017. The reason for choos-
ing this age group was to not include potential partici-
pants for the coming pilot RCT, which is planned for
young adults < 40 years [27]. We identified eligible par-
ticipants from the endocrinology outpatient clinic’s
planned consultations. Approximately 1 week prior to
the consultations, administrative staff sent a written in-
formation and consent form by postal mail inviting eli-
gible participants to take part in the study. We asked the
patients to come to the hospital at least 10 min before
the scheduled consultation. People who were unable to
read or complete the PROMs on the touchscreen com-
puter were excluded. Furthermore, we did not invite pa-
tients with the following conditions recorded in their
medical records: cognitive deficiency (e.g. Down’s syn-
drome, Alzheimer), severe medical comorbidity (e.g.
end-stage renal disease, severe heart failure, severe
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cancer), and/or a major psychiatric diagnosis (e.g. severe
depression or bipolar disorder, schizophrenia) as the
burden to complete PROMs might be too challenging.
Data collection
Sample characteristics
We collected the following sociodemographic and
diabetes-related information from the participants’ EPR:
age, sex, ethnicity, diabetes type, diabetes duration, dia-
betes long-term complications, glycosylated haemoglo-
bin (HbA1c) level and insulin injection device. We also
obtained self-report data on first language, current edu-
cational level, marital/cohabitation status and work affili-
ation. In addition, the ethical committee permitted us to
register age and sex of those who declined participation,
using the EPR’s patient administration system.
Recruitment
We recorded the number of eligible participants who
were invited to participate, number of people who
attended consultations, and number of people who
agreed to participate. In addition, we observed whether
eligible participants approached the touchscreen com-
puter by themselves or if they needed a reminder from a
project member (IH, RBS or AH), who were present in
the waiting area during the recruitment period.
Technical and practical procedures for collecting PROMs
The touchscreen computer (17″ screen) was placed in-
side a metal cabinet (kiosk). We gathered data on the
technical and practical performance of the computer
and observed participants’ ability to complete the
PROMs. The leading supplier of eHealth systems to
Norwegian hospitals, DIPS AS [28], developed the tech-
nical application which included the software for
completing the PROMs, a secure data repository for
temporary PROMs data storage and the method for
transferring the PROMs data to the participants’
diabetes-specific health records. This diabetes-specific
record is also the Norwegian Diabetes Register for
Adults’ electronic tool for collecting register data from
outpatient clinics [29]. We used the hospital’s wireless
local area network (WLAN) and a USB dongle to boost
connectivity. The kiosk was situated next to the out-
patient clinic’s waiting area to ensure visibility. “Ques-
tions for people with diabetes” was displayed on the
screen and a poster with information was placed next to
the screen. By tapping the screen, information concern-
ing the data collection procedure and the measured con-
structs were displayed, and the PROMs appeared one
item at a time. Respondents could either tap “next” or
wait 2 s for the computer to automatically continue to
the next item. In addition, respondents could also tap
“back” to review or change their previous responses. On
the top of the screen, a row of small boxes signalled how
many of the items were responded to and the number
left to complete.
The software utilised time stamps to track time needed
(minutes and seconds) for completing the PROMs. Par-
ticipants were not required to log in using personal
identification; instead, the application generated a
four-character code with a mix of letters (A–Z, except I
and O) and numbers (1–9) for each session. Participants
were instructed to write down their unique code on a
paper form placed next to the computer and to bring
this form to the consultation. The code was then used to
download the PROM data from the secure data reposi-
tory to the diabetes-specific records.
Instruments and participants’ perceptions about the PROMs
We used the Problem Areas in Diabetes scale (PAID) to
assess diabetes-related distress related to living with
diabetes and its treatment [30–32]. This instrument is
considered appropriate in achieving therapeutic and
goal-oriented consultations [33, 34]. We used the
Perceived Competence for Diabetes Scale (PCDS) to map
self-perceived ability for diabetes self-management [35,
36], and “The Gold” scale to assess awareness of
hypoglycaemia [37]. In addition, we developed three ques-
tions asking the participants to assess self-perceived occur-
rence of hyperglycaemia, hypoglycaemia and fluctuating
glucose levels over the latest couple of weeks. Further-
more, we included the World Health Organization 5-
Well-Being Index (WHO-5), a generic measure for psy-
chological well-being [38, 39], and the RAND-12 Health
Status Inventory (RAND-12) to assess health-related qual-
ity of life [40, 41]. Finally, we added items related to the
use of glucose monitoring devices and frequency of glu-
cose measurements. In total, 47 items were included in
the questionnaire. A description of the included PROMs is
shown in Additional file 1. Acceptable psychometric prop-
erties have been reported for the PAID [42], the PCDS
[43], “the Gold” [37], the WHO-5 [39], and the RAND-12
[40]. Cronbach alphas in the present study were PAID
0.94, PCDS 0.94, WHO-5 0.84, and RAND-12 0.89.
The PROMs were originally developed for paper-based
administration, with an introductory sentence preceding
all items. In our electronic versions, one item appeared
at a time, thus the introductory sentences were adapted
and placed directly above all items to avoid respondents
having to scroll back and forth to read this information.
We did not alter the wording of any items or response
options. However, for the response options to fit the
screen, we had to alter the layout from horizontal to ver-
tical positioning for all instruments, except “the Gold”.
In addition, we added “unanswered” as the default re-
sponse option for all items, allowing participants to skip
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a question and proceed to the next one, and it was only
possible to choose one response option per item.
The participants also responded to a paper-based
questionnaire concerning their perceptions about the
PROMs. The questionnaire comprised questions regard-
ing comprehension, perceived relevance, and acceptance
of the number of items included in the PROMs. Finally,
we asked about participants’ willingness to complete
electronic PROMs annually. We looked to the Norwe-
gian Institute of Public Health’s user experience ques-
tionnaires for item wording and response alternatives
[44]. Finally, we added space for individual written feed-
back and encouraged the participants to comment on
the procedures, the included items and scales in their
own words. In addition, the project member present in
the clinic was available if any of the participants pre-
ferred to share opinions verbally. We wrote field notes
based on observations and comments from participants
and those who were invited to participate but declined.
Analysis
We used Stata SE 15 for Windows for all statistical ana-
lyses [45]. We applied descriptive statistics for demo-
graphic characteristics. In order to estimate the
proportion of participants who would meet the inclusion
criteria for the planned pilot RCT [46], we calculated the
proportion of participants with single-item PAID scores
≥ 3 or total scores ≥ 30. Prior to analyses, we substituted
missing PAID items by participants’ mean score if mini-
mum 18 (of 20) items were completed [47, 48]. Further-
more, we examined differences between male and female
participants regarding total PAID scores, PAID ≥ 30,
PAID ≥ 40 and item scores ≥ 3.
In order to evaluate the recruitment strategy, we regis-
tered the number of invited participants. Then we calcu-
lated the number and percentage of people who
attended consultations and number and percentage of
people who agreed to participate. We quantified the pro-
portion of missing items (frequencies and percentages)
and calculated the duration of the PROM sessions (me-
dian, minimum and maximum). In addition, we quanti-
fied the variables concerning comprehension of the
PROMs, acceptability of number of items, relevance of
PROMs and willingness for annual completion of elec-
tronic PROMs using frequencies and percentages.
Finally, we organised the field notes concerning our
observations of technical and practical aspects and
participants’ comments chronologically by the date
these were collected. Two of the researchers (IH and
RBS) independently read the document and sum-
marised the content describing the activities that took
place in the waiting area. The text was adjusted and
agreed by the project members who had been present
in the waiting area.
Results
Recruitment
We invited 137 adults with T1D (72 men, 65 women) of
whom 24 (17.5%) did not attend their scheduled out-
patient clinic consultations (median age 47 yrs. (41–71),
58.3% men), leaving 113 potential participants (51.3%
men) (Fig. 1). Five eligible participants (2 men, 3
women) did not participate due to technical (n = 2) or
medical (n = 3) issues, and 20 (17.7%) declined participa-
tion (median age 48 yrs. (40–71), 55% men). On occa-
sions where project members were not available for
guidance at the outpatient clinic, 19 (out of 32) eligible
participants did not approach the kiosk and thus did not
participate (median age 48 years (41–59), 52.6% men).
Finally, 69 (61.1%) participants (35 men, 34 women)
completed the PROMs on the touchscreen computer.
Most of the invited participants had to be reminded
about the invitation and shown the location of the kiosk.
Therefore, we included a picture of the kiosk in the
Changed appointment (n= 19)
Did not attend nor cancel (n= 3)
Cancelled due to illness (n= 2)
Met for scheduled appointment 
(n = 113)
Technical problems (n= 2)
Visual impairment (n= 1)
Hypoglycaemia (n= 2)
Did not approach the kiosk (n= 19)
Study sample 
(N = 69)
Assessed for eligibility 
(n = 137)
Declined participation (n= 20)
Fig. 1 The recruitment and inclusion of adults with type 1 diabetes
in a Western Norway university hospital outpatient clinic. The
DiaPROM trial feasibility study
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information letter halfway through the recruitment
period, which appeared to lead to more participants
finding the kiosk by themselves.
Characteristics of the participants are presented in
Table 1. All but three reported Norwegian as their first
language. Over one half reported having university or col-
lege education, and 27 (41.5%) were in full-time employ-
ment. Women were slightly older than men, but men had
longer diabetes duration (31 vs. 19 years). The median
HbA1c value was 60.7mmol/mol (7.7%). Thirty-five (50%)
participants had at least one diabetes long-term complica-
tion, and retinopathy was the most frequent complication
seen in 28 (40.6%). We found that nearly half of the partic-
ipants met the inclusion criteria for the planned pilot
RCT, and that two thirds of these were women (Table 2).
Technical and practical procedures for collecting PROMs
The touchscreen computer mostly functioned well.
However, we noticed that PROM sessions had been
started but not finished on several occasions, which
meant that sometimes a participant who was to start a
new session found parts of the PROMs displayed instead
of the start screen. As a result, technicians from DIPS
programmed the application to display a 1 min inactivity
notification with a 15-s countdown, and to stop the ses-
sion if the screen was not touched during the count-
down. Participants’ median duration (minutes and
seconds) for completing PROMs was 8 min 19 s (min 3
min 41 s–max 24 min 54 s) (Fig. 2). One man and one
woman used > 20 min.
Comments expressed by the participants and logged in
the field notes, indicated that participants in general
expressed a positive attitude towards completing PROMs
in the waiting area, favouring this option compared to
an internet-based solution (e.g. from home). However,
limited time spent in the waiting area ahead of the
consultation was stated as a motive for wanting to
complete PROMs at home in the future. Some partici-
pants found the two methods for proceeding to the
next item confusing and suggested that it should be ei-
ther automatic or touch-based. Regarding the four-
character code, some handwritten letters and numbers
were difficult to interpret (e.g. A and 4, B and 8, G and
6 and also Z and 2). Consequently, we will avoid these
letters in the pilot RCT.
Participants’ perceptions about the PROMs
Of the 69 participants, 65 completed the paper question-
naire regarding their perceptions about the PROMs. The
PROM items were reported to be comprehensible to a
large or very large degree by 62 (95.4%) participants, and
46 (70.8%) found the PROMs relevant at least to a large
degree (Fig. 3). Fifty-one (78.1%) participants reported
that the number of items was acceptable to a large or
very large degree, and 54 (83.1%) reported willingness to
complete PROMs annually at least to a large degree.
Twenty-nine (42.0%) participants completed all PROMs
without any missing items, 13 (18.8%) had one missing
item, 12 (17.4%) had two missing items and the
remaining 15 (21.2%) had three to 12 missing items
(Table 3). The instruments’ completion rates varied from
72.5 to 91.3% (Table 3) with an average rate of 81.4%.
In the field notes, we found that the majority of par-
ticipants who commented verbally on the PROMs’
Table 1 Demographic characteristics among adults with type 1
diabetes attending an outpatient clinic in a Western Norway
university hospital
Total N = 69
Male sex, n (%) 35 (50.7)
Age (years) (median, min-max) 51.0 (40–74)
First language, n (%) 2
Norwegian 62 (95.4)
Other Scandinavian language 1 (1.5)
Other European language 2 (3.1)
Educational level, n (%) 3
Primary school 5 (7.8)
Secondary school 25 (39.1)
University/college ≤ 4 years 17 (26.55)
University/college > 4 years 17 (26.55)
Work affiliation, n (%) 2
Full-time work 27 (41.5)
Part-time work 9 (13.9)
Unpaid work 2 (3.1)
Unemployed 2 (3.1)
On sick leave/benefits 16 (24.6)
Retired 6 (9.2)
Other/not specified 3 (4.6)
Living alone, n (%) 2 9 (13.9)
Diabetes duration (years) (median, min-max) 26.0 (1–67)
HbA1c (mmol/mol) (median, min-max) 60.7 (41.0–107.7)
HbA1c (%) (median, min-max) 7.7 (5.9–12.0)
At least one long-term complication, n (%) 35 (50.7)
Insulin injection device, n (%)
Pen 43 (62.3)
Pump 26 (37.7)




HbA1c haemoglobin A1c, SBGM self-blood glucose monitoring, FGM flash
glucose monitoring, CGM continuous glucose monitoring
1n = 66, 2n = 65, 3n = 64 due to missing data
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contents found them relevant and valued the focus on
experiences of living with diabetes. However, partici-
pants interpreted the question concerning relevance of
items differently. Some regarded it as being relevant to
them personally at that point in time, while the ques-
tion was intended to ask about general relevance for
people with diabetes. Some questions were reported by
participants as somewhat overlapping, but it was noted
by other participants that some overlap could yield
more nuanced information.
Discussion
In this study, we found that using a touchscreen com-
puter for capturing PROMs electronically in our out-
patient clinic setting was technically and practically
feasible. The majority of participants reported the in-
cluded PROMs to be acceptable and relevant. One half
of the participants had either a PAID score ≥ 30 or a
minimum one item scored ≥ 3, which indicated
diabetes-related distress of concern, and participants
with such scores qualify for extra follow-up in the up-
coming pilot RCT. The mean PAID scores were in line
with other studies of similar patient groups [43, 49].
Nearly two thirds of participants with elevated diabetes-
related distress scores were women. Others have re-
ported similar sex differences, especially in younger
adults with T1D [50, 51].
Recruitment strategy
The recruitment of the 69 participants took 6 weeks.
Keeping track of eligible participants who changed or
did not keep their appointments was demanding. We
observed that only a handful of invited participants who
attended the clinic seemed to have considered participa-
tion prior to coming to the hospital, and the majority
did not approach the touchscreen computer by them-
selves. After we included a picture of the kiosk in the
information letter, more participants approached it with-
out guidance. Nonetheless, efficient recruitment ap-
peared to depend on the presence of a person who could
Table 2 PAID scores in adults with type 1 diabetes, including the proportion eligible for extra follow-up according to the planned
intervention inclusion criteria. The DiaPROM trial feasibility study
Total (N = 69) Men (n = 35) Women (n = 34)
PAID score (0–100) 1
Median (min-max) 22.4 (1.3–65.0) 21.3 (1.3–58.8) 32.5 (2.5–65.0)
Mean (SD) 25.9 (16.2) 21.4 (13.8) 31.1 (17.3)
PAID score ≥ 30, n (%) 1 26 (39.4) 9 (25.7) 17 (50.0)
PAID score ≥ 40, n (%) 1 11 (16.7) 3 (8.6) 8 (25.8)
Minimum one PAID item ≥ 3, n (%) 28 (40.6) 11 (31.4) 17 (50.0)
#PAID score ≥ 30 and/or minimum one item scored ≥ 3, n (%) 34 (49.3) 12 (34.3) 22 (64.7)
#The planned intervention inclusion criteria for the DiaPROM trial are a total score ≥ 30 or single-item PAID scores ≥ 3
1n = 66 due to missing data (3 women)
Fig. 2 Time needed to complete an electronic questionnaire on a touchscreen computer by adults with type 1 diabetes in an outpatient clinic at
a Western Norway university hospital. The DiaPROM trial feasibility study
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provide information, support participants and manage
the recruitment logistics, a phenomenon also identified
by Treweek [52]. Establishing new routines is in general
challenging and will often require extra resources,
especially in the earlier phases of implementation initia-
tives. Those who arrived shortly before the consultation
did not have time to complete the PROMs and could
therefore not participate unless the healthcare personnel
was delayed. This may indicate that our recommenda-
tion of coming to the clinic at least 10 min ahead of the
appointment was not adequately emphasised in the
information letter. Preparing written study information
requires the researchers to carefully consider wording
and amount of text. The ethics committees’ demands for
compulsory text makes this task even more demanding.
Thus, user involvement in preparing information is of
utmost importance.
Technical and practical procedures for collecting PROMs
Electronic capturing of PROMs using a touchscreen
computer was the only administration method offered in
this feasibility study. Although we found no indication
Fig. 3 Adults with type 1 diabetes and their perceptions about completing an electronic questionnaire on a touchscreen computer in an
outpatient clinic at a Western Norway university hospital. The DiaPROM trial feasibility study
Table 3 Number of individuals, n (%) with missing PROMs items among adults with type 1 diabetes attending an outpatient clinic
in a Western Norway university hospital. The DiaPROM trial feasibility study
Self-report instruments No. items 0 missing 1 missing 2 missing 3 missing 4 missing 5 missing
The WHO 5-Well-Being Index (WHO-5) 5 50 (72.5) 16 (23.2) 3 (4.3) 0 (0.0) 0 (0.0) 0 (0.0)
The Problem Areas in Diabetes scale (PAID) 1 20 53 (76.8) 10 (14.5) 3 (4.35) 1 (1.45) 0 (0.0) 1 (1.45)
Perceived Competence in Diabetes Scale (PCDS) 4 59 (85.5) 8 (11.6) 1 (1.45) 0 (0.0) 1 (1.45) –
Perceived elevated, low and varied blood glucose values 3 59 (85.5) 5 (7.25) 0 (0.0) 5 (7.25) – –
Awareness of hypoglycaemia (“Gold”) 1 63 (91.3) 6 (8.7) – – – –
RAND-12 Health Status Inventory (RAND-12) 2 12 53 (76.8) 9 (13.0) 3 (4.35) 1 (1.45) 2 (2.9) 0 (0.0)
PROMs patient-reported outcome measures
1 One person had seven missing PAID items. 2 One person did not complete the RAND-12 (n = 68)
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that the data collection method represented an obstacle
for participation, it may have influenced recruitment due
to perceived technology barriers or the location of the
kiosk. Recent meta-analyses and reviews refer to mixed
results on preferences for electronic versus paper-based
administration, ranging from 50% [18] to 87% [53] in
favour of the electronic format. This suggests that pa-
tients of all ages have become increasingly more familiar
with electronic devices, and using multiple methods for
collecting PROMs and allowing multiple places for com-
pleting them might improve response rates [54]. How-
ever, the general recommendation is to avoid mixing
modes within a study [22], since different administration
methods require somewhat different skills and resources
of those completing the PROMs [23].
We had to perform some minor layout changes when
we adapted the paper-based PROMs to the electronic
interface, but this was done in accordance with recom-
mendations supporting equivalence of paper- and
computer-administered PROMs [19–21]. However, the
visual look thus turned out to differ a bit as multiple
items are generally presented on the same page in
paper-based PROMs, whereas electronic formats present
one item at a time [20, 22]. We used a relatively large
screen (17″), but still it was not possible to retain all
items and response options of each self-report instru-
ment on the same screen without compromising the
font size. Hence, we chose the single item per screen ap-
proach to provide consistency across all instruments
[22]. This also meant that we could present the items
with relatively large fonts, making it more accessible to
people with minor visual impairments.
We chose to locate the kiosk in close proximity to the
outpatient clinic’s waiting area to make it visible and
easy to access, but at the same time not too close to the
seating area for privacy reasons [23]. We received no
negative comments on the location, neither about how
the PROM items were presented on the screen. How-
ever, 19 out of 32 eligible participants did not approach
the kiosk when the project members were not available
for guidance. Furthermore, we registered that a number
of PROM sessions had been started but not finished.
This could be a result of questions being presented one
at a time and the total number of items appearing to be
too many for some people. In addition, people not eli-
gible for the study might have been curious about the
screen and its contents and thus might have started a
PROM session without finishing. According to recom-
mendations [55], completing PROMs in a clinical setting
should not take more than 12–15min. In our study, the
median session duration was less than 9 min. Nonethe-
less, 16 participants (23.1%) used more than 10 min and
4 (5.7%) used more than 15min. Hence, in similar stud-
ies, participants completing a questionnaire of 47 items
should be encouraged to come to the clinic at least 15
min before their consultation.
We experienced few technical and practical problems
during the study. WLAN connectivity problems could
have been avoided using a cabled network. Due to pos-
sible misinterpretation of handwriting, we considered
using printers for delivering the four-character code on
slips of paper, but this could entail other logistical and
technical issues, plus extra costs. Other in-clinic PROM
studies report involving clinicians for logging the re-
spondents into the electronic solution [56]. We did not
develop this option as the outpatient clinic leaders were
clear that it would not be possible to allocate personnel
for this task in the future. In addition, we chose to avoid
personal identification solutions such as BankID, a Nor-
wegian cloud infrastructure allowing electronic ID,
authentication and signing [57]. Due to the application’s
integration with the EPR, this would involve greater sys-
tem security needs. Using the personal codes as de-
scribed, the participants were in charge and control of
their codes, available for interpretation, and we avoided
security risks.
Participants’ perceptions about the included PROMs
We chose a mix of generic and diabetes-specific instru-
ments, which could have affected the perceived rele-
vance of the PROMs. However, combining generic and
condition-specific PROMs may result in a more
in-depth assessment of health-related outcomes [23].
Although generic measures might not be considered
relevant in follow-up of diabetes, condition-specific in-
struments may miss other health-related dimensions
possibly unrelated to the condition, but still affecting pa-
tients [17, 58]. Several participants’ expressed appreci-
ation of the focus on psychosocial aspects of living with
diabetes. Using PROMs to capture the participants’ per-
ceptions of their own health and thereby informing clin-
ical practice thus has the potential to facilitate increased
person-centred care [14, 17, 55].
The average PROM completion rate of 81.4% was rela-
tively high. Therefore, our method for electronic captur-
ing of data seems adequate. In addition, it might also
reflect that the number and relevance of the questions
were acceptable. Some argue that electronic PROM sys-
tems can lead to more complete and accurate datasets
due to a reduction of missing or unusable data [16, 17,
19]. The method ensures that out-of-range, contradict-
ory and/or extraneous responses are not possible. Fur-
thermore, data entry errors are minimised since manual
punching is not needed [17, 19, 23]. Although computer
technologies require investment in software and hard-
ware, collecting PROMs electronically is regarded as
more economical concerning time and personnel re-
sources compared to traditional paper-based collection
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[23, 59]. However, 40 (58.0%) participants did not re-
spond all items, where 25 (37.9%) completed all but one
or two items. Except for one case, the missing data were
due to incomplete instrument sections. The results are
similar to another recent feasibility study reporting on
collecting electronic PROMs (33 items), where 47.1% of
the participants completed all items [56]. Lack of
complete datasets is one of the greatest practical chal-
lenges related to the use of PROMs. Unfortunately, there
is no generally accepted standard approach for handling
missing PROMs data, and preventing missing data with
a design that supports PROM completion is probably
the most effective solution [60].
Strengths and limitations
We consider it a strength that the study included both
men and women with long diabetes duration and experi-
ence with attending outpatient clinic consultations.
Moreover, we collaborated with healthcare professionals
with highly specialised information technology (IT) com-
petence who had the skills to make necessary and timely
improvements of the touchscreen application. Further-
more, it is a strength that we incorporated healthcare
user involvement from the beginning of the design and
development of the study in accordance with the
GRIPP2 short form [61].
A relatively small, homogenous Norwegian sample
limits generalisability. The findings were analysed de-
scriptively due to the small sample and cross-sectional
design. Recruitment was challenging since most partici-
pants had to be reminded about the study invitation and
therefore did not approach the kiosk by themselves.
Non-response is always a concern in recruitment and
data collection since non-responders may be systematic-
ally different from those providing complete data [62],
and the distribution of missing data across a range of
measures also suggests this. Since we only used an elec-
tronic method for collecting PROMs, participation was
limited to individuals capable of and interested in using
the touchscreen computer. Therefore, participation may
have been biased towards educated and younger infor-
mants. Our sample’s educational level was higher than
the Norwegian average for 40- to 67-year-olds, where
35% have university or college education and 22% have
primary school only [63]. Consequently, our results may
be limited to those familiar with electronic devices. Not-
withstanding that, the public is becoming more experi-
enced with using IT [53]. According to the 2018 Digital
Economy and Society Index, 77% of Norwegian people
have basic digital skills at least, and 96% are internet
users [64], indicating capability of using a computer. By
excluding groups of people unable to complete the elec-
tronic PROMs, we might lack potentially valuable insight
regarding the impact of diabetes on these people’s lives.
For this group, completing PROMs with assistance could
be an option. At this point, we chose to focus on an
electronic data collection method. Finally, we consider it
a limitation that the healthcare service users were not
involved in preparing the written information for the
present study.
Conclusions
We found that capturing PROMs on a touchscreen com-
puter in the waiting area in connection with attending
an outpatient clinic consultation was technically and
practically feasible, and we identified only minor tech-
nical issues that will be improved prior to the pilot
study. The majority of participants found the PROMs
relevant and acceptable with a manageable number of
items, and reported willingness to complete electronic
PROMs annually in the future.
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AbstrACt
Introduction Although diabetes distress is found 
to be associated with decreased glycaemic control 
among adults with type 1 diabetes, the psychological 
and emotional impact of living with the condition 
is often not recognised and often under-reported 
in diabetes care. Therefore, regular assessment of 
diabetes distress is recommended. Assessment of 
diabetes distress using patient-reported outcome 
measures (PROMs) in clinical practice has the 
potential to enhance care for people with diabetes by 
identifying problems and improving patient–clinician 
communication. In this study protocol, we describe a 
pilot randomised controlled trial (RCT) aiming to test 
the feasibility of all components of an empowerment-
based intervention using PROMs as dialogue support 
in clinical diabetes consultations, and to address the 
uncertainties associated with running a fully powered 
evaluation study.
Methods and analysis We will undertake a two-
arm pilot RCT of an intervention using the Problem 
Areas In Diabetes (PAID) scale in clinical diabetes 
consultations in order to conclude whether a fully 
powered trial is appropriate and/or feasible. The study 
will also include qualitative indepth interviews with 
participants and healthcare providers. Our objectives 
are to (1) evaluate the recruitment procedures 
and attrition rates; (2) evaluate the performance 
of the randomisation procedure; (3) evaluate the 
participants’ mean scores on the outcome measures 
before and after the intervention; (4) evaluate if the 
intervention consultations are acceptable and feasible; 
and (5) explore patients’ and healthcare providers’ 
experiences with the use of PAID as dialogue support 
and empowerment-based communication skills in 
clinical diabetes consultations. The quantitative data 
analysis includes descriptive statistics (frequencies, 
percentages, means, SD and CI). For the qualitative 
data, we will perform thematic analysis.
Ethics and dissemination Ethical approval has been 
obtained from the Western Norway Regional Committee 
for Medical and Health Research Ethics (2017/1506/
REC west). We will present the findings from the study 
phases at national and international conferences and 
submit manuscripts to peer-reviewed journals and 
popular science journals. 
trial registration number NCT03471104; Pre-results.
IntroduCtIon 
The management of type 1 diabetes (T1D) is 
complex, and people living with the condition 
need to make numerous daily choices related 
to their medical treatment.1 2 They need to 
monitor their blood glucose and administer 
insulin several times each day. The burden of 
living with T1D remains a challenge despite 
new insulin types and advances in insulin 
delivery and glucose monitoring technolo-
gies.3 Many Norwegian adults with T1D do 
not achieve the recommended treatment 
goals for glycaemic control.4 5 This poor goal 
attainment might be due to inappropriate 
choice of insulin regimen for the individual, 
but research has also shown psychological 
strengths and limitations of this study
 ► This is a study with the potential to provide new 
knowledge about the use of patient-reported out-
come measures (PROMs) as dialogue support in 
clinical diabetes consultations among patients with 
type 1 diabetes.
 ► The use of the Medical Research Council’s frame-
work as a guide for the development of study inter-
vention initiatives like this is a strength because the 
feasibility and uncertainties related to a fully pow-
ered randomised controlled trial (RCT) can be illu-
minated before a resource-intensive fully powered 
RCT is conducted.
 ► A key challenge includes possible contamination of 
the control group, although the completed PROMs 
will not be available in the electronic patient records 
of the participants in the control group.
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and emotional aspects as important barriers for satisfac-
tory diabetes self-management.6 
The psychological and emotional impact of living with 
diabetes is often unrecognised and/or under-reported 
in diabetes care.7 8 Diabetes distress, which reflects the 
emotional response to the burden, worries, anxieties, frus-
trations and stressors associated with managing diabetes 
in everyday life,9 10 is found to be associated with decreased 
glycaemic control.11 12 Therefore, regular assessment of 
diabetes distress is recommended.13 Such assessment is 
considered feasible and beneficial to promote the recog-
nition of psychological and emotional issues that affect 
diabetes self-management.9 14
Collecting patient-reported outcome measures 
(PROMs) involves asking people to complete question-
naires concerning the impact of their condition and its 
treatment on their health.15 The integration of PROMs 
in clinical practice has the potential to improve care 
for people with diabetes and other chronic conditions 
by screening for and identifying problems, monitoring 
progress over time, improving patient–clinician commu-
nication and enabling people to become more involved 
in managing their own health.16 17 However, using PROMs 
in itself may not affect health outcomes. The collection 
of PROMs should be accompanied by a discussion of 
results to elaborate on any problems identified by the 
assessment.14 17 Previous research has shown that the use 
of PROMs to monitor diabetes psychological distress and 
general well-being followed by a discussion of outcomes 
improves psychological well-being in both adults and 
youth with diabetes.14 18 19 In the Cross-National Diabetes 
Attitudes, Wishes, and Needs (DAWN) Monitoring of Indi-
vidual Needs in Diabetes (MIND) study,14 the skills used 
in discussions of PROMs data regarding diabetes distress 
and well-being were based on empowerment theory 
and patient-centred communication. Empowerment 
in nursing and healthcare is defined as a motivational 
approach and process using specific counselling and 
communication techniques to assist patients in making 
health-promoting behaviour changes.20 The approach 
is patient-centred, with the healthcare providers facili-
tating and providing information and knowledge to assist 
the patients in taking informed decisions. The desired 
outcomes in the empowerment process are control and 
self-determination. A systematic review by Chen et al21 
states that interventions aiming to empower people with 
chronic illnesses are able to improve health status, improve 
outcome indicators of psychological and social aspects, 
and improve self-management. The authors of the DAWN 
MIND study suggest further research on process evalua-
tions to explore the role of empowerment-centred and 
patient-centred skills such as active listening, use of open-
ended questions and promoting active patient participa-
tion in the decision-making process.14
The overarching aim of the Diabetes Patient-Reported 
Outcome Measures trial (DiaPROM trial) is to develop, 
test and evaluate a structured empowerment-based 
intervention using PROMs regarding diabetes distress 
as dialogue support in clinical diabetes consultations 
among adults with T1D. Our proposition is that the 
DiaPROM intervention initiative will reduce diabetes 
distress and further improve overall well-being, improve 
perceived competence for diabetes management and 
improve glycaemic control. Based on experiences and 
research,14 18 19 we also believe that improved focus on the 
psychological and emotional burden of the disease will 
improve satisfaction with diabetes follow-up. This paper 
describes the protocol for a pilot randomised controlled 
trial (RCT) to test the feasibility of and uncertainties asso-
ciated with a fully powered evaluation study.
the development of the diaProM trial
The DiaPROM trial is part of the implementation of 
PROMs in the Norwegian Diabetes Register for Adults. 
We wanted to design a study to test a method for using 
the PROMs data in clinical diabetes practice. The study 
is multidisciplinary and consists of several interacting 
components and a number of behaviours required by 
those receiving and delivering the intervention. Thus, 
we consider the study as a complex intervention with a 
need to develop and test the various components gradu-
ally before conducting a fully powered RCT. As guidance 
in this process, we used the Medical Research Coun-
cil’s framework (MRC framework) for the evaluation of 
complex interventions.22 23 The framework describes four 
important phases in the development, evaluation and 
implementation of a new intervention initiative: (1) the 
development phase, (2) the feasibility and piloting phase, 
(3) the evaluation phase and (4) the implementation 
phase (figure 1).
The development of the DiaPROM trial took place 
during 2016 and 2017. Initially, the essential tasks were 
to determine which PROMs to include and how patients 
should complete the PROMs.
ProMs to include
We reviewed the literature to identify published articles on 
the use of PROMs as dialogue support in clinical diabetes 
practice. We wanted to identify the most commonly used 
PROMs to measure diabetes distress. We recognised that 
studies have primarily used PROMs to evaluate interven-
tions’ effects; relatively few publications have reported 
on the use of PROMs in clinical diabetes care. We did 
identify, however, the DAWN MIND study which tested 
the feasibility and impact of the computer-assisted ‘Moni-
toring of Individual Needs in Diabetes’ procedure aimed 
to improve recognition and management of the psycho-
logical needs of patients with diabetes by implementing 
PROMs in routine diabetes care.14 24 Regular assessment 
of psychological needs was implemented as part of the 
annual review in diabetes clinics across eight countries. 
The assessment included, among others, diabetes distress 
measured by the Problem Areas in Diabetes (PAID) scale. 
Accordingly, Schmitt et al25 emphasise the necessity of 
a justified choice of measurement and recommend the 
use of the PAID when the clinical purpose is to bear in 
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mind a variety of emotional concerns related to living 
with diabetes. Some other studies have reported PAID 
as an appropriate instrument for use in clinical diabetes 
consultations, as well.26–30 The scale may contribute 
to improved communication by making the dialogue 
between healthcare providers and patients more thera-
peutic and goal-oriented.
Patient and public involvement
Involving health service users throughout all phases 
of a study is important to provide insight into patients’ 
perspectives and ensure that the research focuses on 
issues relevant for the health service users and the 
public.31 32 Patient and public involvement (PPI) is also 
useful in terms of shaping the research processes.31 In 
this study, we used the Guidance for Reporting Involve-
ment of Patients and the Public 2 (GRIPP2) short form 
as guidance for including and reporting PPI.32 To include 
the voice of the health service users throughout the 
study, two people with diabetes have been included in the 
DiaPROM project group, both experienced with PPI and 
research. They will contribute to all phases of the study. 
Furthermore, we have included additional people with 
diabetes to share their views on the various phases of the 
study, recruited mainly from national and local diabetes 
associations.
A crucial question when we considered which PROMs 
to include in the study was what adult people with T1D 
perceived as the most important and relevant aspects to 
emphasise in diabetes follow-up. Thus, in parallel with the 
literature review, we consulted the health service users. In 
addition to the health service users in the project group, 
we met the leader of the Norwegian Diabetes Associa-
tion and a group of four representatives from the local 
diabetes association (two with T1D and two parents of 
children with T1D where one had type 2 diabetes herself). 
First, we used open question to the health service users 
to determine which topics they perceived as important 
and relevant to include in a set of PROMs. After an 
open discussion, we asked them to review several generic 
instruments (eg, WHO’s 5-Item Well-Being Index [WHO-
5], RAND-12 Health Status Inventory, Patient Activation 
Measure) and diabetes-specific instruments (eg, PAID, 
Diabetes Distress Scale [DDS], Perceived Competence for 
Diabetes Scale [PCDS]). The user representatives consid-
ered the advantages and shortcomings of using the 20 
statements in PAID as dialogue support in the interven-
tion. They found the instrument relevant and suitable to 
be used in the intervention.
the PAId
Based on the literature review and in accordance with the 
input from the health service users, we chose the PAID 
scale for use in the study intervention. The participants’ 
PAID scores will constitute the basis for the dialogue in 
the clinical consultations. The scale was developed to gain 
insight into the breadth of emotional responses to living 
with diabetes and consists of 20 statements regarding 
diabetes distress (eg, ‘feeling constantly concerned about 
food and eating’, ‘worrying about low blood sugar reac-
tions’).33–35 The scores are on a 5-point Likert scale from 
0 (not a problem) to 4 (serious problem). An item score 
of 3 (somewhat serious problem) or 4 (serious problem) 
indicates moderate to serious diabetes distress related to 
the specific item. Scale scores are transformed to a 0–100 
scale, with higher scores indicating greater distress, and 
a PAID total score >40 suggests serious diabetes-related 
distress. To identify both moderate and serious distress, 
we defined scores of concern as PAID total scores ≥30 or 
single item scores of 3 or 4. The scale has been translated 
into several languages, including Norwegian.36
Method for completing ProMs
The literature describes various methods for adminis-
tration of PROMs, such as paper-based self-administra-
tion at home or in the clinic, interviews by telephone or 
personal meetings, computer-assisted self-administration 
in the clinic, or mail-based or web-based administration 
from patients’ homes.16 17 Electronic PROMs collection is 
preferred since the patients’ responses can be transferred 
Figure 1 Key elements in the Medical Research Council’s guidance for developing, evaluating and implementing complex 
interventions (MRC framework). Reproduced from Craig et al22  with permission.









pen: first published as 10.1136/bm




4 Haugstvedt A, et al. BMJ Open 2019;9:e024008. doi:10.1136/bmjopen-2018-024008
Open access 
to the electronic patient records (EPRs) without scanning 
paper forms or punching data.17 In our study, we decided 
on computer-assisted administration on a touchscreen 
computer in the outpatient clinic. Using this method has 
advantages, such as efficient and simultaneous data entry 
and minor privacy challenges.
Feasibility study
We conducted a feasibility study in 2017 to examine the 
technical and practical feasibility of collecting PROMs 
on a touchscreen computer in the outpatient clinic, and 
evaluate the participants’ perceived understanding and 
relevance of the items on the PAID and the included 
outcome measures. We also evaluated the acceptability 
of completing PROMs annually. Field observations and 
comments from the participants provided data on the 
technical and practical procedures. Sixty-nine individuals 
with T1D ≥40 years participated in the study and 83% of 
them reported that, to a high or a very high degree, they 
would be positive about an annual completion of PROMs. 
However, almost 20% of 137 invited patients did not show 
up at the clinic (change of appointments, sick, no reason 
given), and most of the invited ones did not go directly 
to the computer on arrival at the clinic as instructed in 
the information sheet. Thus, we developed clearer infor-
mation and procedures for the pilot study to avoid loss of 
potential participants among those invited. Further anal-
yses of the results from the feasibility study are ongoing, 
and we plan to publish these in a separate article.
Aims
The purpose of the pilot RCT reported here is to test the 
feasibility of the proposed DiaPROM trial components 
and address the uncertainties associated with running a 
fully powered RCT in order to conclude whether such a 
trial is appropriate and/or feasible. The following are our 
objectives:
1. Evaluate the recruitment procedures and attrition 
rates.
2. Evaluate the performance of the randomisation pro-
cedure.
3. Evaluate the participants’ mean scores on the outcome 
measures before and after the intervention.
4. Evaluate if the intervention consultations are accept-
able and feasible.
5. Explore patients’ and healthcare providers’ experi-
ences with the use of PAID as dialogue support and 
empowerment-based communication skills in clinical 
diabetes consultations.
MEthods And AnAlysIs
We will undertake a two-arm pilot RCT with embedded 
qualitative study on participants’ and healthcare 
providers’ views of the DiaPROM intervention initiative. 
We report our protocol here using the Standard Protocol 
Items: Recommendations for Interventional Trials 
checklist (http://www. spirit- statement. org/ wp- content/ 
uploads/ 2013/ 01/ SPIRIT- Checklist- download- 8Jan13. 
pdf).
Participants and eligibility criteria
As recommended for pilot RCTs,37 we will include 
80 participants: 40 in the intervention group and 40 
controls. Participants will have T1D for at least 1 year and 
be aged ≥18 to <40 years. We will exclude people who are 
unable to read or complete the PROMs on the touch-
screen computer. Furthermore, we will exclude pregnant 
women, patients with known and recorded cognitive defi-
ciency (eg, Down’s syndrome, Alzheimer), severe somatic 
comorbidity (eg, end-stage renal disease, severe heart 
failure, severe cancer), and/or a major psychiatric diag-
nosis (eg, severe depression or bipolar disorder, schizo-
phrenia) as diabetes distress is often neither ethical nor 
possible to discuss with these groups of patients. Eligible 
participants will receive information and consent forms 
by regular mail before their annual diabetes consultation 
at the clinic. The information form will include informa-
tion about the possibility to withdraw from the study at 
any time point without consequences.
randomisation procedure and allocation concealment
We will randomise eligible and consenting participants, 
using computer-generated block randomisation at the 
patient level, stratified for gender, immediately after the 
participants have completed both the PAID and the self-re-
ported outcome measures. When participants complete the 
measures on the touchscreen computer in the outpatient 
clinic, they will receive an individual four-character code. 
When the physician downloads the PROMs data using the 
code, a concealed computerised allocation will take place. 
Information about which group the person is allocated to 
will appear on the computer screen and the physician will 
inform the participant immediately. It is not possible to 
blind either participants or healthcare providers.
trial intervention
After participants have completed the PAID scale, physi-
cians download the scores into the participants’ EPR as 
part of the annual consultation (figure 2). Physicians then 
review and discuss the PAID scores briefly with the partici-
pants. Participants with one or more single PAID item(s) 
score of 3 or 4 (somewhat serious or serious problem), 
or PAID total score ≥30, will be referred to additional 
diabetes nurse consultations. Participants with lower 
scores will receive regular follow-up according to usual 
clinical protocols.
Additional nurse follow-up will consist of at least two 
consultations. The first will take place within 4 weeks after 
randomisation, and the second within a further 3 months. 
After the second nurse consultation, the nurse and the 
participant will agree any further follow-up until the next 
annual consultation with the physician. Diabetes nurses 
will review the PAID scores and discuss the reported 
problem areas and distress with participants by following 
a communication manual based on key elements from 
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empowerment theory and self-determination theory, such 
as empathetic communication and autonomy support.38–40 
These communication skills involve ‘active listening’, 
‘asking open questions’, ‘responding’, ‘summing up’ 
and ‘agreeing on goals and actions to take’. Nurses will 
record their work on participants’ problem areas, goals 
and actions. The intervention will last for a maximum of 
1 year, until the next annual consultation.
Control procedure
The control group will receive ‘care as usual’, which 
does not include a structured focus on psychological 
and emotional diabetes distress. For most patients the 
annual consultation normally constitutes ‘care as usual’. 
Although all participants will complete the PAID before 
randomisation, for control participants the scores will not 
be accessible to clinicians in the EPR until the study is 
completed. For ethical reasons, we will not prevent physi-
cians discussing psychological or emotional issues with 
participants in the control group if participants specifi-
cally raise such an issue. Unlike participants in the inter-
vention group, such discussions will not be structured 
with reference to the PAID data. We will identify to what 
extent such discussions have taken place by reviewing 
participants’ EPR.
training of healthcare providers
Before the study commences, we will have a 1-hour 
meeting with the participating physicians, and they will 
be trained in how to download the PAID scores into the 
EPR and how to briefly discuss the scores in the annual 
consultations. Further, they will get both oral information 
and written instructions regarding the interpretation of 
the PAID scores including instructions on the criteria for 
referral of participants to extra follow-up by the diabetes 
nurses. Nurses will get both oral and written information 
and a 2×1 hour training in how to interpret scores and 
discuss the reported problem areas, how to follow the 
communication manual in the consultations, and how to 
agree on goals and actions to take with the participants.
data collection and outcome measures
All participants (both intervention and control groups) 
will complete the outcome measures electronically 
before the annual consultation at baseline and after 12 
months. After the annual consultation, the participants 
will complete a paper-based questionnaire about their 
experience and satisfaction with the diabetes follow-up. 
We will evaluate the recruitment procedures and attrition 
rates by observing and monitoring the number of eligible 
participants invited, number of invited people declining 
participation, number of people who attended the clinic, 
number of intervention participants who attended 
the nurse consultations and number of consultations 
conducted. We will also observe and document the tech-
nical performance of the randomisation procedure. 
Finally, we will document all types of contacts between 
participants and the diabetes outpatient clinic for all 
participants throughout the study period.
To describe the study sample and evaluate the technical 
procedure of data retrieval from EPR, we will perform a 
computerised retrieval of the following variables from the 
participants’ EPR: sex, age, ethnicity, body mass index, 
diabetes duration, haemoglobin A1c (HbA1c) (secondary 
outcome), insulin regimen, insulin doses, severe hypogly-
caemic episodes needing assistance in the past year, hospi-
talisations, comorbidities and diabetes late complications.
The outcome measures to evaluate the effect of the 
intervention in the evaluation phase of the study (phase 
Figure 2 The study intervention in the Diabetes Patient-Reported Outcome Measures trial (DiaPROM). PAID, Problem Areas In 
Diabetes scale.
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III) were chosen based on a literature review and consid-
erations among the researchers and the health service 
users. We decided on the DDS as primary outcome. 
DDS measures diabetes distress and contains 17 items 
and 4 subscales: emotional burden (five items), physi-
cian-related distress (four items), regimen distress (five 
items) and diabetes-related interpersonal distress (three 
items).41 The scores are on a 6-point Likert scale from 
1 (not a problem) to 6 (serious problem), with a mean 
total or subscale score from 1 to 6.42 The total or subscale 
scores >3 are defined as high levels of distress. The DDS 
has previously shown satisfactory psychometric properties 
to map diabetes distress and might have advantages for use 
as outcome measure in clinical trials because it contrib-
utes to identification of subdomains of distress.11 25 36 To 
measure the secondary outcomes, overall well-being and 
perceived diabetes competence, we have included the 
WHO-543–45 and the PCDS.46–48 We will use HbA1c as the 
target for glycaemic control.
We will invite all participants from the intervention 
group and all healthcare providers (physicians and 
diabetes nurses) participating in the intervention group 
to individual indepth interviews to collect qualitative data 
on their experiences with the intervention, including the 
use of PAID as dialogue support in clinical consultations. 
This will provide a sample of about 15–20 participants 
and 10–15 healthcare providers. All interviews will be 
conducted at the outpatient clinic and will be audio-re-
corded after obtaining consent from participants.
data analysis
We will use Stata SE V.15 for Windows for all statistical 
analyses,49 and for data entry range checks for data values 
will be performed. We will report the recruitment of 
participants and the number of trial dropouts descrip-
tively (frequencies and percentages). Further, we will 
report the means, SD and CI of the DDS and the other 
outcome measurements before and after the intervention 
period for both the intervention and control groups. As 
the study is a pilot and the sample size is small, we will not 
perform inferential statistics and analyse between-group 
calculations. The participants’ PAID scores will be anal-
ysed descriptively (mean, SD), as well.
We will transcribe verbatim and analyse participants’ 
and healthcare providers’ experiences with the interven-
tion by using thematic analysis.50 Thematic analysis is a 
flexible qualitative method without any specific theoret-
ical foundation and consists of six steps: (1) transcribing, 
reading and rereading, (2) generating initial codes, (3) 
searching for themes, (4) reviewing themes, (5) defining 
and naming the themes, and (6) producing the report.
EthICs And dIssEMInAtIon
Haukeland University Hospital, Bergen, Norway, is the 
responsible research institution (trial sponsor) where the 
study data will be stored on a secure research server. In 
order to protect confidentiality, names of the potential 
and enrolled participants will be stored separate from 
the other study data. Only the principal investigator and 
other clearly identified members of the project group 
have access to the study data. If important protocol modi-
fications happen, this will be communicated to the ethics 
committee and  ClinicalTrials. gov. Further information 
can be obtained from  ClinicalTrials. gov, trial registration 
number NCT03471104.
Completing the PROMs may activate latent psycholog-
ical or psychosocial problems and negative feelings. To 
care for any participants in the control group reporting 
worryingly high levels of distress (eg, above cut points for 
severe levels of distress measured by PAID and/or DDS), 
the research team will continuously review the reported 
distress levels. We will discuss potential needs for more 
intensive care or referral to psychological or psychiatric 
follow-up for those reporting worryingly levels of distress 
with the physicians and diabetes nurses.
We will present the findings of the study phases at 
national and international conferences and submit manu-
scripts to peer-reviewed journals and popular science jour-
nals. Further, we will also publish the findings in popular 
science journals, public newspapers and journals for rele-
vant health service user groups. One of the health service 
users included in the project group will participate in the 
writing and publication process.
dIsCussIon
In the pilot RCT study described in this protocol, we aim 
to test the feasibility of and address the clinical and meth-
odological uncertainties associated with running a fully 
powered RCT testing the effect of an intervention incor-
porating the use of PAID to decrease diabetes distress 
among people with T1D. The study will provide knowl-
edge on the use of PAID in clinical diabetes practice, 
although the purpose primarily is to prepare the ground 
for the design and conduct of a fully powered RCT. In 
addition, the qualitative evaluation will provide important 
knowledge on the specific empowerment-based commu-
nication skills used to discuss PAID scores of concern in 
the clinical consultations. In an upcoming fully powered 
evaluation study (phase III), we plan to test the effect of 
the entire intervention package including both the use 
of PAID and the empowerment-based follow-up. A major 
limitation of such an effect study is the lack of informa-
tion on how specific parts of the intervention may affect 
the results.
Diabetes distress has been shown to be a barrier to satis-
factory glycaemic control,11 12 and a more structured focus 
on diabetes distress may have the potential to improve 
long-term health for people with T1D by reducing distress 
and improving glycaemic control. A previous literature 
review by Carlsen et al51 found that the use of PAID could 
benefit patients but emphasised the need for follow-up 
studies to evaluate whether the PAID should be imple-
mented in routine diabetes care to enhance a more struc-
tured focus on diabetes distress.
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The choice of using PAID as dialogue support in the 
intervention and the DDS as the primary outcome measure 
is in accordance with previous research. Both instruments 
have previously shown satisfactory psychometric proper-
ties to map individual levels of diabetes distress, but it 
has been claimed that the PAID has advantages for use in 
clinical practice and that the DDS has advantages for use 
in clinical trials, because it also contributes to identifying 
subdomains of distress.11 25 36 However, there will be an 
overlap between the intervention measure (PAID) and 
the primary outcome measure (DDS) in this study. Using 
PAID in the intervention may prime the participants’ 
responses to the DDS, but the inclusion of WHO-5 and 
the PCDS as additional outcomes may compensate for the 
overlap between PAID and DDS. Previous research has 
shown links between diabetes distress measured by PAID, 
and well-being and perceived competence. Snoek et al14 
indicated an overlap between predictors for diabetes 
distress and general well-being measured by WHO-5, 
and Mohn et al48 showed an association between greater 
diabetes distress and lower perceived competence for 
diabetes self-management measured by PCDS.
strengths and limitations
The use of the MRC framework is a strength in the devel-
opment of this study because it includes several complex 
and interacting components that need to be considered 
and tested with the purpose to reveal uncertainties before 
conducting a fully powered RCT. In addition, the use of 
the GRIPP2 short form to guide the PPI throughout all 
phases of the development of the intervention initiative is 
considered a strength. The health service users included 
in the project have influenced, among others, the choice 
of PROMs, the choice of the theoretical foundation for 
the intervention and the discussions related to the quali-
tative component of the study.
We have included primarily disease-specific outcome 
measures, but also one generic PROM (WHO-5). 
Disease-specific PROMs are used to capture informa-
tion that is most pertinent to particular patient groups, 
but they might miss domains affecting the patient that 
are unrelated to their disease.16 52 Generic instruments 
may capture broad dimensions of health and allow for 
comparisons between populations but might not be sensi-
tive to changes in disease-specific health domains over 
time or in relation to interventions.15
The fact that the control group in the study will also 
complete the PAID and the evaluation PROMs before the 
annual diabetes consultation, and that the same physi-
cians meet participants from both the intervention and 
the control groups, might lead to intervention contami-
nation challenges. This might be a challenge, although 
the scores will not be accessible in the EPRs of partici-
pants in the control group.
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ABSTRACT
Objective To pilot test the proposed DiaPROM trial 
components and address uncertainties associated with 
conducting a full- scale randomised controlled trial (RCT) to 
evaluate whether such a trial is feasible.
Design Two- arm pilot RCT.
Participants Adults aged ≥18–39 years, with minimum 
1 year type 1 diabetes duration, attending outpatient 
follow- up. Exclusion criteria were pregnancy, severe 
cognitive, somatic or psychiatric conditions and impaired 
vision.
Randomisation and intervention All participants 
completed electronic Patient- Reported Outcome Measures 
(PROMs) prior to the annual diabetes consultation. Using 
computer- generated block- randomisation without blinding, 
we assigned participants in a 1:1 ratio stratified by sex 
to receive standard care or an intervention. Physicians 
reviewed diabetes distress scores (Problem Areas In 
Diabetes scale) and referred individuals with scores 
≥30 or single item(s) ≥3 to minimum two diabetes nurse 
consultations where reported problems were reviewed and 
discussed.
Outcomes Recruitment and retention rates; participants 
perceptions about intervention components. Variance and 
estimated between- group differences in follow- up scores 
(Diabetes Distress Scale (DDS), WHO 5- Well- being Index, 
Perceived Competence for Diabetes Scale and glycaemic 
control) and DDS correlation with baseline scores, to assist 
sample size calculations.
Results We randomised 80 participants to the control 
or intervention arm (one participant was later excluded). 
23/39 intervention arm participants qualified for additional 
consultations and 17 attended. 67/79 attended the 
12- month follow- up (15.2% attrition); 5/17 referred to 
additional consultations were lost to follow- up (29.4% 
attrition). Participants reported PROMs as relevant (84.6%) 
and acceptable (97.4%) but rated the usefulness of 
consultations as moderate to low. Baseline mean±SD DDS 
score was 2.1±0.69; DDS SD was 0.71 (95% CI: 0.60 
to 0.86) at follow- up; correlation between baseline and 
follow- up DDS scores was 0.8 (95% CI: 0.7 to 0.9).
Conclusions The pilot trial revealed need for intervention 
modifications ahead of a full- scale trial to evaluate use of 
PROMs in diabetes consultations. Specifically, participant 
acceptability and intervention implementation need further 
investigation.
BACKGROUND
Type 1 diabetes (T1D) is a chronic, auto-
immune disease which requires lifelong 
insulin therapy.1 Self- management of T1D, 
the cornerstone of diabetes care, can be 
described as a 24- hour activity with a constant 
need to make complex medical decisions 
and perform challenging diabetes self- 
management tasks.2 During emerging and 
young adulthood, multiple transitions and 
developmental stressors can trigger addi-
tional self- management difficulties.3 Despite 
advancements in glucose monitoring, insulin 
therapy and insulin delivery devices, the 
burden of living with T1D remains a signif-
icant challenge.4 5 Only 20%–30% of young 
adults with T1D achieve recommended 
glycaemic treatment goals.6–9 Poor general 
Strengths and limitations of this study
 ► This pilot trial systematically addressed procedural 
uncertainties associated with designing a large- 
scale randomised controlled trial.
 ► The pilot trial allowed us to test the feasibility of 
Patient- Reported Outcome Measures as dialogue 
support tools in clinical diabetes consultations.
 ► Well- known, validated tools for measuring the pri-
mary and secondary outcomes facilitated compar-
ison with other studies.
 ► One of the limitations was that we did not specifi-
cally predefine retention and attrition criteria for trial 
progression.
 ► Logistical challenges concerning cancelled appoint-
ments and non- attendance contributed to difficulties 




pril 14, 2021 at H










pen: first published as 10.1136/bm





2 Hernar I, et al. BMJ Open 2021;11:e042353. doi:10.1136/bmjopen-2020-042353
Open access 
well- being and emotional distress are known barriers for 
self- management, and performing behavioural adjust-
ments necessary to promote effective self- management 
can be challenging.10 In addition, individual efforts to 
achieve beneficial outcomes may not produce desired 
results.11 Diabetes guidelines recommend routine assess-
ment of psychological, emotional and psychosocial 
factors that impact personal ability to self- manage, like 
diabetes distress.2 12 Nevertheless, recent studies indicate 
that biomedical outcomes receive disproportionate atten-
tion in routine follow- up compared with what people with 
diabetes find important, such as psychosocial aspects.13 14
The construct diabetes distress refers to specific nega-
tive emotional experiences related to the challenges of 
living with and managing diabetes and the risk of acute 
and long- term complications.10 15 16 Diabetes distress is 
regarded as an expected reaction first of all impacting 
on well- being.17 In T1D studies, regimen distress, fear of 
hypoglycaemia and complications, feeling overwhelmed 
and worrying about the future is most commonly 
reported.18 Furthermore, diabetes distress is more prev-
alent among younger than older adults3 and associated 
with problematic self- management behaviours related to 
insulin treatment, glucose monitoring and unsatisfactory 
glycaemic control.19–22 Regimen distress appears to drive 
these associations.18 However, distress may also occur in 
individuals who reach recommended treatment goals.23 
Left untreated, mild cases may develop into severe and 
even chronic distress.24 In addition, diabetes distress is 
found to be a risk factor for symptoms of depression.25 
This highlights the importance of addressing diabetes 
distress in routine diabetes care.17 26
Patient- reported outcome measures (PROMs) are 
self- report questionnaires measuring patients’ subjec-
tive appraisal of a condition, treatment or other health- 
related outcomes.27 In clinical consultations, PROMs can 
be used to increase attention to individual needs, values 
and preferences. By using PROMs regularly, healthcare 
providers can screen for self- reported health outcomes, 
track progress over time and enhance communication 
with patients.27–30 Prior to implementation in clinical care 
settings, studies are needed to evaluate the feasibility, 
acceptability and effect of using PROMs in routine consul-
tations. We used the Medical Research Council’s (MRC) 
framework for developing and evaluating complex 
interventions for guidance.31 32 Accordingly, we devel-
oped the Diabetes Patient- Reported Outcome Measures 
(DiaPROM) trial ( ClinicalTrials. gov ID: NCT03471104). 
The overarching aim was to develop, test and evaluate 
a structured empowerment- based intervention using 
PROMs regarding diabetes distress as dialogue support in 
diabetes consultations among adults with T1D.33 Further-
more, we hypothesise that the DiaPROM intervention will 
reduce diabetes distress and improve overall well- being, 
perceived competence for diabetes management and 
glycaemic control. First, we conducted a feasibility study 
to test the technical and practical feasibility and accept-
ability of capturing PROMs on a touchscreen computer 
in an outpatient clinic.34 Then, we conducted the present 
pilot trial to test all the components of an upcoming fully 
powered randomised controlled trial (RCT), to deter-
mine if such a trial is feasible and appropriate. Here we 
report the results of the pilot trial using the Consolidated 
Standards of Reporting Trials 2010 statement: extension 
to randomised pilot and feasibility trials.35 Findings from 




To pilot test the proposed DiaPROM trial components 
and address uncertainties associated with conducting 
a full- scale RCT in order to evaluate whether the trial 
methods and the intervention are feasible. The pilot trial 
objectives were thus to:
1. Evaluate the recruitment procedures, randomisation 
procedure and attrition rates.
2. Evaluate the acceptability, appropriateness and imple-
mentation of the intervention components.
3. Estimate variance and between- group differences in 
participant outcomes (diabetes distress; general well- 
being; perceived diabetes competence and glycaemic 
control) following intervention or standard care, and 
correlation between participants’ diabetes distress 
scores at baseline and 12 months, in order to assist fu-
ture sample size calculations.
Design
The study was designed as a single- centre two- arm pilot 
RCT.
Setting and participants
In Norway, people with T1D are followed up at hospital 
clinics. We conducted the pilot trial at a university hospital 
endocrinology outpatient clinic where approximately 
80% of the patients with diabetes have T1D. Eligible 
participants aged ≥18–39 years with T1D duration for at 
least 1 year were identified using the clinic’s attendance 
list. We sent invitation letters with consent forms by mail 
10–14 days prior to the patients’ annual diabetes consul-
tations. Informed by pilot trial sample size guidance and 
the diabetes distress proportions documented in our 
feasibility study,34 38 we aimed to recruit 80 participants, 
40 in each arm. Using information from the electronic 
patient records (EPR), we applied the following exclu-
sion criteria: ongoing pregnancy, severe cognitive defi-
ciency, severe somatic comorbidity (eg, end- stage renal 
disease, severe heart failure, severe cancer), major psychi-
atric diagnosis (eg, severe depression or bipolar disorder, 
schizophrenia) and/or impaired vision.
Pilot trial intervention
We have described the intervention in detail in our 
protocol paper.33 Briefly, DIPS, eHealth systems supplier to 
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for capturing and transferring electronic PROMs to the 
diabetes- specific EPR.39 We asked all participants to arrive 
15 min early to complete PROMs on a stationary touch-
screen computer located in the outpatient clinic’s waiting 
area prior to two annual diabetes consultations (baseline 
and 12 months). While completing PROMs, participants 
received an individual four- character code which was 
used to download the PROMs to the EPR. The length of 
the annual consultations was increased from 30 to 45 min. 
Furthermore, we used the 20- item Problem Areas In Diabetes 
(PAID) scale to assess diabetes distress.40–42 PAID items are 
rated on a 5- point Likert- like scale (0, ‘not a problem’ 
to 4, ‘serious problem’), and an overall diabetes distress 
score of 0–100 is calculated, with higher scores indicating 
greater distress. A score ≥40 suggests serious diabetes 
distress.10 41 The PAID is widely used, and the Norwegian 
version is available in the diabetes- specific EPR.43
We developed a manual to guide the physicians to down-
load PROMs and review and discuss PAID scores with 
intervention arm participants, and to identify moderate 
and serious distress, specifically PAID total score ≥30 or 
at least one item scored 3 or 4. Next, the physicians were 
to offer individuals with such scores a minimum of two 
30- min diabetes specialist nurse consultations; the first 
within 4 weeks after randomisation and the second within 
a further 3 months. We also developed a communica-
tion manual where we guided the nurses to review base-
line PAID and discuss reported problem areas with the 
participants using person- centred, empowerment- based 
communication skills; ‘asking open questions’, ‘active 
listening’, ‘responding’, ‘summing up’ and ‘agreeing on 
goals and actions to take’. In addition, we requested the 
nurses to record problem areas discussed, goals, action 
strategies and plans in the EPR. In the second consulta-
tions, we asked the nurses and participants to discuss the 
problem areas, goals and actions and to decide whether 
to continue with consultations (optional number) until 
the next annual physician consultation. Intervention arm 
participants with lower PAID scores received follow- up 
according to standard clinical protocols after the brief 
review of their PAID scores with the physicians. Control 
arm participants, whose scores were inaccessible to the 
clinicians in the EPR, received ‘care as usual’.
Outcomes
Recruitment
We recorded the number of individuals invited, number 
of people attending consultations and number of people 
who consented to participate in the pilot trial. At base-
line, we observed if eligible participants started the PROM 
sessions by themselves and provided a friendly reminder 
or assistance to those who did not. At 12 months, we 
performed similar observations and guidance.
Sample characteristics
Sociodemographic and diabetes- related information 
was gathered from the participants’ EPR: age, sex, 
ethnic origin, diabetes duration, diabetes long- term 
complications, comorbidities, body mass index, glyco-
sylated haemoglobin (Haemoglobin A1c (HbA1c)) level, 
number of self- reported symptomatic hypoglycaemic 
events in the previous month, history of hypoglycaemia 
requiring assistance and hospitalisation due to ketoac-
idosis and insulin injection device. We also obtained 
self- report data on current type of glucose monitoring 
device, daily glucose measurement count, first language, 
educational level, cohabitation status and work affilia-
tion. In addition, we received ethical approval to record 
age, sex and HbA1c of eligible participants who declined 
participation.
Primary outcome measure
To avoid using the same questionnaire for diabetes distress 
assessment as an element of the intervention and as an 
outcome measure, we chose the Diabetes Distress Scale (DDS) 
as our primary outcome.43 The 17- item DDS measures 
diabetes- specific problems rated on a 6- point Likert- like 
scale (1, ‘no problem’ to 6, ‘serious problem’).44 The scale 
yields an overall diabetes distress score and four subscales: 
emotional burden (five items; eg, ‘Feeling that diabetes 
controls my life’), physician- related distress (four items; 
eg, ‘Feeling that my doctor doesn't take my concerns seri-
ously enough’), regimen- related distress (five items; eg, 
‘Feeling that I am not testing my blood sugars frequently 
enough’) and diabetes- related interpersonal distress 
(three items; eg, ‘Feeling that friends or family are not 
supportive enough of self- care efforts’). Item scores are 
averaged to form a total and subscale scores from 1 to 6, 
with higher values indicating greater distress.45 Scores are 
then categorised as little or no distress (<2.0), moderate 
distress (2.0–2.9) and high distress (≥3.0). Moderate and 
high distress is considered clinically relevant.45
Secondary outcomes measures
We used the WHO 5- Well- being Index (WHO-5) 5- item 
measure of current general well- being.46 Items are scored 
on a 6- point Likert- like scale (0, ‘at no time’ to 5, ‘all the 
time’). A 0–100 score is calculated and scores <50 suggest 
impaired well- being, while ≤28 indicate likely depres-
sion.46 47 A 10- point change is considered clinically rele-
vant.46 The measure is reported to be psychometrically 
sound, acceptable and suitable for diabetes outpatient 
settings.48–50 The 4- item Perceived Competence for Diabetes 
Scale (PCDS) assesses the degree to which people with 
diabetes feel they can manage daily aspects of diabetes 
care (1, ‘strongly disagree’ to 7, ‘strongly agree’).51 Item 
scores are averaged to form a score. Finally, we obtained 
information about glycaemic control from routinely 
performed blood samples measuring HbA1c (mmol/mol) 
recorded in the EPR.
Experiences with the pilot trial intervention
After each annual consultation, participants were asked 
to complete a paper questionnaire, which included the 
DDS (primary outcome measure) and questions about 
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components. We asked all participants PROMs accept-
ability questions (five response options from ‘not at 
all’ to ‘very large degree’): relevance, number of items 
and willingness for annual completion. In addition, we 
asked about preferred completion method (electronic 
or paper). Intervention arm participants were also asked 
about PAID use and consultation usefulness. Finally, we 
reviewed the nurses’ EPR notes for intervention arm 
participants referred to additional follow- up, to evaluate 
intervention consultation fidelity (per- protocol).
Randomisation
We randomised participants in a 1:1 ratio to an inter-
vention or control arm using computer- generated 
block- randomisation at the patient level, developed and 
administered by DIPS.39 The computerised allocation 
took place when the physicians downloaded PROMs to 
the EPR. Group allocation information appeared on the 
computer screen, and the physicians told the partici-
pants. Furthermore, we stratified by sex to ensure equal 
numbers (20) of male and female participants in each 
arm. Due to the nature of the intervention, blinding of 
group allocation to participants, healthcare providers 
and research personnel was not possible.
Analyses
All analyses were carried out using Stata SE 16 for 
Windows.52 At each timepoint, we estimated means, 
SD and 95% CI of SDs of outcome measures for both 
groups. To examine within and between- group variation 
of paired differences in outcome measures from base-
line to 12- month follow- up, we estimated means and SDs, 
and means and 95% CIs, respectively. Using Spearman’s 
correlation coefficient, we estimated correlation with 
95% CI between participants’ primary outcome measure 
scores at baseline and 12 months. The primary outcome 
measure SD, 95% CI of SD and correlation coefficient was 
used to assist in full trial sample size calculations. In all 
analyses, we computed missing items using person- mean 
substitution if at least 50% of the items per scale were 
completed.53 54
Patient and public involvement
In the protocol paper,33 we have provided a detailed 
description of health service user involvement based on 
the Guidance for Reporting Involvement of Patients and the 
Public 2 (GRIPP2) short form.55
RESULTS
Recruitment, randomisation, sample characteristics, and 
retention
Between 15 January and 7 May 2018, we assessed 149 
patients with T1D for eligibility and randomised 80 
participants, 40 (50%) to each trial arm (figure 1). The 
randomisation procedure yielded two groups with equal 
distribution of men and women. Baseline characteris-
tics for the total sample and trial arms are presented in 
table 1. Compared with the included participants, the 
22 who declined had longer diabetes duration (13.7±7.0 
years (95% CI: 12.2 to 15.3) vs 18.6±10.2 years (95% CI: 
14.1 to 23.1)), while there were no differences in gender 
distribution, age or HbA1c level. Furthermore, 24/40 
(60.0%) intervention arm participants qualified for addi-
tional nurse follow- up (figure 1). One participant was 
later excluded due to newly discovered language prob-
lems. In total, 17/23 (73.9%) were referred and attended 
1–5 consultations (mean±SD 2.2±1.1); 12/17 (70.6%) 
attended the per- protocol minimum. After reviewing the 
nurses’ EPR notes, we registered that 28/38 consultations 
were performed according to the protocol, while 10/38 
focused on other aspects than diabetes distress assessed 
by the PAID. Therefore, a mean of 1.65 (0–2) interven-
tion consultations was conducted, and 9/17 received 
per- protocol follow- up of minimum two sessions. The 
12- month follow- up was performed from 5 December 
2018 to 17 June 2019. Twelve participants were lost to 
follow- up (overall attrition rate 15.2%; intervention arm: 
8 (20.5%); control arm: 4 (10%)), but none withdrew 
consent (figure 1). Furthermore, 5/17 referred to addi-
tional nurse consultations were lost to follow- up (attrition 
rate 29.4%).
Acceptability, appropriateness and implementation of the 
intervention components
At baseline, 21/79 (26.6%) participants located the 
touchscreen computer without guidance, 43 (54.4%) 
confirmed they had read the written study information. 
At 12 months, five participants completed PROMs on 
paper; four because of a defective touchscreen and one 
asked for a telephone consultation. Of the remaining 62 
participants, we had to remind 30 (48.4%) to complete 
PROMs. Furthermore, 2/17 participants referred to addi-
tional nurse follow- up delayed the first consultation for 
4–6 months. The remaining 15/17 were offered the first 
consultation within 27.0±4.8 (19–35) days after randomis-
ation. However, due to five participants postponing at least 
once, the consultations were conducted after 42.5±27.7 
(22–123) days. The second appointments (n=15) were 
offered after 85.5±30.6 (20–133) days and attended by 12 
participants after 100.8±35.3 (20–153) days.
Total WHO-5, PAID and PCDS completeness was 99.4% 
at baseline and 99.2% at 12 months. When asked about 
preferred method for completing PROMs in the future, 
two (2.6%) individuals chose paper- completion, whereas 
42 (54.5%) opted for in- clinic computerised PROMs 
and 33 (42.9%) favoured home- based web- completion 
(online supplemental figure 1). Seventy- five (97.4%) 
reported that number of items were acceptable to a large 
or very large degree, 72 (92.3%) found the items relevant 
and 66 (84.6%) were willing to complete PROMs annu-
ally (online supplemental figure 1).
Among intervention arm participants, 23/39 (59.0%) 
and 13/31 (41.9%) reported PAID items scored ≥3 and/
or a total score ≥30 (moderate to high distress) at baseline 
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The control arm participants’ corresponding proportions 
were 19/40 (47.5%) and 20/36 (55.6%). Thirty (76.9%) 
intervention group participants reported that the PAID 
results were discussed at baseline, of which 15 (38.5%) 
found it useful to a large or very large degree and 10 
(25.6%) to some degree. At 12 months, 20/24 (83.3%) 
reported that PAID was discussed and 11 (45.8%) found it 
useful to a large or very large degree. Only 10/17 referred 
to additional follow- up completed all items about PAID 
use; five found the discussions useful; four reported to 
have benefitted to a large degree, whereas three had not 
benefitted at all. In total, 17/53 (32.1%) participants 
stated that completing PROMs had to some degree led 
to discussions related to diabetes- related challenges 
which would not otherwise have been discussed (similar 
in both trial arms). Furthermore, 14 (26.4%) reported 
that completing PROMs had been a positive experience, 
while 24/53 (45.2%) found it somewhat positive (similar 
in both trial arms).
Outcome measures
In total, 67/79 (84.8%) participants responded to all 
DDS items at baseline and 58/67 (86.6%) at 12 months 
(online supplemental table 2). Mean scores and SDs of 
the outcome measures at baseline and follow- up for each 
trial arm are reported in tables 2 and 3. At follow- up, 
the sample’s SD of DDS score was 0.71 (95% CI: 0.60 to 
0.86) (table 2). From baseline to follow- up, we observed a 
Figure 1 The DiaPROM pilot trial’s consolidated standards of reporting trials flow diagram.  
(CONSORT, Consolidated Standards of Reporting Trials; DiaPROM, Diabetes Patient- Reported Outcome Measures; DDS, 
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reduction in DDS overall score by an average of 0.25 (SD: 
0.42) in the intervention arm but no apparent reduction 
in the control arm (0.00, SD: 0.47). The intervention 
arm’s DDS subscale scores were all improved (−0.14 to 
−0.39, SDs: 0.66 to 0.86), while the control arm’s changes 
in subscales scores ranged from −0.07 to 0.09 (SDs: 0.54 
to 0.82). For other outcome variables (WHO-5, PCDS 
and HbA1c), only small changes were seen (table 3). The 
correlation coefficient between baseline and follow- up 
DDS scores was 0.8 (95% CI: 0.7 to 0.9) (online supple-
mental table 3).
In addition, 18/33 (54.5%) and 11/26 (42.3%) inter-
vention arm participants reported moderate to high 
distress measured by the DDS overall score at baseline 
Table 1 Baseline sociodemographic and clinical characteristics of the DiaPROM pilot trial participants with type 1 diabetes 
aged 18–40 years (n=79)
All Groups
  n=79 Intervention, n=39 Control, n=40
Gender, women 40 (50.6) 20 (50.6) 20 (50.0)
Age, years 27.2±5.0 27.1±4.7 27.3±5.3
European origin 79 (100.0) 39 (100.0) 40 (100.0)
Norwegian first language 74 (93.7) 36 (92.3) 38 (95.0)
Living alone 17 (21.5) 4 (10.3) 13 (32.5)
University/college education 37 (46.8) 21 (53.9) 16 (40.0)
Work affiliation
  Full- time work 36 (45.6) 18 (46.2) 18 (45.0)
  Part- time work 5 (6.3) 0 (0.0) 5 (12.5)
  Student 25 (31.7) 15 (38.5) 10 (25.0)
  Other 13 (16.4) 6 (15.3) 7 (17.5)
Diabetes duration, years 13.7±7.0 13.6±6.4 13.9±7.6
Long- term complication(s) 16 (20.3) 4 (10.3) 12 (30.0)
  Retinopathy* 15 (19.0) 4 (10.3) 11 (27.5)
  Nephropathy 1 (1.3) 0 (0.0) 1 (2.5)
Comorbidities/other autoimmune diseases
  Thyroid disease 5 (6.3) 2 (5.1) 3 (7.5)
  Coeliac disease 8 (10.1) 4 (10.2) 4 (10.0)
HbA1c (mmol/mol)† 65.4±14.5 64.8±13.2 66.0±15.8
HbA1c (%) 8.1±1.3 8.1±1.2 8.2±1.4
HbA1c ≤53 mmol/mol (≤7.0%)‡ 15 (19.0) 7 (18.0) 8 (20.0)
Body Mass Index (kg/m2) 24.6±5.6 24.2±7.1 25.0±3.6
Symptomatic hypos last month 9.8±10.5 11.4±12.6 8.1±7.5
Severe hypoglycaemic event ever§ 34 (43.0) 18 (46.1) 16 (40.0)
Ketoacidosis (ever hospitalised) 17 (21.5) 7 (17.9) 10 (25.0)
Insulin pump 38 (48.1) 20 (51.3) 18 (45.0)
Continuous glucose monitoring (CGM) 22 (27.9) 11 (28.2) 11 (27.5)
Self- blood glucose monitoring (SBGM) 53 (67.1) 27 (69.2) 26 (65.0)
Flash glucose monitoring (FGM) 2 (2.5) 1 (2.5) 1 (2.5)
  Daily SBGM/FGM¶ 47 (85.5) 25 (89.3) 22 (81.5)
  Weekly count SBGM/FGM 32.8±22.9 39.4±25.3 26.7±18.9
Data are shown as n (%) (of patients with valid values) or mean±SD.
*Any degree of retinopathy
†Haemoglobin A1c.
‡HbA1c target achieved.
§At least one severe hypoglycaemic event with need of assistance (yes).
¶Total n based on participants using SBGM or FGM.
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and follow- up, respectively (online supplemental table 4). 
Corresponding proportions for control arm participants 
were 15/39 (38.5%) and 17/34 (50.0%). Regarding 
DDS subscales, the percentage of participants reporting 
moderate to high emotional burden and regimen- 
related distress was persistent at ~60%, across groups and 
timepoints.
DISCUSSION
In this randomised controlled pilot trial, we found that it 
was feasible to recruit and randomise young adults with 
T1D attending routine diabetes consultations to a trial 
using PAID and communication techniques as dialogue 
support tools. The participants were positive towards 
completing PROMs. Furthermore, we were able to retain 
67/79 (84.8%) participants at 12 months. However, we 
identified implementation challenges related to the inter-
vention consultations, and 5/17 (29.4%) participants 
referred to additional consultations were lost to follow- up 
at 12 months.
Strengths and limitations
The pilot trial’s key strengths were that it systematically 
addressed uncertainties associated with designing a large- 
scale RCT. Moreover, well- known, validated tools for 
measuring primary and secondary outcomes allowed for 
comparison with other studies. The results inform tech-
nical and practical issues of conducting a full- scale trial. 
Similar to our feasibility study,34 findings suggest that 
completing electronic PROMs was generally accepted and 
technically feasible. We were able to recruit and randomise 
80 participants over 15 weeks. However, one fundamental 
limitation was that the 12- month follow- up lasted nearly 
twice as long (28 weeks), mainly caused by cancelled 
appointments, non- attendance and loss to follow- up. 
Another limitation was not having predefined criteria for 
retention and attrition progression rates. However, this is 
not yet common.56 Furthermore, complete follow- up was 
not achieved, and attrition differed by trial arm: 10% in 
the control arm, 20% in the intervention arm and 29% 
among those who were referred to additional follow- up. 
Systematic differences between completers and drop- outs 
may have introduced attrition bias.57 However, clinic non- 
attendance is not uncommon among young adults with 
T1D and has been linked to difficulties communicating 
with the services, conflicting schedules, low perceived 
value of attendance and challenges with developing rela-
tionships.58 59 The retention, implementation and accept-
ability issues are further explored in qualitative interviews. 
In summary, these issues will impact power calculations 
by increasing the target sample needed, in addition to 
affecting intervention implementation and the duration 
of a full- scale RCT.
Generalisability and transferability to other settings and 
populations may be limited due to our use of electronic 
technologies for completing PROMs, our choice of only 
including young adults with T1D, and that the Norwegian 
health insurance system differs from other countries. 
Finally, although PAID scores were not accessible in 
the control arm participants’ EPRs, we cannot rule out 
contamination. Since all participants completed PROMs 
in the same manner, control arm participants’ consulta-
tions may have been influenced by individual responses 
and thoughts about the questionnaires. Moreover, 
consulting styles within a service probably differs between 
clinicians. For ethical reasons, we could not instruct the 
physicians to avoid discussing diabetes distress in the 
control arm if participants requested it.
Implications and future research
Using current pilot trial data and a conservative DDS SD 
estimate to calculate the minimal clinically important 
difference (0.5 x SD),60 and assuming that SD (0.71) is 
equal for each trial arm in a full- scale, single- site RCT, we 
estimate at least 107 participants will be required per arm 
to provide 90% power based on a two- sided 5% signifi-
cance level. The calculation was based on the formula of 
a two- sample t- test for difference post- intervention and 
allowed for 25% attrition.
Since 10% of the participants did not complete the 
paper- based measures, and there was considerably 
more missing DDS items than other PROM items, we 
will strive for capturing all future data electronically. 
Furthermore, only a minority of participants approached 
the touchscreen computer by themselves. Therefore, 
we will continue with in- clinic guidance and e- mail or 
SMS reminders to support data collection. A web- based 
PROMs platform, recently available in Norway, will 
possibly enable more complete data collections in future 
studies. Moreover, we observed that 36 (45.6%) partici-
pants had not read the study information prior to coming 
to the clinic but still consented. The drop- out rates and 
other findings suggest that consultations were not consid-
ered useful, adequate or appropriate by the participants. 
This could in part be explained by protocol inflexibility 
and/or the waiting time between PROMs completion and 
additional consultations. In addition, we may not have 
provided sufficient detailed information about the nature 
of the intervention components, especially the additional 
follow- up. Also, this key intervention component may 
not have fitted the participants’ personal beliefs, pref-
erences, capabilities and/or life circumstances.61 We 
may also have underestimated the contribution of the 
baseline review of scores and discussions between inter-
vention arm participants and physicians. Furthermore, 
our criteria for offering additional follow- up may have 
led to overinclusion of cases but we must also consider 
barriers to clinic attendance and dissatisfaction with the 
follow- up.14 58 Another aspect which requires consider-
ation, is that simply answering questions for assessment 
purposes, such as PROMs, may affect research partici-
pants by stimulating new thinking about problem areas or 
behaviours, which then may lead to action- taking.62 This 
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Diabetes distress scores were similar to previous 
studies.20 21 63 Approximately half of the participants 
reported moderate to serious distress, which supports 
statements that diabetes distress is common and worthy 
of individual attention in diabetes care.4 12 15 Although 
the pilot trial was not powered for inferential statements, 
the observed between- group differences in DDS scores 
suggest promising effects of assessing and addressing 
diabetes distress. Compared with lack of assessment and 
follow- up, education- based or emotion- focused interven-
tions targeting diabetes distress in adults with T1D have 
been found clinically effective.24 64 65 In the pilot trial, 
we focused on real- life clinical consultations. Hence, the 
clinicians meet individuals with different needs which 
may entail applying either education- based or emotion- 
focused interventions or both, depending on individual 
diabetes distress foci, discussions with each individual 
and clinical experience. Personalising diabetes care by 
addressing diabetes distress systematically, may increase 
healthcare providers’ attentiveness towards the individual 
experiences of living with diabetes.
Implementation fidelity and difficulties in delivering 
the intervention as designed appeared challenging for 
the clinic. One aspect was providing the consultations 
within the specified timeframe. Recommendations of 
2- week to 1- month intervals between consultations23 66 
may be difficult to achieve within regular working hours 
unless telephone or digital communication are used.67 
The observed lack of intervention fidelity, for example, 
not reviewing the PAID during annual consultations, 
may be partly explained by low sense of project owner-
ship from the clinicians. This highlights the importance 
of organisational incentives, management facilitation of 
new intervention initiatives and possibly cultural aspects 
in this setting. Our efforts to encourage intervention 
fidelity by providing information, developing manuals 
and arranging meetings and training for the clinicians 
may not have been sufficient. Consequently, we must seek 
to further identify key contextual, organisational and 
behavioural factors and mechanisms of impact. The pilot 
trial results show that we must involve health service users 
and clinicians in further development of the intervention 
and undertake more feasibility work with process evalua-
tions to inform the design of a full- scale trial.68
CONCLUSIONS
Results from this randomised controlled pilot trial show 
that it is feasible to recruit and randomise young adults 
with T1D attending an outpatient clinic to a study using 
electronically captured PROMs to assess diabetes distress. 
However, the intervention was not provided as planned. 
Low perceived usefulness and high attrition rate among 
intervention arm participants also suggest low accept-
ability or overinclusion. The pilot trial revealed problems 
with design and deliverability and highlighted the need 
for several intervention modifications before initiating 
a full- scale evaluation of using electronic PROMs in 
diabetes consultations.
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DiaPROM pilot trial supplementary figure 
 
Supplementary figure 1: Young adults’ (18-39 years) perceptions about completing 
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Supplementary table 3: Correlation between participants’ outcome measure scores at 
baseline and 12-month follow-up – the DiaPROM pilot trial. 
 
1 Diabetes Distress Scale (1-6), 2 Emotional burden (1-6), 3 Physician-related distress (1-6), 4 Regimen-related 
distress (1-6), 5 Interpersonal distress (1-6), 6 World Health Organisation five-item wellbeing index (0-100),  
7 Perceived Competence for Diabetes Scale (1-7), 8 Haemoglobin A1c (target for glycaemic control in mmol/mol). 
Association Participants n Spearman’s ρ 
95% CI around 
Spearman’s ρ 
Primary outcome     
DDS1 score  
at baseline and 12 months 
All 55 0.8 0.7, 0.9 
Intervention 22 0.8 0.6, 0.9 
Control 33 0.8 0.6, 0.9 
Secondary outcomes     
WHO-56 score  
at baseline and 12 months 
All 67 0.5 0.3, 0.7 
Intervention 31 0.5 0.2, 0.7 
Control 36 0.5 0.2, 0.7 
PCDS7 score  
at baseline and 12 months 
All 66 0.7 0.5, 0.8 
Intervention 31 0.6 0.3, 0.7 
Control 35 0.8 0.6, 0.9 
HbA1c value8   
at baseline and 12 months 
All 66 0.7 0.5, 0.8 
Intervention 31 0.6 0.3, 0.7 
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Abstract
Aim: To explore young adults' experiences of outpatient follow- up appointments, 
completing electronic Patient- Reported Outcome Measures (PROMs), and using 
the Problem Areas In Diabetes (PAID) scale during the Diabetes Patient- Reported 
Outcome Measures (DiaPROM) pilot trial.
Methods: We performed a qualitative study among 19 young adults (aged 22– 
39 years) with type 1 diabetes who participated in the pilot trial. Between February 
and June 2019, we conducted individual, semi- structured telephone interviews with 
participants from the intervention and control arms. We analysed the data using the-
matic analysis.
Results: Our analyses generated three themes, each with two subthemes: (1) 
Follow- up with limitations; (i) Marginal dialogue about everyday challenges, (ii) 
Value of supportive relationships and continuity, indicate that previous follow- up had 
been experienced as challenging and insufficient. (2) New insights and raised aware-
ness; (i) More life- oriented insights, (ii) Moving out of the comfort zone, suggest 
mostly positive experiences with completing questionnaires and discussing the PAID 
scores. (3) Addressing problem areas with an open mind; (i) Need for elaboration, (ii) 
Preparedness for dialogue, indicate that both openness and explanations were vital in 
the follow- up.
Conclusions: Participants characterised the previous follow- up as challenging and 
insufficient. They described completing and using the PAID as somewhat uncomfort-
able yet worthwhile. Our findings also suggest that by utilising diabetes distress data 
alongside health and biomedical outcomes, consultations became more attuned to the 
young adults' wishes and needs, mainly because the dialogue was more focused and 
direct. Hence, the PAID has the potential to facilitate person- centredness and improve 
patient– provider relationships.
2 of 9 |   HERNAR Et Al.
1 |  INTRODUCTION
Managing type 1 diabetes is a persistent activity performed 
outside the diabetes care setting. Due to the nature of the 
disease, self management extends beyond glycaemic con-
trol and other biomedical outcomes, also affecting emotional 
health and social functioning.1 Finding a balance between 
diabetes and living can be challenging regardless of age but 
especially so in young adulthood.2 Experiences of burden, 
stress, anxiety and/or concern that arise from daily self man-
agement are referred to as diabetes distress.3 About one- third 
of adults with type 1 diabetes will experience distress levels 
likely to impact on self management and clinical outcomes.4 
Furthermore, diabetes distress is more prevalent in younger 
adults than other age groups2 and associated with problematic 
self management behaviours and poor glycaemic control.5,6 
However, achieving recommended glucose targets does not 
necessarily exclude distress.3 Diabetes distress is viewed as a 
predictable response to having diabetes, not as psychopathol-
ogy, and should, therefore, be addressed in routine diabetes 
care.3
For more than two decades, diabetes guidelines and 
position statements have acknowledged person- centred 
approaches to promote optimal well- being and disease man-
agement.7 Recommendations include routine assessment of 
psychological, emotional and psychosocial factors, such as 
diabetes distress, to identify problems and improve health 
outcomes. Diabetes distress can be assessed using Patient- 
Reported Outcome Measures (PROMs).3 Previous research 
suggests that PROMs can improve chronic care delivery by 
assessing, identifying and monitoring health outcomes, im-
proving patient– provider communication, and promoting 
involvement in self management.8 However, recent studies 
indicate that healthcare providers (HCPs) still place exces-
sive focus on biomedical outcomes compared to those that 
people with diabetes find important.9,10
Guided by the Medical Research Council's framework 
for developing and evaluating complex interventions,11 we 
have designed, feasibility tested and piloted an intervention 
to address diabetes distress in the Diabetes Patient- Reported 
Outcome Measures (DiaPROM) trial.12- 14 The pilot trial 
targets young adults (age ≥18 to <40) with type 1 diabe-
tes receiving outpatient follow- up and is described in detail 
elsewhere.12 Briefly, we used the 20- item Problem Areas in 
Diabetes (PAID) scale to identify distress sources and inten-
sity.15,16 Items are scored from 0 ‘not a problem’ to 4 ‘serious 
problem’ and transformed to a 0– 100 scale, where scores ≥40 
are considered seriously elevated. Before the annual appoint-
ment with a physician, all participants (N = 79) completed 
the PAID on an in- clinic touchscreen computer and were ran-
domly assigned (1:1) to an intervention (n = 39) or control 
arm (n = 40). In the intervention arm, physicians reviewed 
and discussed the PAID with the participants, guided by a 
manual about how to interpret and act on the scores. Twenty- 
three individuals reported a score ≥30 or at least one item 
scored ≥3, therefore qualifying for additional diabetes spe-
cialist nurse consultations, of which 17 accepted. To lessen 
or prevent serious distress, the nurses reviewed and discussed 
reported problem areas with the participants, guided by a 
study manual with specific person- centred communication 
techniques (active listening, asking open questions, respond-
ing, summing up and agreeing on goals and actions to take). 
Control arm participants received standard outpatient care 
with no review of scores. Finally, all participants completed 
the PAID again at 12 months (reported elsewhere).
We have conducted two qualitative studies alongside the 
DiaPROM pilot trial to inform the quantitative findings by 
exploring participants' and HCPs' experiences and views 
on feasibility and acceptability.12 The findings from HCP 
experiences are published.17 In the present study, we aimed 
to explore young adults' experiences of outpatient follow- up 
appointments, completing electronic PROMs, and using the 
PAID scale during the DiaPROM pilot trial.
K E Y W O R D S
diabetes mellitus, empowerment, outpatient care, patient- centred care, professional– patient 
relations, self report, type 1 adult
Whats’ New?
• Diabetes distress is common among young adults 
with type 1 diabetes.
• We found that the Problem Areas in Diabetes 
(PAID) scale encouraged reflective thinking, pro-
moted the young adults' narratives and facilitated 
person- centred dialogue in consultations.
• Implications are that healthcare services need to 
adapt to and acknowledge young adults' wishes 
by addressing diabetes distress during appoint-
ments. However, continuity of care and develop-
ment of young adult– provider relationships are 
essential ingredients for utilising the PAID in the 
follow- up.
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2 |  PARTICIPANTS AND METHODS
2.1 | Study design
We performed an exploratory qualitative study among 
DiaPROM pilot trial participants. Our approach was induc-
tive and descriptive, focusing on experiences with outpatient 
appointments and specific pilot trial components.
2.2 | Setting and participants
We undertook the randomised controlled pilot trial and quali-
tative studies at a Norwegian diabetes outpatient clinic.13 The 
clinic employs endocrinologists, physicians specialising in 
endocrinology (or other internal medicine specialities), dia-
betes nurse specialists and health service secretaries. About 
1500 adults with type 1 diabetes were registered there in 
2019. Our eligibility criteria for the present study were pilot 
trial participation with completed 12- month follow- up. We 
sent study invitations to the 67 eligible participants 3– 7 days 
after their 12- month follow- up and asked them to respond 
by e-mail, telephone or SMS. None replied within 14 days; 
therefore, we sent SMS reminders. Finally, 19 individuals 
responded positively: age 22– 39  years, diabetes duration 
5– 32 years (Table 1); eight control arm and 11 intervention 
arm participants, of which six had received additional nurse 
follow- up.
2.3 | Data collection
We offered individual interviews face- to- face or by tele-
phone. All participants chose telephone interview. Between 
26 February and 24 June 2019, the first author conducted and 
audio- recorded the interviews (average duration 39 minutes). 
The semi- structured interview guide received minor adjust-
ments after the first two interviews (Data S1). First, partic-
ipants in both trial arms were invited to share experiences 
with previous follow- up. Next, all participants were asked 
about electronic completion and relevance of the PROMs. 
Also, we encouraged intervention arm participants to share 
experiences with the physicians' review of the PAID scores 
and, where relevant, with attending additional nurse follow-
 up. The first author transcribed the interviews verbatim and 
checked the transcripts against the recordings for accuracy. 
We obtained clinical and socio- demographic characteristics 
from the pilot trial dataset. At the time, these characteristics 
were unknown to the interviewer.
2.4 | Data analysis
We analysed the data using thematic analysis, which focus 
on identifying, analysing and reporting patterned meaning 
(themes) across a dataset.18 Thematic analysis is theoretically 
flexible and characterised by an iterative, rigorous process 
of data familiarisation, open- coding, development of themes 
and revision. We applied an inductive approach and com-
bined semantic and latent levels of analyses. The Norwegian- 
speaking authors (IH, MG, RBS, SSL, AKS, BCHK, AH) 
which constituted the analysis team, first read and reread all 
interviews to familiarise with the dataset. Next, each author 
recorded their preliminary ideas and generated initial codes. 
The team then met for two workshops. In the first workshop, 
each member shared initial thoughts and preliminary codes. 
We discussed features relevant to the aim, collated codes by 
pattern, prepared a schematic overview and formed candidate 
themes by identifying similarity and clustering. In the second 
workshop, we reviewed, discussed and revised the candidate 
themes, which also included creating new codes and themes 
for data falling outside the previous coding. IH continued the 
process and drafted the paper. Finally, we identified meaning-
ful, coherent patterns and agreed on themes and subthemes.
2.5 | Ethics
The study received ethical approval by the Western Norway 
Regional Committee for Medical and Health Research 
Ethics (2017/1506/REK vest). This study was specifically 
described in the pilot trial's written information. All partici-
pants provided written consent and could withdraw at any 
T A B L E  1  Characteristics of adults with type 1 diabetes 






Participants 19 (100) 11 (58) 8 (42)
Women 11 (58) 6 (55) 5 (63)
Referred to nurse 
follow- up
6 (32) 6 (55) NA




Late complications* 4 (21) 2 (18) 2 (25)
Insulin pump 
therapy
12 (63) 7 (64) 5 (63)
Continuous glucose 
monitor
10 (53) 6 (55) 4 (50)
HbA1c (mmol/mol) 59 ± 11.7 58 ± 9.1 59 ± 15.3
HbA1c (%) 7.5 ± 1.1 7.5 ± 0.8 7.5 ± 1.4
Data are n (%) or mean ± SD. NA = not applicable.
*All cases of untreated retinopathy. 
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time, without giving a reason and without it affecting their 
follow- up. Participants chose the interview method and de-
cided on timing. Audio- recordings were started after the in-
terviewee had consented and pauses were provided if needed. 
Afterwards, participants were given time to debrief and, if 
deemed necessary by the interviewer, provided with informa-
tion on clinical supervision and support. Participants' identi-
fying information was removed from the transcripts before 
a digitally encrypted document was shared with the analysis 
team. Data are stored on Haukeland University Hospital's se-
cure research server.
3 |  RESULTS
The analyses generated three themes: ‘Follow- up with limita-
tions’, ‘New insights and raised awareness’ and ‘Addressing 
problem areas with an open mind’, each with two subthemes 
(Table 2).
3.1 | Follow- up with limitations
The participants described previous outpatient follow- up as 
challenging and insufficient, which is further explored in the 
subthemes ‘Marginal dialogue about everyday challenges’ 
and ‘Value of supportive relationships and continuity’.
3.1.1 | Marginal dialogue about 
everyday challenges
Several participants characterised the follow- up as challeng-
ing and conveyed hesitance and reluctance about attending, 
especially physician check- ups. One expressed: 
“[It is] a bit like sitting for an exam, going to 
a check- up. I don't think it's deliberate, but you 
feel a bit like they're wagging a finger, right. 
You worry about your HbA1c because then you 
might be seen as ‘a not so good diabetic’. That 
kind of follow- up is the reason why I've hardly 
attended. It's been a problem.” 
(Participant 8, control arm)
According to interviewees, annual check- ups typically 
focused on biomedical ‘numbers’, for example, blood tests, 
glucose values and insulin doses, often at the expense of con-
versations about everyday life. However, opinions varied. Some 
experienced that such check- ups were not worthwhile. One par-
ticipant put it like this: 
“I feel that I'm only there for them [physicians] 
to tick off something on a checklist and do their 
job in a way. … I feel that there's no point in 
being there then because what do I gain from 
them weighing me and measuring me? Uh. 
I don't feel that we're talking about important 
issues.” 
(Participant 19, control arm)
Others stated that check- ups provided a sense of security 
about their disease management. While some did not know 
what to expect beyond information about test results. In ad-
dition, experiences were compared to previous paediatric fol-
low- up, as described by one: 
"I do expect to be able to talk to someone about 
diabetes itself and not just how the test results 
are, you know, bodily in a way. At the paediat-
ric clinic, they were much better at that because 
there was more of a holistic focus there I felt. 
When I was transferred to the adult clinic, I felt 
they were less focused on that." 
(Participant 15, intervention arm)
The young adults conveyed being accustomed to questions 
like ‘How are you doing?’. However, such inquiries were often 
perceived as superficial and difficult to address and therefore 
often answered half- heartedly, without promoting dialogue 
where they opened up. Although stating a wish to be asked 
about the emotional aspects of self management, they also ex-
pressed ambivalence due to previous unpleasant experiences. 
One said: 
“I think it's a good idea to ask patients questions 
about what we think about our lives, our diabe-
tes and situation. We're after all the ones who 
know best, but at the same time, I quickly feel 
that I'm put on the spot and that I have to answer 
very properly, and then I, like, don't really get to 
T A B L E  2  Themes and subthemes generated by the analyses of 
interviews with 19 young adults with type 1 diabetes their experiences 
with outpatient follow- up and participation in the DiaPROM pilot trial
Themes Subthemes
Follow- up with limitations Marginal dialogue about 
everyday challenges
Value of supportive relationships 
and continuity
New insights and raised 
awareness
More life- oriented insights
Moving out of the comfort zone
Addressing problems areas 
with an open mind
Need for elaboration
Preparedness for dialogue
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answer what I think. I feel that it's a pressured 
situation. Uhm yeah.” 
(Participant 16, intervention arm)
Moreover, participants specified that the pilot trial's focus 
on diabetes distress further highlighted that previous follow- up 
had been deficient. One stated: 
“That [questionnaire] underlined the fact that 
there are very many issues a physician can bring 
up. So, I mean, a lot is missing there. At least 
when you're there just once a year and if you're 
a ‘good patient’.” 
(Participant 15, intervention arm)
3.1.2 | Value of supportive 
relationships and continuity
The young adults expressed a wish to be met as a person with 
diabetes, not a diabetes patient, by empathetic and caring 
HCPs with diabetes expertise and communication competen-
cies. However, many described negative experiences with 
the existing services, such as considering whether they were 
comfortable opening up to HCPs. This consequently affected 
conversations. One said: 
“Everyone is probably professionally skilled, 
but not everyone, maybe, uh, I call it human 
understanding, communicates equally well. It's 
a bit to do with confidence, and it's to do with 
chemistry, but you don't want to automatically 
open up to everyone. While with physicians you 
know listen to what you say, it's okay to maybe 
open up a bit more.” 
(Participant 6, intervention arm)
In seeking trust- based and supportive relationships, they de-
scribed wanting to become comfortable with sharing concerns 
and challenges, but with as few HCPs as possible. However, 
many had experienced rarely meeting the same physician twice. 
One participant described the importance of relational compe-
tence and continuity like this: 
“A good relation is quite important for you 
to speak about things you might dread or be 
ashamed of. Or sorts of things that are about 
struggling with self- management or other 
things. So, I think about that relational compe-
tence bit and actually appreciating that there's 
some continuity. I think they still have some 
way to go in that regard.” 
(Participant 18, control arm)
The participants also reflected on the need for HCPs to 
be attentive to individual wishes and needs for them to expe-
rience being seen and heard. Compared to challenges usually 
conveyed to physicians, they expressed that they more often 
addressed emotional and psychosocial concerns with nurses. 
These challenges were considered less specific and more 
complex than biomedical outcomes. One described a diabetes 
nurse's contribution: 
“The focus [in nurse appointments] is what's 
difficult. That's kind of the question when I 
come in. Like what's challenging and then we 
take it from there. So, I get to be a lot more in-
volved, and I feel that I'm seen and heard, and if 
I'm having a bad day, she doesn't give up, and I 
think that's very nice." 
(Participant 19, control arm)
3.2 | New insights and raised awareness
The young adults conveyed experiencing new- found insights 
and awareness concerning the complexity of diabetes after 
completing PROMs, which is described in two subthemes: 
‘More life- oriented insights’ and ‘Moving out of the comfort 
zone’.
3.2.1 | More life- oriented insights
Completing questionnaires made the young adults reflect 
upon their everyday lives, which enabled further insight 
about their situation, also regarding issues that some had 
not previously thought about. The realisation or increased 
consciousness about emotional and psychosocial aspects of 
diabetes self- management helped participants from both trial 
arms to reflect upon how they were feeling before engaging 
with HCPs. It also helped them understand that they were 
not alone in being faced with diabetes- related challenges, as 
described by one participant: 
"I think the questions are very good, and I think 
they might help you think of other things to dis-
cuss with the physician. The way the questions 
are set up, and that maybe you feel that you're 
not the only one who can think about different 
things. That you're not alone with those thoughts 
and what you feel about your diabetes." 
(Participant 17, control arm)
Furthermore, the PAID items were characterised as highly 
relevant, concrete diabetes- related concerns and challenges put 
into words. As some were made aware of possible yet unfamiliar 
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diabetes- related challenges, they expressed that inquiry into di-
abetes distress should have been part of the existing follow- up. 
One said: 
"I mean, this is something I'll live with for the 
rest of my life, so it [diabetes distress] should've 
been opened quite early, so that one might've 
been prepared for things that can become dif-
ficult and that it can affect your head in many 
ways, plus your body too, physically. How your 
psyche and your head are affected by diabetes 
when you work with it all the time." 
(Participant 3, intervention arm)
3.2.2 | Moving out of the comfort zone
Although the questionnaires mostly contributed positively, 
interviewees from both trial arms also shared a variety of 
challenges. In general, they found it difficult to decide on 
response options and characterised this as rating or plac-
ing themselves on a scale. The reflectiveness and increased 
awareness also evoked rather demanding thoughts about 
life with diabetes. Completing the items and the prospect of 
disclosing responses were labelled as moving outside one's 
comfort zone. They used words like vulnerable, uncomfort-
able, exposed, scary, super close, genuine and real. One par-
ticipant articulated it like this: 
"It's quite scary because you feel so exposed in 
one respect, and no one's seen that before… It's 
crazy how things get so real, both to yourself 
and to others when you sit and tick off ‘how 
you feel’ or ‘how you are’, or what you've been 
thinking and stuff." 
(Participant 19, control arm)
The young adults also revealed insights about sincerity 
while completing PROMs, which varied between finding it 
unproblematic to choosing to size up the situation. They com-
municated that responses could be affected by insecurity about 
which HCP they were seeing afterwards. In addition, they 
conveyed that openness was interconnected with willingness 
for self- sincerity and evaluating this against sharing one's true 
problems. One said: 
"Some questions [items] can be somewhat diffi-
cult and painful to respond to. If you really an-
swer exactly the right thing, I guess that's really 
what can be a bit inhibiting, how honest you are 
with yourself. As a diabetic, you become a bit 
like… you lie to yourself sometimes (laughs), 
you think things are somewhat better than they 
really are. I mean, it's difficult at times, but I 
think some awareness and thoughts about how 
you're actually doing is a good thing. I think 
that's healthy." 
(Participant 11, intervention arm)
Overall, participants expressed appreciation about the em-
phasis on diabetes distress, which covered areas many were un-
familiar with discussing and could struggle with addressing at 
appointments.
3.3 | Addressing problem areas with an 
open mind
When using the PAID in consultations, the participants high-
lighted the importance of addressing problem areas with 
an open mind. This is further exemplified in the subthemes 
‘Need for elaboration’ and ‘Preparedness for dialogue’.
3.3.1 | Need for elaboration
Young adults in both trial arms communicated a need to 
elaborate on and share underlying experiences associated 
with their PAID responses. This was also deemed necessary 
by intervention arm participants since some experienced that 
HCPs placed greater importance into their responses than 
was intended. Hence, nuances, clarity and/or explanations 
were particularly important. One said: 
"I felt that I responded honestly, but it was al-
most a bit … the nuance that ‘yes, I'm very wor-
ried and I think this is very scary and…’, but 
it's not as if I can't manage, like, or it's not as 
if… Yeah, there was a nuance that disappeared 
somewhat because in a way it's possible to be 
quite worried but still not so bothered by it." 
(Participant 9, intervention arm)
In addition, some discovered that the physicians were sur-
prised by their diabetes distress scores but experienced in-
creased understanding since the distress was acknowledged. 
They characterised this as sharing new insights into the chal-
lenges of seemingly ‘well- functioning patients’ and viewed it 
as an opportunity for physicians to engage with their distress 
and initiate dialogue.
3.3.2 | Preparedness for dialogue
Interviewees characterised the PAID as a tool used to focus 
on diabetes- related issues ahead of check- ups. Intervention 
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arm participants further stated that it served as a vent to com-
municate frustration and, without them having to initiate, as 
a conversation starter that facilitated a more constructive dia-
logue. One said: 
"I think it was all right that the physician could 
see my [PAID] responses. Then the physician 
could address problem areas, or what I was dis-
satisfied with or worried about. We had some-
thing constructive to work from, it [the dialogue] 
didn't get as vague as… Yes, I find it difficult to 
put into words what I really want from appoint-
ments. It probably became more apparent in the 
questionnaire." 
(Participant 16, intervention arm)
Completing the questionnaire made it difficult to postpone 
challenging issues. However, getting on track was considered 
positive, and using the PAID also contributed to an experience 
of being taken seriously. Nevertheless, intervention arm par-
ticipants referred to additional nurse follow- up, conveyed not 
preparing for these appointments. Some also described a lack 
of flexibility where the PAID took up too much space and char-
acterised the dialogue as unnatural and difficult for both parties. 
Furthermore, they conveyed that the nurses did not seem suffi-
ciently prepared to receive, attend to or discuss their problems. 
Therefore, the follow- up did little to alleviate their distress. One 
depicted a consultation like this: 
"It was a bit like: ‘Yes, do you want to say any-
thing about what you find difficult? No? Then 
we'll move on to the next item.’ So, it was a 
bit like you felt that you exposed yourself a bit 
more than she was comfortable with." 
(Participant 6, intervention arm)
However, some participants defended the nurses and argued 
that they simply followed the study manual, further specifying 
that the PAID had set the agenda. Nevertheless, the overall es-
sence communicated by the young adults, was that using the 
PAID was somewhat uncomfortable but still worthwhile.
4 |  DISCUSSION
In this study, young adults described finding previous follow-
 up lacking in content and continuity of care, hindering the 
development of supportive patient– provider relationships. 
Furthermore, our data provided insights about how they ex-
perienced and were affected by completing the PAID and the 
importance of an open- minded approach while addressing 
diabetes distress in consultations. We have identified, there-
fore, important considerations for further trial development.
In keeping with other studies, we identified that young 
adults want the complexity of diabetes to be addressed at 
appointments.19- 21 Their calls for continuity in care and 
person- centred, holistic approaches to follow- up extending 
beyond biomedicine and highlighting motivational and emo-
tional challenges, are also supported in the literature.9,10,19,22 
Biomedical outcomes are undeniably important but do not 
necessarily reflect aspects most important to people with 
diabetes.9,23 In this pilot trial context, participants conveyed 
appreciation about the PAID's content in addition to how it 
functioned as an eyeopener and promoted dialogue about 
important matters. In accordance with PROM literature, it 
created an opportunity for reflective thinking and validated 
their narrative,8,24,25 which in turn seemed to facilitate and 
enhance the patient– provider dialogue.8
Our findings also support the ‘red flag’ approach (target-
ing higher scored items), which can help identify specific 
distress sources and thereby narrow the focus in consulta-
tions.3,16 However, sharing PROM data can be difficult due 
to individual factors and/or patient– provider interpersonal 
factors. This suggests that when collecting PROMs in clin-
ical settings, we need to be aware of selective reporting and 
other biases possibly affecting self- report and subsequently 
score interpretation.26 Furthermore, our data emphasised the 
initiation of dialogue about underlying rationales behind re-
sponses to specific items, providing further insights about 
the young adults' lived experience. In a related study, HCPs 
described striving to balance recommendations for biomed-
ical measurements with addressing young adults' emotional 
concerns due to limited resources and organisational chal-
lenges.17 However, this clinical conflict was not linked to un-
willingness in applying supportive, person- centred strategies.
For people with diabetes, relationships with providers 
are essential for their ability to self- manage and have been 
shown to influences behavioural, emotional and biomedical 
outcomes.27 Likewise, good quality relationships seem im-
perative for the beneficial use of PROMs in the clinical con-
text. Adding the PAID may serve as a catalyst for starting 
dialogues about diabetes distress and may provide important 
insights that complement biomedical measures. However, for 
this approach to contribute, the essential ingredients are how 
the PAID information is used and how clinicians communi-
cate.24 Overall, the HCPs require further training in using 
dialogue tools. Since the development of the pilot trial, new 
evidence- based resources are available that will be useful for 
this purpose.3,28
4.1 | Strengths and limitations
We have previously reported quantitative data regarding 
the feasibility and acceptability of the proposed DiaPROM 
trial.13,14 In this study, all interviews were performed after 
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the 12- month follow- up to avoid influencing quantitative 
data and outcomes.29 We consider the qualitative approach 
a strength for the research project as it allowed for fur-
ther exploration of the participants' experiences. We have 
gained insights about contextual factors such as the follow-
 up the participants were accustomed to before the pilot trial, 
in addition to intervention acceptance, fidelity and delivery 
that will aid further trial development.11 Credibility and 
confirmability were strengthened by the research team's 
extensive diabetes knowledge and by involving research-
ers with considerable qualitative research experience in 
the analysis.30 Furthermore, we used reporting standards to 
improve study transparency and credibility.29 However, in-
terviews concerning the previous follow- up should ideally 
have been performed prior to the pilot trial. Also, we had 
limited information about the HCPs previous training and 
general attitudes towards consultations, which may have 
affected the participants' experiences. Although our find-
ings may not be directly transferable to other contexts, we 
believe that HCPs and people with diabetes will recognise 
at least parts.
5 |  CONCLUSION
Our data provide insights into how young adults with type 
1 diabetes experienced the DiaPROM pilot trial's contextual 
circumstances. Participants characterised the previous follow-
 up as challenging and insufficient. They further described 
completing and using the PAID as a somewhat uncomfort-
able yet worthwhile experience. Our findings also suggest 
that by utilising electronic self- reported diabetes distress data 
alongside health and biomedical outcomes, consultations be-
came more attuned to the young adults' wishes and needs, 
mainly because the dialogue was more focused and direct. 
Therefore, the PAID has the potential to facilitate person- 
centredness and improve patient– provider relationships.
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DiaPROM Prosjektnummer: 2017/1506/REK vest 
 
Bruk av pasient-rapporterte målinger for å bedre kvaliteten  
på oppfølgingen av personer med diabetes  
 
 
WHO-5 Well-being Index - Spørsmål om trivsel og velvære 
 

























1. følt meg glad og i godt 
humør 
5 4 3 2 1 0 
2. følt meg rolig og 
avslappet 
5 4 3 2 1 0 
3. følt meg aktiv og sterk 5 4 3 2 1 0 
4. følt meg opplagt og 
uthvilt når jeg våkner 
5 4 3 2 1 0 
5. følt at mitt daglige liv 
har vært fylt av ting 
som interesserer meg 
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PAID - Problem Areas In Diabetes – Diabetesrelaterte problemområder 
De neste utsagnene handler om vanlige diabetesrelaterte utfordringer.  
Hvilke av de følgende forhold er for tiden et problem for deg?  
 
  




    
Middels     
problem 
Nokså        




1. Har ikke klare og konkrete mål for  
diabetesomsorgen min  
0 1 2 3 4 
2. Behandlingsplanen for min diabetes 
gjør meg motløs                 
0 1 2 3 4 
3. Føler meg engstelig når jeg tenker på 
at jeg må leve med diabetes 
0 1 2 3 4 
4. Opplever ubehagelige sosiale 
situasjoner knyttet til min 
diabetesomsorg (f.eks. folk som 
forteller meg hva jeg bør spise)                                                                         
0 1 2 3 4 
5. Føler forsakelse og tap i forhold til mat 
og måltider 
0 1 2 3 4 
6. Føler meg deprimert når jeg tenker på 
at jeg må leve med diabetes 
0 1 2 3 4 
7. Vet ikke om humøret eller følelsene 
mine er knyttet til diabetes 
0 1 2 3 4 
8. Føler meg overveldet av diabetes-  
sykdommen 
0 1 2 3 4 
9. Bekymrer meg for å få føling 0 1 2 3 4 
10. Føler sinne når jeg tenker på at jeg må 
leve med diabetes 
0 1 2 3 4 
11. Føler meg konstant opptatt av mat og 
spising 
0 1 2 3 4 
12. Bekymrer meg for fremtiden og sjansen 
for alvorlige komplikasjoner 
0 1 2 3 4 
13. Føler skyld og/eller engstelse når jeg 












14. “Aksepterer” ikke at jeg har diabetes 0 1 2 3 4 
15. Føler meg misfornøyd med 
diabeteslegen min 
0 1 2 3 4 
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(Fortsettelse)  
Hvilke av de følgende forhold er for tiden et problem for deg? 
  




    
Middels     
problem 
Nokså        




16. Føler at diabetes tar for mye av min  
fysiske og psykiske energi i det daglige 
0 1 2 3 4 
17. Føler meg alene med min diabetes 0 1 2 3 4 
18. Føler at familie og venner ikke støtter 
meg i mine anstrengelser for å 
håndtere min diabetes 
0 1 2 3 4 
19. Å kunne mestre komplikasjoner til min 
diabetes 
0 1 2 3 4 
20. Føler meg “utbrent” av den konstante 
anstrengelsen diabeteshåndteringen 
krever 
0 1 2 3 4 
 
 
PCDS - Perceived Competence in Diabetes Scale - oppfatning av egen diabeteskompetanse 
I hvor stor grad stemmer de følgende fire påstandene for deg når det gjelder hvordan du håndterer 










Jeg føler meg trygg på at jeg klarer 
å håndtere min diabetes 
1 2 3 4 5 6 7 
2. 
Jeg er i stand til å håndtere min 
diabetes nå 
1 2 3 4 5 6 7 
3. 
Jeg klarer å utføre 
diabetesomsorgen min nå 
1 2 3 4 5 6 7 
4. 
Jeg føler at jeg klarer å møte 
utfordringen med å regulere min 
diabetes 
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Spørsmål om blodsukker og blodsukkermåling 
 
Nå følger 4 spørsmål om ditt blodsukker og symptomer på lavt blodsukker.  
 
1. Hvor ofte har blodsukkeret etter din mening vært for høyt de siste ukene? 
 
 Ikke i det 
hele tatt 
     Mesteparten   
av tiden 
 1 2 3 4 5 6 7 
2. Hvor ofte har blodsukkeret etter din mening vært for lavt de siste ukene?  
 
 Ikke i det 
hele tatt 
     Mesteparten 
av tiden 
 1 2 3 4 5 6 7 
3. I hvilken grad har blodsukkeret etter din mening svingt for mye de siste ukene? 
 
 Ikke i det 
hele tatt 
     Mesteparten 
av tiden 
 1 2 3 4 5 6 7 




     Kjenner det 
aldri 
 1 2 3 4 5 6 7 
 
 
Nå følger noen spørsmål om utstyr og hyppighet av blodsukkermålinger.  
 
Hvilken målemetode bruker du vanligvis for å måle blodsukker/glukoseverdier?  
Sett kryss på det som passer 
 Vanlig blodsukkerapparat (Glukometer) med strimler e.l. □1 
 Flash glukosemåler (Freestyle Libre) □2 
 Kontinuerlig glukosemåler (CGM) □3 
 Måler ikke selv □4 
 
Dersom du har svart 1 eller 2 på spørsmålet over, ønsker vi å vite hvor ofte du sjekker 
blodsukkeret: 
A. Hvor ofte sjekker/måler du vanligvis blodsukker/glukoseverdier? 
Daglig    □1 (gå videre til spørsmål B)   
Ukentlig   □2 (gå videre til spørsmål C) 
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Dersom du svarte at du sjekker/måler daglig på spørsmål A:   
B. Hvor mange ganger per dag sjekker/måler du vanligvis blodsukker/glukoseverdier? 
1-3 ganger per dag   □1 
4-6 ganger per dag  □2 
7-10 ganger per dag  □3 
Mer enn 10 ganger per dag □4 
 
Dersom du svarte at du sjekker/måler ukentlig på spørsmål A:     
C. Hvor mange ganger per uke sjekker/måler du vanligvis blodsukker/glukoseverdier? 
1-3 ganger per uke   □1 
4-6 ganger per uke  □2 
7-10 ganger per uke  □3 
Mer enn 10 ganger per uke □4 
 
RAND-12 (12 spørsmål om generell livskvalitet) 
 
 
De siste spørsmålene handler om hvordan du oppfatter helsen din. Disse opplysningene vil hjelpe 


















TAKK FOR AT DU SVARTE PÅ SPØRSMÅLENE! 
 
 
                                 
 
Prosjektnummer: 2016/2200 - Feasibility-studie, 2017 
 
Bruk av pasient-rapporterte målinger for å bedre kvaliteten  
på oppfølgingen av personer med diabetes 
 
SKRIV FIRETEGNSKODEN SOM ER OPPGITT PÅ PC-SKJERMEN HER:  





Takk for at du har besvart vårt elektroniske spørreskjema. Vi ønsker at du svarer på spørsmålene 
under og deretter legger skjemaet i postkassen ved PC-en i korridoren, etter at konsultasjonen 
hos lege/sykepleier er ferdig. På forhånd takk!   
 
Spørsmål om den elektroniske utfyllingen du har gjennomført:  
 
1. I hvilken grad var spørsmålene/utsagnene du besvarte på pc-skjermen forståelig for deg? 
Ikke i det hele tatt 
 1 
I liten grad  
 2 
I noen grad 
 3 
I stor grad 
 4 






2. I hvilken grad var spørsmålene/utsagnene relevante for deg?  
Ikke i det hele tatt 
 1 
I liten grad  
 2 
I noen grad 
 3 
I stor grad 
 4 






3. I hvilken grad var informasjonen og forklaringene som ble gitt på skjermen, forståelig for 
deg?  
Ikke i det hele tatt 
 1 
I liten grad  
 2 
I noen grad 
 3 
I stor grad 
 4 
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5. I hvilken grad vil du være positiv til å fylle ut et elektronisk diabetes-relatert spørreskjema 
én gang i året før poliklinisk diabetesoppfølging? 
Ikke i det hele tatt 
 1 
I liten grad  
 2 
I noen grad 
 3 
I stor grad 
 4 






Noen spørsmål om deg:  
 





Høgskole/universitet <4 år 
 3 
Høgskole/universitet ≥4 år 
 4 
 











































Bor med partner  
òg barn  
 
 4 













9. Hva er ditt morsmål? (Sett kryss på det alternativet som passer best for deg.) 
Norsk 
 1 
Annet nordisk språk  
 2 
Annet europeisk språk  
 3 





                            DiaPROM Prosjektnummer: 2017/1506/REK vest (Baseline) 
 
Bruk av pasient-rapporterte målinger for å bedre  
kvaliteten på oppfølgingen av personer med diabetes 
 
Vi vil gjerne ha tilbakemelding på hvor tilfreds du er med oppfølgingen du får ved diabetespoliklinikken.  
 
FYLL INN FIRETEGNSKODEN DU FÅR OPPGITT PÅ PC-SKJERMEN 
HER OG PÅ NESTE ARK:  
Ta koden med inn til lege eller sykepleier.  
 
Spørsmålene nedenfor besvares etter konsultasjonen hos lege/sykepleier. Det er plass til å skrive 
kommentarer på siste side. Etter utfylling legges skjemaet i postkassen ved PC-en i korridoren sammen med 
signert samtykkeerklæring. 
 
Om oppfølgingen ved diabetespoliklinikken (Kryss av på det alternativet som passer best for deg) 
 
  Ikke i det 
hele tatt 
I liten  
grad 
I noen  
grad 
I stor  
grad 
I svært  
stor grad 
1. 
Alt i alt, er du fornøyd med 
oppfølgingen du mottar ved 
diabetespoliklinikken? 
 1  2  3  4  5 
 
2. 
Blir du møtt med høflighet og 
respekt ved diabetespoliklinikken? 
 1  2  3  4  5 
 
3. 
Opplever du at helsepersonellet tar 
dine bekymringer på alvor? 
 1  2  3  4  5 
 
4. 
Har du utbytte av oppfølgingen ved 
diabetespoliklinikken? 





Fra 7 til 12 
måneder 
Fra 13 måneder  
til 3 år 
Mer enn  
3 år 
5. 
Hvor lenge har du vært pasient ved 
denne poliklinikken? 

















Hva synes du om antall 
konsultasjoner du har fått ved 
diabetespoliklinikken det siste året? 
 1  2  3  4  5  6 
 
Om utfylling av det elektroniske spørreskjemaet (Kryss av på det alternativet som passer best for deg.) 
 
  Ikke i det 
hele tatt 
I liten  
grad 
I noen  
grad 
I stor  
grad 
I svært  
stor grad 
7. Var spørsmålene forståelig for deg?  1  2  3  4  5 
 
8. 
Var antallet spørsmål akseptabelt for 
deg?  
 1  2  3  4  5 
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  Ikke i det 
hele tatt 
I liten  
grad 
I noen  
grad 
I stor  
grad 
I svært  
stor grad 
9. 
Opplevde du spørsmålene som 
relevante for personer med 
diabetes? 
 1  2  3  4  5 
 
  
Ikke i det 
hele tatt 
I liten  
grad 
I noen  
grad 
I stor  
grad 
I svært  
stor grad 
10. 
Er du positiv til årlig utfylling av et 
slikt diabetesrelatert spørreskjema?  
 1  2  3  4  5 






Ønsker ikke  
fylle ut 
11. 
Hvordan vil du foretrekke å fylle ut 
spørreskjema i fremtiden? 
 1  2  3  4 
 
Om bruk av spørreskjema i samtalen med behandler (Kryss av på det alternativet som passer best for deg.) 
 
  Ja Nei Skjemaet var ikke 
tilgjengelig 
12. 
Fikk du se svarene på spørreskjemaet ditt på 
behandlers PC-skjerm? 
 1  2  3 
 
13. 
Ble svarene på spørreskjemaet ditt snakket 
om i konsultasjonen? 
 1  2  3 
 
  
Ikke i det 
hele tatt 











Dersom svarene spørreskjemaet ble 
snakket om, hadde du utbytte av 
samtalen? 
 1  2  3  4  5  6 
 





Var det du eller behandler som tok initiativ til 
å snakke om innhold i spørreskjemaet? 
 1  2  3 
 






universitet <4 år 
Høgskole/ 
universitet ≥4 år 
16. 
Hva er din høyeste formelle 
utdannelse? 



















17. Hva gjør du til daglig?  1  2  3  4  5  6  7 
 
 











18. Hva er din samlivsstatus nå?  1  2  3  4  5  6 
 






19. Hva er ditt morsmål?  1  2  3  4 
3 
 






Nedenfor følger en liste over 17 mulige problemområder personer med diabetes kan erfare. Vurder 
i hvilken grad hvert av punktene har bekymret deg eller plaget deg i løpet av den siste måneden. 
Sett ring rundt tallet som passer best. 
 
Hvis du føler at et bestemt punkt ikke er et problem eller en plage for deg, kan du sette ring rundt 
"1". Hvis det er til stor plage for deg, kan du sette ring rundt "6".   
 







Jeg føler at diabetes tar for mye tid av min fysiske 
og psykiske energi hver dag.  
1  2  3  4  5  6  
2  
Jeg føler at legen min ikke vet nok om diabetes og 
diabetesomsorg.  
1  2  3  4  5  6  
3.  
Jeg føler meg sint, redd og/eller deprimert når jeg 
tenker på at jeg må leve med diabetes  
1  2  3  4  5  6  
4.  
Jeg føler at legen min ikke gir meg klare nok 
retningslinjer for hvordan jeg skal håndtere min 
diabetes.  
1  2  3  4  5  6  
5.  
Jeg føler at jeg ikke måler blodsukkeret mitt ofte 
nok.  
1  2  3  4  5  6  
6.  
Jeg føler at jeg ofte mislykkes med diabetes-regimet 
mitt.  
1  2  3  4  5  6  
7.  
Jeg føler at venner og familie ikke støtter meg nok i 
mine anstrengelser for å ta vare på meg selv  
(f.eks. ved å planlegge aktiviteter på tvers av min 
timeplan, eller oppmuntre meg til å spise "feil" 
mat).  
1  2  3  4  5  6  
8.  Jeg føler at diabetes kontrollerer livet mitt.  1  2  3  4  5  6  
9.  
Jeg føler at legen min ikke tar bekymringene mine 
alvorlig nok.  
1  2  3  4  5  6  
10.  
Jeg føler meg usikker på min egen evne til å 
håndtere min diabetes i hverdagen.  
1  2  3  4  5  6  
11.  
Jeg føler at jeg vil ende opp med alvorlige 
senkomplikasjoner, uansett hva jeg gjør.  
1  2  3  4  5  6  
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Jeg føler at jeg ikke følger en god måltidsplan nøye 
nok.  
1  2  3  4  5  6  
13.  
Jeg føler at venner og familie ikke har forståelse for 
hvor vanskelig det kan være å leve med diabetes.  
1  2  3  4  5  6  
14.  
Jeg føler meg overveldet av utfordringene ved å 
leve med diabetes.  
1  2  3  4  5  6  
15.  
Jeg føler at jeg ikke har en lege jeg kan kontakte 
regelmessig angående min diabetes  
1  2  3  4  5  6  
16.  
Jeg føler meg ikke motivert til å fortsette å 
håndtere min diabetes.  
1  2  3  4  5  6  
17.  
Jeg føler at venner og familie ikke gir meg den 
følelsesmessige støtten jeg ønsker.  
1  2  3  4  5  6  
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Bruk av pasient-rapporterte målinger for å bedre  
kvaliteten på oppfølgingen av personer med diabetes 
 
FYLL INN FIRETEGNSKODEN DU FÅR OPPGITT PÅ PC-SKJERMEN 
HER OG I TILSVARENDE BOKSER:  
Ta koden med inn til lege eller sykepleier.  
 
Vi vil gjerne ha tilbakemelding på hvor tilfreds du er med oppfølgingen du får ved diabetespoliklinikken og 
med deltakelse i prosjektet. Spørsmålene nedenfor besvares etter konsultasjonen hos lege/sykepleier. 
Etter utfylling legges skjemaet i postkassen ved PC-en i korridoren. 
 
Om oppfølgingen ved diabetespoliklinikken (Kryss av på det alternativet som passer best for deg) 
 
  Ikke i det 
hele tatt 
I liten  
grad 
I noen  
grad 
I stor  
grad 
I svært  
stor grad 
1. 
Alt i alt, er du fornøyd med 
oppfølgingen du mottar ved 
diabetespoliklinikken? 
 1  2  3  4  5 
2. 
Blir du møtt med høflighet og 
respekt ved diabetespoliklinikken? 
 1  2  3  4  5 
3. 
Opplever du at helsepersonellet tar 
dine bekymringer på alvor? 
 1  2  3  4  5 
4. 
Har du utbytte av oppfølgingen ved 
diabetespoliklinikken? 




Fra 7 til 12 
måneder 
Fra 13 måneder  
til 3 år 
Mer enn  
3 år 
5. 
Hvor lenge har du vært pasient ved 
denne poliklinikken? 















Hva synes du om antall 
konsultasjoner du har fått ved 
diabetespoliklinikken det siste året? 
 1  2  3  4  5  6 
 
Om bruk av spørreskjema i samtalen med legen (Kryss av på det alternativet som passer best for deg.) 
 
  Ja Nei 
7. 
Så du på svarene på spørreskjemaet ditt 
sammen med legen? 
 1  2 
8. 
Ble svarene på spørreskjemaet ditt snakket 
om i legekonsultasjonen? 
 1  2 
  
Ikke i det 
hele tatt 











Dersom svarene spørreskjemaet ble 
snakket om, hadde du utbytte av 
samtalen? 
 1  2  3  4  5  6 
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Jeg tok  
initiativ 





Var det du eller legen som tok initiativ til å 
snakke om innhold i spørreskjemaet? 
 1  2  3 
  
Ikke i det 
hele tatt 
I liten  
grad 
I noen  
grad 
I stor  
grad 
I svært stor 
grad 
11. 
Har utfylling av spørreskjema før konsultasjon 
medført at du har tatt initiativ til å samtale 
med legen om diabetesrelaterte utfordringer 
som du ellers ikke ville tatt opp? 
 1  2  3  4  5 
12. 
Synes du at utfylling av det diabetesrelaterte 
spørreskjemaet har vært positivt for deg? 
 1  2  3  4  5 
 
 
Til deg som har fått ekstra oppfølging hos diabetessykepleier grunnet svarene på spørreskjemaet 
(Kryss av på det alternativet som passer best for deg.) 
 
  Ja Nei Ikke aktuelt 
13. 
Fikk du se svarene på spørreskjemaet ditt på 
diabetessykepleierens PC-skjerm? 
 1  2  3 
14. 
Ble svarene på spørreskjemaet ditt snakket 
om i konsultasjonen med diabetessykepleier? 
 1  2  3 
  







Var det du eller diabetessykepleieren som tok 
initiativ til å snakke om innhold i 
spørreskjemaet? 
 1  2  3 
  Ikke i det 
hele tatt 
I liten  
grad 
I noen  
grad 







Dersom svarene spørreskjemaet ble 
snakket om, hadde du utbytte av 
samtalen? 
 1  2  3  4  5  6 
17. 
Har utfylling av spørreskjema medført 
at du har tatt initiativ til å samtale med 
diabetessykepleier om diabetes-
relaterte utfordringer som du ellers ikke 
ville tatt opp? 
 1  2  3  4  5  6 
18. 
Har du hatt utbytte av den ekstra 
oppfølgingen og bruk av 
spørreskjemaet? 
 1  2  3  4  5  6 
19. 
Har du fått nok tid til samtaler med 
diabetessykepleier etter utfylling av 
spørreskjemaet? 
 1  2  3  4  5  6 
 
 




Noen spørsmål om deg (Kryss av på det alternativet som passer best for deg.) 
 
Spørsmål om mulige diabetes-relaterte problemområder 
Nedenfor følger en liste over 17 mulige problemområder personer med diabetes kan erfare. 
Vurder i hvilken grad hvert av punktene har bekymret deg eller plaget deg i løpet av den siste 
måneden. Sett ring rundt tallet som passer best. 
Hvis du føler at et bestemt punkt ikke er et problem eller en plage for deg, kan du sette ring rundt 
"1". Hvis det er til stor plage for deg, kan du sette ring rundt "6".   
 







Jeg føler at diabetes tar for mye tid av min fysiske 
og psykiske energi hver dag.  
1  2  3  4  5  6  
2  
Jeg føler at legen min ikke vet nok om diabetes og 
diabetesomsorg.  
1  2  3  4  5  6  
3.  
Jeg føler meg sint, redd og/eller deprimert når jeg 
tenker på at jeg må leve med diabetes  
1  2  3  4  5  6  
4.  
Jeg føler at legen min ikke gir meg klare nok 
retningslinjer for hvordan jeg skal håndtere min 
diabetes.  
1  2  3  4  5  6  
5.  
Jeg føler at jeg ikke måler blodsukkeret mitt ofte 
nok.  
1  2  3  4  5  6  
6.  
Jeg føler at jeg ofte mislykkes med diabetes-regimet 
mitt.  






universitet <4 år 
Høgskole/ 
universitet ≥4 år 
20. 
Hva er din høyeste formelle 
utdannelse? 



















21. Hva gjør du til daglig?  1  2  3  4  5  6  7 
 
 











22. Hva er din samlivsstatus nå?  1  2  3  4  5  6 
 














Jeg føler at venner og familie ikke støtter meg nok i 
mine anstrengelser for å ta vare på meg selv  
(f.eks. ved å planlegge aktiviteter på tvers av min 
timeplan, eller oppmuntre meg til å spise "feil" 
mat).  
1  2  3  4  5  6  
8.  Jeg føler at diabetes kontrollerer livet mitt.  1  2  3  4  5  6  
9.  
Jeg føler at legen min ikke tar bekymringene mine 
alvorlig nok.  
1  2  3  4  5  6  
10.  
Jeg føler meg usikker på min egen evne til å 
håndtere min diabetes i hverdagen.  
1  2  3  4  5  6  
11.  
Jeg føler at jeg vil ende opp med alvorlige 
senkomplikasjoner, uansett hva jeg gjør.  
1  2  3  4  5  6  
12.  
Jeg føler at jeg ikke følger en god måltidsplan nøye 
nok.  
1  2  3  4  5  6  
13.  
Jeg føler at venner og familie ikke har forståelse for 
hvor vanskelig det kan være å leve med diabetes.  
1  2  3  4  5  6  
14.  
Jeg føler meg overveldet av utfordringene ved å 
leve med diabetes.  
1  2  3  4  5  6  
15.  
Jeg føler at jeg ikke har en lege jeg kan kontakte 
regelmessig angående min diabetes  
1  2  3  4  5  6  
16.  
Jeg føler meg ikke motivert til å fortsette å 
håndtere min diabetes.  
1  2  3  4  5  6  
17.  
Jeg føler at venner og familie ikke gir meg den 
følelsesmessige støtten jeg ønsker.  
1  2  3  4  5  6  
 
 





































TAKK FOR AT DU TOK DEG TID TIL Å SVARE!  
 
    
Interview guide paper IV 
All participants: 
• What are your experiences with and thoughts about routine diabetes follow-up? 
• What do you expect from the follow-up? 
• How did you experience the technical aspects regarding completing the electronic 
PROMs? 
• What are your thoughts about the included items/scales?  
• What was it like for you to complete the questionnaires in this way? 
Control arm: 
• Did the questionnaires prompt you to talk about the content and your answers with the 
physician? 
Intervention arm: 
• Can you describe how PAID was used in the medical consultation?  
• How did you experience sharing diabetes-related problems with the physician? 
• Did the PAID completion result in additional follow-up, and if so, what were your 
experiences with the additional nurse follow-up? 
• What are your experiences with and thoughts about how PAID was used in the nurse 
consultations? 
• How did you experience sharing diabetes-related problems with the nurse? 
• How did the nurse apply the PAID? 
• Did you find it helpful/useful to discuss the diabetes-related challenges with the nurse? 
All: 
• What are your thoughts about participating in the study? 




VEILEDER FOR BEHANDLERE 
Baseline 2018 
 
LESES OG UTFØRES AV BEHANDLER: 
1. Nedlasting av PROM-svar til Noklus diabetes for alle pasienter (18-40 år) som har med seg en 
firetegnskode til konsultasjonen.  
 
Takk for at du spør pasienten om samtykkeskjema er signert!  (Evt. ser til at det signeres.) 





Når firetegnskoden legges inn i Noklus Diabetes, skjer randomiseringen automatisk.  
− For pasienter som randomiseres til intervensjonsgruppen, vil spørreskjemaene bli synlig i 
diabetesjournalen.  
− For de som randomiseres til kontrollgruppen, vil det bli gitt beskjed om at skjemaene er arkivert. 
Skjemaene er ikke synlig i journalen. Du informerer så pasienten om dette.  
 
3. Gjennomgang av PAID* for pasienter i intervensjonsgruppen  
 
Se på pasientens PAID-scorer sammen med pasienten. PAID er intervensjonens hovedinstrument.  
De øvrige instrumenter er studiens effektmål og skal ikke diskuteres om ikke det er spesielt ønsket av 
pasienten.  
 
*Problem Areas in Diabetes scale 
4. Henvisning til sykepleier  
 
Deltakere med PAID sumscore ≥30 eller score 3 eller 4 på minimum ett utsagn (markert med rød stolpe i 
Noklus diabetes), kvalifiserer for henvisning til videre oppfølging hos diabetessykepleier.  
 
Henvisning gjøres i Dips: Legg til «Ny kontakt» med ressurstype sykepleier og skriv DiaPROM som 




OBS WHO-5 score  
Det anbefales å ta en titt på deltakernes WHO-5 score. Totalscore under 28 kan indikere alvorlig 
psykologiske problemer (depresjon) og henvisning til psykolog/psykiater bør vurderes. 
 
 
Informasjon om oppfølgingen hos sykepleier 
Oppfølgingen hos diabetessykepleier består av minimum 2 konsultasjoner i løpet av det kommende året. 
Den første sykepleierkonsultasjonen bør finne sted innen 4 uker. Sykepleierkonsultasjon nr. 2 
gjennomføres maksimum 3 måneder senere. Utover de to «obligatoriske» sykepleierkonsultasjonene, 
avklarer sykepleier og pasient behov for ekstra møter eller telefonkontakt frem mot neste årskontroll. 
Neste årskontroll 
Ved neste årskontroll fyller pasienten igjen ut PROM-spørsmålene.  
Takk for at du minner pasienten på å besvare papirspørreskjemaet om tilfredshet etter konsultasjonen.  



























































































































































































































































































































































































































































































































































































                       VEILEDER FOR KOMMUNIKASJON  
 




Ønsk velkommen og avklar konsultasjonens fokus/innhold.  
 
2. SE GJENNOM PAID-SVAR SAMMEN MED PASIENTEN 
 
Hva er rapportert som problematisk/utfordrende? Se på svarene sammen med pasienten.   
 
3. STILL SPØRSMÅL 
 
Hvis pasientene har rapportert flere problemområder som ikke kan sees i sammenheng:  
Spør hva pasienten vil at dere skal gripe fatt i først (og legg eventuelt en plan for når de øvrige 
problemområder skal tas fatt i).   
Spør videre: Fortell meg mer om utfordringen? Hvordan er dette vanskelig for deg?  
 
4. LYTT  
 
Lytt til pasienten i omlag 5 minutter uten å gi råd eller bryte inn i pasientens fortelling.  
Hvis pauser oppstår, kan du utfordre pasienten til å fortelle mer ved å respondere på en av 
følgende måter:  
− Empatisk respondering: «Det høres ut som om dette er utfordrende for deg. Fortell meg 
mer.» 
− Utforskende spørsmål: «Fortell meg litt mer om hvordan dette er for deg i din hverdag?» 
− Speiling: «Jeg hører du sier.…. Stemmer det? Kan du si litt mer om det?» 
 
5. RESPONDÉR  
 
Etter omlag 5 minutter kan du respondere på pasientens fortelling om sitt problem/sin utfordring. 
Følgende spørsmål kan være nyttige: 
− Hva tenker du må endre seg for at du skal oppleve å ha det bedre med dette problemet?  
− Har du prøvd å gjøre noe med problemområdet/utfordringen tidligere?  
− Kan du tenke deg noe du kan gjøre for å komme nærmere en løsning på 
problemet/utfordringen?  
− Hva kan jeg gjøre for å hjelpe deg på veien mot en løsning?  
 
6. AVSLUTNING: OPPSUMMER OG UTARBEID MÅL/PLAN FOR VIDERE ARBEID  
 
«Skal vi oppsummere og bli enige om en plan for videre arbeid med problemet/utfordringen?» 
− Lag en skriftlig plan med målsetting og tiltak. Bruk eget utviklet skjema for dette formål. 




Forklaringer til kommunikasjonsprinsippene:  
1. ÅPNING 
Det er viktig å skape en god tone og en god relasjon til pasienten innledningsvis. Videre er det viktig å 
avklare konsultasjonens agenda og tiden en har til rådighet.  
 
2. SE GJENNOM PAID-SVAR SAMMEN MED PASIENTEN: 
Det er viktig at pasienten får se besvarelsen på skjermen sammen med deg. Ta for dere de utsagn hvor 
pasienten har svart enten 3 (nokså alvorlig problem) eller 4 (alvorlig problem). Det er først og fremst disse 
utsagnene man deretter jobber videre med. Dersom pasienten har svart 3 eller 4 på flere utsagn, må dere bli 
enige om hvilke utsagn som skal prioriteres først. Vær oppmerksom på at noen kan ha behov for å endre på 
ett eller flere svar.   
    
3. STILL SPØRSMÅL 
Ofte er barrierer eller utfordringer knyttet til god egenbehandling av diabetes skjult fordi vi ikke spør de 
rette spørsmålene. I dette prosjektet vil pasientens PROM-svar hjelpe oss i gang. Videre må vi lytte til 
pasientens historie knyttet til de rapporterte problemområder/utfordringer.  
 
4. LYTT  
Utfordringen for deg som sykepleier er å forstå hva problemområdet består av og hva som er den viktigste 
utfordringen for pasienten. Videre å kunne samarbeide og hjelpe pasienten med å lage en plan for det 
videre arbeid med problemområdet/utfordringen. Dette krever at du først gir deg tid til å lytte til pasienten.  
 
5. RESPONDÉR  
Du skal hjelpe pasienten i en prosess hvor vedkommende i størst mulig grad selv finner løsninger. For å 
lykkes med den daglige håndteringen av diabetes er det helt sentralt at vi hjelper pasientene mot mest 
mulig selvstendighet (autonomi) og tro på egen mestring. Det å gjøre gode valg for seg selv i hverdagen og 
det å ha tro på egen mestring krever imidlertid en opplevelse av å ha tilstrekkelig kompetanse og det krever 
at en ikke opplever å være alene om problemet/utfordringen. Vi som helsepersonell skal være gode 
støttespillere og samtidig gi pasientene nødvendig kunnskap til å kunne håndtere hverdagen.    
 
6. AVSLUTNING: UTARBEID MÅL OG PLAN FOR VIDERE ARBEID OG OPPFØLGING  
Det er viktig å sikre at du som hjelper og pasienten har den samme oppfatning av situasjonen og pasientens 
problemområde før konsultasjonen avsluttes. Det er også viktig å sikre at dere har en plan for det videre 
arbeid som begge er innforstått med. Til slutt er det viktig å gi pasienten en opplevelse av at vedkommende 
ikke er alene om sitt problem. En klar plan og en enighet om den videre oppfølging hos deg kan bidra til en 
slik opplevelse.   
 
TEORETISK FORANKRING  
Denne veilederen er basert på de grunnleggende elementer i empowerment-teori som handler om å skape 
en prosess hvor individet mobiliserer ressurser til å håndtere sine utfordringer selv. Videre er veilederen 
basert på self-determination theory hvor autonomi, kompetanse og støtte fra andre løftes frem som 
sentrale elementer som bidrar til mestring.  
REFERANSER:  
- Marrero, D.G., Ard, J., Delamater, A.M., Peragallo-Dittko, V., Mayer-Davis, E.J., Nwankwo, R. and Fisher, E.B. (2013) Twenty-First Century 
Behavioral Medicine: A Context for Empowering Clinicians and Patients With Diabetes A consensus report. Diabetes Care 2014; 36 (2): 463-
470. 





Arbeid med diabetesrelaterte utfordringer 
 
MÅL OG TILTAK 
 
 




i samarbeid mellom:   
 
………………………………………………. og …...………………………………………… 
















































VEILEDER FOR BEHANDLERE 
12 mnd oppfølging 2019 
 
1. Nedlasting av PROM-svar til NOKLUS diabetes  
 
DiaPROM-deltakere svarer på PROM i forkant av konsultasjonen og har med seg en firetegnskode til 
konsultasjonen (diabetes type 1, 18-40 år). Koden brukes til å laste ned PROM-svar til diabetesjournalen. 
Se baksiden for utfyllende informasjon om nedlasting.  
 
2. Intervensjonsgruppe og kontrollgruppe 
 
Da firetegnskoden ble lagt inn i Noklus Diabetes ved baseline 2018, skjedde en automatisk randomisering.  
− PROM-svar er synlig for intervensjonsgruppen.  
− PROM-svar er ikke synlig for kontrollgruppen (blir synlig etter prosjektslutt).  
 
3. Gjennomgang av PROM for deltakere i intervensjonsgruppen  
 
1. Vurdere og se på PAID*-scorer sammen med pasienten.  
Ved baseline ble totalscore ≥30 eller enkeltscorer ≥3 brukt som kriterier for henvisning til ekstra 
oppfølging hos diabetessykepleier.  
 
2. Vurdere WHO-5# score.  
Totalscore <28 kan indikere alvorlige psykologiske problemer (depresjon) og henvisning til 
psykolog/psykiater bør vurderes. 
 
De andre PROM-skjemaene kan diskuteres dersom du eller pasienten har et spesielt ønske om det.  
 
*Problem Areas in Diabetes scale. # WHO (Five) Well-being Index.   
 
4. Videre oppfølging 
 
DiaPROM pilotstudie avsluttes med denne 12mnd-datasamlingen. Du og pasienten avtaler derfor videre 
oppfølging uten tanke for prosjektet. 
 
5. Papirspørreskjema om erfaringer 
 
Takk for at du minner pasienten på å besvare papirspørreskjemaet om erfaringer med prosjektdeltakelsen 
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 Helse Bergen HF - Haukeland universitetssykehusForskningsansvarlig:
 Ingvild Hernar Prosjektleder:
Vi viser til søknad om prosjektendring datert 03.05.2017 for ovennevnte forskningsprosjekt. Søknaden er
behandlet av sekretariatsleder for REK vest på fullmakt, med hjemmel i helseforskningsloven § 11.
Vurdering
Den omsøkte endringen gjelder utvidelse av aldersgruppen. Formålet med endringen er å raskere oppnå
antall studiedeltakere (n=60).
Prosjekt lederen skriver at i etterkant av denne feasibility-studien planlegges det en pilotstudie og deretter en
intervensonsstudie, samt en registerstudien for alle personer med diabetes.
Vurdering
REK vest har ingen innvendinger til prosjektendringen og gjør oppmerksom på at dersom det blir aktuelt
med flere studier, må REK vest søkes på nytt.
Vedtak
REK vest godkjenner prosjektendringen. 
Klageadgang
Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK vest. Klagefristen
er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK vest, sendes klagen videre til












Forespørsel om deltakelse i forskningsprosjekt med tittelen: 
  
«Bruk av pasient-rapporterte målinger for å bedre kvaliteten på oppfølgingen av personer med diabetes»  
 
Dette er et spørsmål til deg om å delta i et forskningsprosjekt ved medisinsk poliklinikk på Haukeland 
Universitetssykehus. Hensikten er å gjøre oppfølgingen av personer med diabetes mer målrettet mot det den 
enkelte opplever som utfordrende i sin hverdag.  
 
Hva innebærer prosjektet? 
Deltakelse innebærer å besvare et elektronisk spørreskjema neste gang du kommer til diabetesoppfølging i 
poliklinikken. Spørsmålene vil handle om generell helse og diabetesrelaterte forhold som kan oppleves som 
utfordrende eller problematisk. Når du kommer til poliklinikken, vil du se en PC i korridoren ved 
ventearealet, samt en detaljert oppskrift på hvordan du går fram for å besvare spørsmålene. Det vil ta mellom 
5 og 10 minutter å fylle ut det elektroniske spørreskjemaet. Vi ber derfor om at du kommer ca. 10 minutter 
før timeavtalen. 
 
I forbindelse med den elektroniske utfyllingen, får du oppgitt en firetegnskode på PC-skjermen. Du vil bli 
bedt om å notere den på et papirskjema som vil være tilgjengelig ved PCen. Papirskjemaet tas med til 
lege/sykepleier som bruker firetegnskoden til å knytte dine svar på det elektroniske spørreskjemaet til din 
diabetesjournal. På det samme papirskjemaet vil du også bli bedt om å svare på noen spørsmål om hvordan 
du oppfattet det elektroniske spørreskjemaet og utfyllingen av det, samt noe bakgrunnsinformasjon. Disse 
svarene vil også kunne knyttes til din elektroniske besvarelse via firetegnskoden. Det vil ta få minutter å fylle 
ut papirspørreskjemaet, og det leveres i en merket postkasse i korridoren ved ventearealet når du er ferdig på 
poliklinikken. På et senere tidspunkt kan det bli aktuelt å intervjue en mindre gruppe deltakere. Du vil i 
tilfelle få en egen henvendelse om det. 
 
I prosjektet vil vi innhente og registrere opplysninger om deg. Utover spørreskjemaopplysningene 
(elektronisk og på papir), vil vi hente følgende opplysninger fra din sykehusjournal: kjønn, alder, etnisitet, 
diabetestype, diabetesvarighet, siste HbA1c-verdi, insulinbehandling, evt. antall tilleggssykdommer og evt. 
senfølger som følge av diabetes. 
 
Mulige fordeler og ulemper 
Utover tiden det tar å fylle ut spørreskjemaet vil ikke deltakelse i dette prosjektet medføre noen andre 





Frivillig deltakelse og mulighet for å trekke sitt samtykke 
Det er frivillig å delta i prosjektet. Dersom du ønsker å delta, undertegner du samtykkeerklæringen på siste 
side og gir den til din behandler. Du kan når som helst og uten å oppgi grunn trekke ditt samtykke. Dette vil 
ikke få konsekvenser for den øvrige oppfølging og behandling ved Haukeland Universitetssykehus.  
 
Hva skjer med informasjonen om deg? 
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i hensikten med studien. Alle 
opplysningene vil bli behandlet uten navn og fødselsnummer eller andre direkte gjenkjennende opplysninger. 
En kode knytter deg til dine opplysninger gjennom en navneliste. Informasjon om deg vil bli anonymisert 
eller slettet senest fem år etter prosjektslutt. Opplysningene du registrerer i det elektroniske spørreskjemaet 
blir overført til din journal og kan dermed leses av behandler. 
 
Prosjektet er godkjent av Regional komité for medisinsk og helsefaglig forskningsetikk (2016/2200). 
Har du spørsmål om prosjektet kan du kontakte prosjektleder: Anne Haugstvedt, e-post: ahau@hvl.no,  
tlf: 47 82 92 20 eller diabetessykepleier/stipendiat: Ingvild Hernar, e-post: iher@hvl.no, tlf: 90 68 36 41. 
 
Bergen, 16. februar 2017 
Vennlig hilsen 
 
Anne Haugstvedt   Hrafnkell B. Thordarson Ingvild Hernar 
 
Prosjektleder/førsteamanuensis  Seksjonsoverlege  Diabetessykepleier/stipendiat 
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FORESPØRSEL OM DELTAKELSE I FORSKNINGSPROSJEKTET: 
BRUK AV PASIENT-RAPPORTERTE MÅLINGER FOR Å BEDRE  
KVALITETEN PÅ OPPFØLGINGEN AV PERSONER MED DIABETES  
Dette er et spørsmål til deg med type 1 diabetes i aldersgruppen 18-39 år om å delta i et 
forskningsprosjekt ved medisinsk poliklinikk på Haukeland Universitetssykehus. Hensikten med 
studien er å prøve ut et tiltak for å gjøre diabetesoppfølgingen ved poliklinikken mer målrettet mot 
forbedring av det som kan oppleves som utfordrende i hverdagen med diabetes. 
HVA INNEBÆRER PROSJEKTET? 
Du møter på poliklinikken 15 minutter før avtalt time til årskontroll. Før årskontrollen besvarer du et 
spørreskjema om generell helse og diabetesrelaterte forhold på en PC ved poliklinikkens venterom (se bildet). 







Det vil ta ca. 10 minutter å svare på spørsmålene. Du får oppgitt en kode på PC-skjermen som du blir bedt om å 
notere på et eget papirskjema som tas med inn til legen. 
Legen laster ned svarene dine til diabetesjournalen ved hjelp av koden. Du fordeles deretter tilfeldig til enten å 
være i prosjektets tiltaksgruppe eller i en kontrollgruppe. Deltakelse i prosjektet innebærer følgende:  
For tiltaksgruppen: Legen ser gjennom svarene du gav på spørreskjemaet sammen med deg. Dersom du 
rapporterte noen problemer som krever oppfølging, vil du få tilbud om minimum 2 ekstra oppfølgings-
samtaler hos diabetessykepleier i perioden frem mot neste årskontroll.   
For kontrollgruppen: Dine svar vil ikke bli synlig i journalen din. Det skjer først etter at forskningsprosjektet 
er avsluttet. Din behandler vil dermed ikke kunne ta initiativ til å diskutere svarene dine med deg i denne 
konsultasjonen.  
I etterkant av årskontrollen vil alle deltakere, fra både tiltaks- og kontrollgruppen, bli bedt om å svare på et 
papir-spørreskjema om tilfredshet med oppfølgingen ved poliklinikken, samt noen diabetesrelaterte spørsmål. 
Det utfylte papirskjemaet leveres i en postkasse ved PC’en ved ventearealet før du forlater poliklinikken.  
Utover informasjonen du har gitt på spørreskjemaet, vil følgende opplysninger hentes fra din sykehusjournal: 
kjønn, alder, etnisitet, høyde og vekt, hvor lenge du har hatt diabetes, siste HbA1c-verdi, type 
insulinbehandling, doser og eventuelt skifte av behandlingsopplegg, mulige komplikasjoner som følge av 
diabetes (inkludert alvorlig hypoglykemi, senkomplikasjoner og eventuelle sykehusinnleggelser som følge av 
dette), samt eventuelle andre sykdommer. 
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MULIGE FORDELER OG ULEMPER 
Det tar noe tid å fylle ut spørreskjemaene på PC og papir. En fordel med prosjektet er at helsepersonell får mer 
kunnskap om utfordringer personer med type 1 diabetes kan oppleve, og om det å diskutere disse 
utfordringene i oppfølgingen bidrar til en bedre hverdag med diabetes. Å besvare skjemaene kan fremkalle 
vonde følelser hos noen. Deltakere i tiltaksgruppen vil få tilbud om ekstra oppfølging for nettopp dette, mens 
deltakere i kontrollgruppen vil stå fritt til å ta opp sine følelser/utfordringer med behandler.  
FRIVILLIG DELTAKELSE OG MULIGHET FOR Å TREKKE SITT SAMTYKKE 
Det er frivillig å delta i prosjektet. Dersom du ønsker å delta, undertegner du samtykkeerklæringen på siste 
side. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke. Dette vil ikke få konsekvenser for 
din videre behandling og oppfølging ved Haukeland Universitetssykehus. Dersom du trekker deg fra prosjektet, 
kan du kreve å få slettet innsamlede opplysninger, med mindre opplysningene allerede har inngått i ferdige 
analyser eller brukt i vitenskapelige publikasjoner. Dersom du senere ønsker å trekke deg eller har spørsmål til 
prosjektet, kan du kontakte prosjektleder/postdoktor Anne Haugstvedt, e-post: anne.haugstvedt@hvl.no, tlf: 
47 82 92 20 eller stipendiat/diabetessykepleier Ingvild Hernar, e-post: ingvild.hernar@hvl.no, tlf: 90 68 36 41. 
HVA SKJER MED INFORMASJONEN OM DEG?  
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i hensikten med studien øverst på 
første side. Du har rett til innsyn i hvilke opplysninger som er registrert om deg og rett til å få korrigert 
eventuelle feil i de opplysningene som er registrert. Alle opplysningene vil bli behandlet uten navn og 
fødselsnummer eller andre direkte gjenkjennende opplysninger. En kode knytter deg til dine opplysninger 
gjennom en navneliste. 
Prosjektet har fått tillatelse til å registrere kjønn, alder, diabetes varighet og HbA1c på dem som takker nei til 
deltakelse i studien. Denne informasjonen vil kun bli brukt til å gjøre en frafallsanalyse, dvs. til å evaluere 
prosjektets tiltak. Dersom du ønsker å reservere deg mot dette kan du melde fra til prosjektledelsen.   
Prosjektleder har ansvar for den daglige driften av forskningsprosjektet og for at opplysninger om deg blir 
behandlet på en sikker måte. Informasjonen om deg vil bli anonymisert eller slettet senest fem år etter 
prosjektslutt.  
OPPFØLGINGSPROSJEKT  
På et senere tidspunkt kan det bli aktuelt å intervjue en mindre gruppe blant alle som har deltatt i prosjektet. 
Du vil i så tilfelle få en egen henvendelse om det. 
GODKJENNING 
Prosjektet er godkjent av Regional komite for medisinsk og helsefaglig forskningsetikk, saksnr. (2017/1506/REK 
vest). Prosjektet avsluttes 01.10.2021. 
Dersom du ønsker å delta, signerer du samtykkeskjemaet på neste side og tar det med til poliklinikken.  
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SAMTYKKE TIL DELTAKELSE I PROSJEKTET: 
BRUK AV PASIENT-RAPPORTERTE MÅLINGER FOR Å BEDRE  
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